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3 
Abstract  
 
Haemoglobin (Hb) within erythrocytes establishes a fundamental link between 
oxygen (O2) in ambient air and aerobic metabolism by transporting O2 in the 
blood from lung to tissue. Historically, blood O2 carriage has been quantified 
using the concentration of Hb in whole blood ([Hb]).  Anaemia, defined as a fall 
in [Hb] below 130 g.l-1 in males and 120 g.l-1 in females may cause fatigue and 
impaired fitness.  [Hb] is dependent on both plasma volume (PV) and total 
haemoglobin mass (tHb-mass).  Thus, anaemia may result when tHb-mass falls 
but also when PV is expanded.  Therefore, reliance on [Hb] may be misleading.  
tHb-mass may represent a better guide to O2 carrying capacity and of aerobic 
fitness than [Hb]. The relationship between tHb-mass and [Hb] has, however, 
been studied little across disease states, nor has the relationship between tHb-
mass and preoperative cardiopulmonary exercise testing (CPET) variables.  I 
used the optimised carbon monoxide rebreathing (oCOR) method to determine 
tHb-mass, first seeking its test-retest reliability in healthy volunteers (HV).  
Typical error of repeat tHb-mass measurements was low in my hands, in 
keeping with other studies. Subsequently, the relationship between tHb-mass 
and [Hb] in HV and in different diseases was studied; inflammatory bowel 
disease (IBD), chronic liver disease (CLD), heart failure (HF) and those awaiting 
surgery.  I found the relationship between tHb-mass and [Hb] varied 
considerably across disease states, with PV a key confounding variable 
affecting both [Hb] and the diagnosis of anaemia.  Subsequently, in a separate 
cohort of surgical patients I determined the relationship between tHb-mass, [Hb] 
and physical fitness quantified by CPET.  Unlike [Hb], I found tHb-mass to be 
an important variable associated with preoperative fitness.  The oCOR method 
is feasible and well tolerated by patients and provides a more comprehensive 
assessment of haematological and volume status compared to relying on [Hb] 
and its future use is advocated.  
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Chapter 1 
1 General introduction 
 
Anaemia, meaning “without blood” in ancient Greek is a common haematologic 
disorder affecting both developing and developed countries and is quantified by 
a deficiency in the iron containing oxygen (O2) carrier haemoglobin (Hb) stored 
within erythrocytes.  The World Health Organisation (WHO) states that in the 
assessment of anaemia, “Hb concentration ([Hb]) is the most reliable indicator 
of anaemia at the population level” [1].  The WHO defines anaemia as an 
insufficient circulating [Hb] of <130 g.l-1 in men and <120 g.l-1 in women, with 
further adjustment made in pregnancy (<110 g.l-1) [2].  Anaemia can occur at all 
stages of the human lifespan but is more commonly an affliction in older age.  
From a worldwide perspective, anaemia is a global burden to human health with 
an estimated quarter of the world’s population affected.  Specifically, anaemia 
affects 1.62 billion people (95% CI: 1.50–1.74 billion), which corresponds to 
24.8% of the global population (95% CI: 22.9–26.7%) [2].  A systematic analysis 
of global anaemia burden spanning 1990 to 2010 revealed that anaemia 
accounted for 68.4 million years of life lived with disability (YLD) in 2010, 
equating to 8.8% of global total disability from all conditions [3]. Updated figures 
from the Global Burden of Disease, Injuries and Risk Factors Study in 2013 
showed that the total number of anaemia cases had increased to 1.93 billion, 
which corresponded to an increased age-standardised prevalence of 27%, 
although YLD (61.5 million YLDs) decreased compared to figures from 2010 [4]. 
 
Iron deficiency is the single greatest underlying cause of anaemia (iron 
deficiency anaemia, IDA) at the global level in both sexes, accounting for 63% 
of the global total in 2013 [4].  IDA is also the leading cause of anaemia-
attributable disability although the cause of anaemia does vary with geography, 
age and sex. Other leading causes of anaemia in both sexes are 
haemoglobinopathies (12% in females, 10% in males), gastrointestinal losses 
(5% in females and males), and malaria (5% in males) with gynecologic 
conditions (5%) unique to females and non-malarial infectious tropical diseases 
to males (4%) [3, 4].  In addition, many chronic (and especially inflammatory) 
19 
states also yield a ‘functional iron deficiency’ and blunted erythropoiesis, 
thereby resulting in ‘the anaemia of chronic inflammation’ (ACI) [5]. 
 
Anaemia is thus a clinically important haematological condition encountered in 
various clinical settings and across many different disease states from the 
surgical patient, where it affects around one third of cases preoperatively [6], to 
patients with inflammatory bowel disease (IBD) [7], liver disease (LD) [8] and 
chronic heart failure (CHF) [9].  Anaemia is associated with increased fatigue 
[10], impaired functional capacity [11, 12] and adverse surgical outcome [6, 13] 
as well as worsened prognosis in a variety of diseases from CHF [14], cancer 
[15] and chronic obstructive pulmonary disease (COPD) [16].  In the context of 
surgery, the reduced O2 carrying capacity of blood in anaemic individuals with 
resulting tissue malperfusion may be one mechanism increasing susceptibility 
to adverse postoperative outcomes [17, 18]. 
 
For all these reasons, circulating haemoglobin concentrations are routinely 
measured in clinical practice. Once anaemia is identified, the cause of impaired 
haemoglobin synthesis or erythrocytosis, or of increased red cell destruction, is 
often sought and treatment (either of the underlying cause, or through the 
administration of packed donor red cells) initiated.  However, it is now becoming 
clear that this approach may be somewhat simplistic.  [Hb] may be an imperfect 
index of the blood’s O2 carrying capacity, being reduced not only when the 
absolute mass of circulating haemoglobin (tHb-mass) falls, but also by an 
increase in the volume of plasma (PV) in which the red blood cells (RBCs) are 
suspended.  But a low [Hb] might also be found when haemoglobin synthesis 
and erythrocytosis are normal, and when tHb-mass is normal (or even high), if 
PV is disproportionately expanded.  Therefore, both tHb-mass and PV can 
affect [Hb] independently of one another.  Despite this, neither factor is routinely 
considered or measured in clinical practice.  However, such assessment may 
be important if the drivers of an altered [Hb]- and the appropriate therapeutic 
response- are to be truly understood.  
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Total haemoglobin mass, being independent of PV may represent a better 
guide of Hb content and systemic O2 carrying capacity given that each gram of 
Hb has the maximum capacity to bind 1.39 ml of O2 and a trivial amount of O2 is 
transported in plasma.  Despite this, the relationship between tHb-mass and 
[Hb] has, however, been little studied in patient populations or across disease 
states and this is the first aim of my thesis to explore.  Total haemoglobin mass 
can now be safely and reliably measured using the optimised carbon monoxide 
(CO) rebreathing (oCOR) method, refined by Schmidt and Prommer in 2005 
[19].  The oCOR method has been widely used in sports medicine to measure 
tHb-mass and blood volume derivatives in elite athletes [20-29], following 
exposure to hypoxia (altitude training) [30-41] and in the context of blood doping 
[42-47], but has rarely been applied in the clinical setting [48-50].  If [Hb] is an 
imperfect index of tHb-mass and thus O2 carrying capacity, then this raises 
important questions about the way in which we measure and quantify Hb and 
define anaemia in patients.  For example, should tHb-mass be measured as an 
adjunct to or used instead of [Hb] as a means of assessing Hb in patients? 
Furthermore, do we need to readdress ‘anaemia’ as a concept and should we 
be defining volume excess and tHb-mass deficit separately instead? 
 
Surgery, like exercise, places significant systemic hormonal and metabolic 
stress on the body.  Whilst subject to some debate, O2 supply at a rate 
inadequate to prevent skeletal muscle anaerobiosis may underpin the 
occurrence of the anaerobic threshold (AT) during exercise, although other 
mechanisms may include the recruitment of muscle fibres with differing 
metabolic features [51].  Regardless, the AT is an important submaximal marker 
of cardiorespiratory fitness [52] in health and disease.  The maximal rate at 
which O2 can be transported from the environment to the mitochondria and 
utilised to support oxidative phosphorylation is termed the maximal or peak 
oxygen uptake (V̇O2max, V̇O2 peak).  The classical view is that V̇O2max is 
constrained by the limits of the cardiovascular system [53, 54], although this is 
not without controversy [55].  Nonetheless, it is widely considered that O2 
delivery, and not O2 extraction at the muscle which predominates in limiting 
V̇O2max in exercising humans [54], with cardiac output (Q̇) and the O2-carrying 
globular protein molecule Hb pivotal in this process [53].   
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Preoperative cardiopulmonary exercise testing (CPET) is considered the gold 
standard assessment of exercise capacity before surgery and is used to 
determine exertional O2 consumption (V̇O2) at AT and V̇O2 peak, as measures 
of ability to meet increasing O2 demands. The degree of surgical insult and the 
ability to meet the resulting additional postoperative O2 demand appear to be 
fundamental determinants of surgical outcome: individuals in whom such ability 
is impaired, and thus with reduced V̇O2 peak and AT, are at greater risk of 
adverse surgical outcome [56-59].  The cause of uncoupling of O2 supply and 
demand is multifactorial but likely an interaction between a patient’s existing 
comorbidities (e.g. cardiac disease or respiratory disease), and other conditions 
that impact O2 delivery &/or Q̇.  While Q̇ is well recognised as a key variable 
limiting exertional V̇O2 [53], the impact of anaemia and reduced concentration 
of oxygen-carrying Hb is less recognised, although others have shown 
associations between [Hb] and cardiorespiratory fitness [11] and enhanced 
exercise performance following acute changes in [Hb] [60]. 
 
I, and collaborators conducted a large, multicentre study of 1,777 patients 
awaiting elective surgery to try to address this by determining the association 
between preoperative [Hb] and cardiopulmonary exercise testing variables.  
This study (published during my PhD studies in 2013, see appendix G [11]) 
formed the foundations and background of this PhD and allowed a UCL Impact 
PhD Studentship to be successfully awarded.  I found that to a weak extent 
anaemia (lower [Hb]) was independently associated with lower exertional V̇O2 
at AT and V̇O2 peak, although this statistically significant finding may have been 
related to the large sample of patients studied, given that the correlation 
between [Hb] and V̇O2 at AT was only r= 0.24 and r= 0.30 between [Hb] and 
V̇O2 peak.  In addition, only a very small amount of the variance in exertional 
V̇O2 at both AT and V̇O2 peak was explained by [Hb], suggesting that other 
factors may play a more important role in determining aerobic capacity such as 
maximal Q̇ (primarily maximum stroke volume), skeletal muscle characteristics 
(e.g. mitochondrial density and quality, muscle fibre typing, and microcirculatory 
function), pulmonary diffusing capacity and the O2 carrying capacity of blood 
[54], the latter being highly dependent on tHb-mass.  
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To date, however, no studies have measured tHb-mass in the preoperative 
CPET patient awaiting major surgery.  Therefore, the importance of tHb-mass 
as a determinant of CPET-derived physical fitness in patients prior to surgery 
remains unstudied and is the second aim of this thesis to explore.  If tHb-mass 
is strongly related with exertional V̇O2, this provides a potential mechanism by 
which to enhance fitness for surgery and thus improve postoperative outcome.  
Overall thesis hypotheses and the aims of individual chapters are outlined 
below.  
 
1.1.  Hypotheses 
 
i) Total haemoglobin mass is poorly correlated with haemoglobin 
concentration, and 
 
ii) Unlike haemoglobin concentration, total haemoglobin mass is an 
important determinant of patient physical fitness associated with 
exertional oxygen consumption. 
 
1.2.  Overall aims and objectives of individual chapters 
 
i) Chapter 4:  
a. To determine the test retest reliability of the optimised carbon 
monoxide rebreathing method in our laboratory, and 
b. To quantify the repeatability of percent carboxyhaemoglobin 
(%COHb) measurements using the Cobas b 221 POC 
Hemoximeter (Roche Diagnostics, Rotkreuz, Switzerland). 
 
ii) Chapter 5 
a. To determine the degree to which total haemoglobin mass is 
correlated with haemoglobin concentration in different patient 
populations and disease states, and 
b. To assess the feasibility of using the optimised carbon monoxide 
rebreathing method in patients.  
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iii) Chapter 6: To explore the relationship between both haemoglobin 
concentration and total haemoglobin mass and measures of patient 
physical fitness, as determined by cardiopulmonary exercise testing. 
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Chapter 2 
2 Review of the Literature 
 
This section outlines the key factors involved in and affecting O2 transport, O2 
consumption and O2 delivery before moving onto discuss how to quantify and 
define O2 carrying capacity of blood. I then go on to discuss anaemia in varying 
clinical contexts before examining the relationships between markers of 
haemoglobin and objective measures of physical fitness. 
 
2.1 Oxygen transport 
 
O2 must be transported effectively from the atmosphere to the tissues in order 
to maintain essential cellular metabolic pathways [61].  The transport of O2 in 
the blood is achieved in main two ways; i) a small and trivial amount dissolved 
in the fluid portion of blood (plasma), and ii) the majority bound to the iron 
protein molecule Hb within red blood cells (RBCs) [51].  
 
2.1.1 Dissolved oxygen 
 
Under normal physiological conditions, a trivial amount of O2 is dissolved in 
plasma, partly related to oxygen’s relative insolubility in water, which keeps its 
concentration low in fluid.  Specifically, the amount of O2 dissolved in blood 
plasma is proportional to the partial pressure of oxygen (pO2) (i.e. adheres to 
Henry’s law [62]).  Specifically, at a physiological pO2 (being 100 mmHg in 
normal arterial blood), 0.3 ml O2 per 100 ml of blood is dissolved [63].  This 
amount of O2 is simply insufficient to sustain tissue O2 requirements and an 
additional transport method is necessary to sustain life.   
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2.1.2 The haemoglobin molecule 
 
Hb is an iron-containing globular protein pigment molecule carried within RBCs 
in the human body [64] and functions to carry almost all of the O2 in the blood 
(98% of the total) [65].  Importantly, Hb establishes a fundamental connection 
between the O2 available in ambient air and aerobic metabolism at the cellular 
level by transporting O2 in the blood from the lungs to the tissues where O2 is 
consumed and utilised to facilitate oxidative phosphorylation [66].  The structure 
of the HbA molecule can be seen see below in Figure 2-1, comprising four 
polypeptide chains, two alpha (α) and two beta (β) chains forming two αβ-pairs 
[66].  Each polypeptide globin chain contains one porphyrin ring structure called 
heme, bound covalently with a central ferrous iron ion [67] which facilitates O2 
binding [68] in a reversible reaction to give oxyhaemoglobin (see Equation 2-1). 
 
Equation 2-1. Oxygen binding with haemoglobin. 
 
Hb4+4 O2 ⇌ Hb4O8 
 
 
 
Figure 2-1. Structure of haemoglobin A showing in red, two α-chains and 
blue, two β-chains. In green are the four-iron containing heme groups. 
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The blood of a normal human adult contains at least 6 different forms of Hb 
molecule, largely with the same principle structure and function of which 
haemoglobin A (HbA) makes up approximately 95% of the total Hb 
concentration in a normal adult human [64].  When fully saturated with O2, 
assuming a normal [Hb] level (e.g. 150 g.l-1 in men) and a constant theoretical 
maximum O2 binding capacity of Hb (Hüfner’s constant of 1.39 ml.g-1, see 
section 2.1.3 for discussion of Hüfner’s constant), Hb carries nearly 20 ml of O2 
per dl of whole blood [64].  This reflects the maximum amount of O2 that can be 
combined with Hb when all binding sites are occupied by O2, this being the 
oxyhaemoglobin saturation.   
 
Blood O2 content is calculated from the sum of O2 bound to Hb and O2 
dissolved in plasma and equates to the amount of O2 in each 100 ml of blood. 
Oxygen content is calculated using the Equation 2-2 below (taken from [51]): 
 
 
Equation 2-2. Calculation of oxygen content  
 
CaO2=(1.31 × Hb × SaO2 × 0.01)+(0.0225 × PaO2) 
 
Where 1.31 is Hüfner’s constant, Hb is the amount of Hb in grams per decilitre, 
SaO2 being the arterial Hb saturation percentage, 0.0225 the coefficient of 
solubility for O2 at body temperature and PaO2 the partial pressure of O2 in 
arterial blood (in kilopascals).  
 
2.1.3 Hüfner’s constant 
 
Hüfner’s constant refers to Hb O2 carrying capacity and is defined as the 
maximum volume of O2 that can combine with 1 gram of Hb [69].  The 
calculated/theoretical value of 1.39 ml of O2 per gram commonly used is 
calculated from the molecular weight of Hb (64458 g), and that one molecule of 
Hb combines with four molecules of O2 at a standard temperature and pressure 
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of 0°C and 760 mmHg, respectively [69].  However, there is debate over the O2 
combining capacity with Hb under physiological conditions [70].  As Gorelov 
[69] highlights, the volume of gas at 37 °C (i.e. body temperature) will be larger, 
and thus Hüfner’s constant should be increased to reflect physiological 
conditions, so that the calculated value becomes 1.58 ml g-1. However, given 
that other forms of Hb are present in the blood (e.g. carboxyhaemoglobin which 
contributes to 0.2 - 0.8% of total Hb in adults and methaemoglobin ~1% of total 
Hb), this reduces the capacity of Hb to bind with oxygen [71].  Therefore, the Hb 
O2 binding capacity may be lower than when calculated. Taking this into 
consideration, McLellan and Walsh [70] suggest this could reduce the value of 
Hüfner’s constant to 1.31 ml g-1 (as used in Equation 2-2 above in the 
calculation of O2 content).  Despite this, it is still accepted that 1 gram of Hb has 
the maximum/theoretical capacity to bind 1.39 ml of O2.  Similarly, the 
maximum binding capacity of carbon monoxide (CO) to Hb is the same, i.e. one 
gram of Hb binds 1.39 ml of CO, as per Hüfner’s constant.     
 
2.1.4 P50  
 
The partial pressure of O2 at which Hb is 50% saturated is called the P50 [51] 
and is therefore a measure of Hb-O2 affinity.  A change in the P50 value informs 
us as to whether the oxyhaemoglobin dissociation curve has shifted to the left 
or right [68], thus altering the affinity between O2 and Hb.   
 
2.1.5 Oxyhaemoglobin dissociation curve 
 
The oxyhaemoglobin dissociation curve (ODC) shown in Figure 2-2 shows the 
saturation of Hb with O2 at various pO2 (mmHg) values.  As displayed, this 
relationship is not linear but sigmoid in shape, which has a number of important 
physiological advantages as West highlights [63]: 
 
i) The upper right portion of the curve is flat meaning that if the pO2 in 
alveolar gas falls, there will be limited impact on O2 loading. 
ii)  As RBCs take up O2 along the pulmonary capillary, a large partial 
pressure gradient between alveolar gas and blood continues even 
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when most O2 has been transferred, which hastens the diffusion 
process.  
iii) The lower left portion of the ODC results in peripheral tissues being 
able to withdraw/extract large amounts of O2 for only a small drop in 
capillary O2, which assists the diffusion of O2 into the tissues.  
   
At sea level, alveolar pO2 is 100 mmHg and Hb achieves 98% O2 saturation. In 
other words, the when partial pressure of O2 is high, the affinity between O2 and 
Hb (Hb-O2) is very high (as occurs in the lung).  In order to allow optimised O2 
delivery by Hb, a change in Hb-O2 affinity is required that allows unloading of 
O2 from the Hb molecule [72].  Several factors have been described that assist 
O2 content loading in the pulmonary circulation and unloading of O2 in the 
peripheral circulation, described below.     
 
 
Figure 2-2. Oxygen dissociation curve. Adapted from [73]. 
 
As can be seen in Figure 2-2 there are various physiological and chemical 
factors that affect the position of the ODC and thus affect the P50 value and O2 
loading and unloading consequently.  Specifically, a leftward shift in the ODC 
results in a reduction in the P50 value and increased Hb-O2 affinity/binding and is 
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caused by factors outlined below, with a rightward shift in the ODC (resulting in 
an increase in the P50 value and reduction in Hb-O2 affinity/binding) caused by 
the opposite [51, 74]: 
 
i) an increase in pH (reduction in hydrogen ions) 
ii) a reduction in temperature 
iii) a fall in arterial carbon dioxide content (PaCO2) 
iv) a reduction in 2,3-diphosphoglycerate (being the organic phosphate 
found in RBCs that is produced as a consequence of glycolysis), 
which promotes Hb-O2 release [51] 
 
2.2 Oxygen delivery, consumption and extraction 
 
The lungs, heart, vasculature and blood function to deliver a sufficient supply of 
O2, as well as substrate to the tissues to allow effective resynthesis of 
adenosine triphosphate (ATP) in the electron transport chain (ETC) [75].  
Specifically, as shown in Equation 2-3 [75], O2 delivery (DO2) is the product of 
cardiac output (Q̇), arterial O2 content (CaO2) and Hb, where 1.39 is Hüfner’s 
constant, being the amount of O2 (in ml) carried per g of Hb at sea level.   
 
Equation 2-3. Calculation of oxygen delivery 
 
DO2 = Q̇ x Hb x SaO2 x 1.39 ml 
 
O2 is the final step in this process by acting as the final electron acceptor in the 
ETC [76].  Without adequate O2 flow from the blood to mitochondria, energy 
generating mechanisms within the mitochondria would come to a halt [77].  At 
sites with insufficient O2 flow to mitochondria, anaerobic metabolism begins to 
predominate energy provision to complement ongoing aerobic ATP production 
[77].  This has particular relevance in the context of energy provision during 
exercise described below.   
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Approximately 90% of the body’s oxygen consumption (V̇O2) is utilised in the 
ETC by the cytochrome-c-oxidase system as part of oxidative phosphorylation, 
which is the most efficient means of energy production in the body, yielding 37 
ATP molecules from the complete oxidation of each glycosyl unit (see Equation 
2-4) [78].  
 
Equation 2-4. Aerobic phosphorylation  
 
C6H12O6 + 6O2 = 6CO2 + 6H2O + energy 
 
The quantity of V̇O2 has classically been expressed using the Fick equation, a 
product of heart rate and stroke volume, being cardiac output (Q̇) and the 
arteriovenous oxygen content difference (CaO2-CvO2), see Equation 2-5 [53].  
 
Equation 2-5. Fick equation  
 
V̇O2 = Q̇ x CaO2-CvO2 
 
It is widely accepted or ‘classically viewed’ that the physiological parametric 
limits of the Fick equation determine the maximal rate at which O2 can be 
transported from the environment to the mitochondria to support the oxidative 
phosphorylation of ATP and has been termed the maximal oxygen uptake or 
maximal oxygen consumption (V̇O2max) [53]. In health, although subject to 
debate, the finite rate of maximal oxygen consumption is determined by the 
ability of the cardiorespiratory system (heart, lungs, and blood) to transport O2 
to the muscles, not the ability of the muscle mitochondria to consume O2 [54].  
As such, V̇O2 dictates the amount of ATP that can be resynthesised aerobically.  
 
Under normal physiological circumstances, V̇O2 remains unaffected by DO2 over 
a wide range and thus remains supply independent [78].  This allows the body 
to initially manage a drop in DO2 without disturbing aerobic respiration and V̇O2, 
which confers survival advantage and can been seen under stress conditions 
such as exercise or anaemia.  This spare capacity is highlighted by normal 
resting values for DO2 of 1000 ml.min-1 and V̇O2 of around 250 ml.min-1 [75].  
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This indicates that only 25% of the delivered O2 is utilised by the tissues (based 
on a normal 70 kg adult undertaking normal daily activity) and represents the 
oxygen extraction ratio (O2ER), being the ratio of V̇O2 to DO2 [79].  As metabolic 
demand (V̇O2) increases or supply (DO2) is reduced, the O2ER rises to maintain 
aerobic metabolism up until the maximum O2ER is reached at 60-70% in most 
tissues.  At this point, termed the critical DO2 (DO2crit) being around 4 ml.kg-1min-
1 in humans,  V̇O2 becomes supply dependent [51].  Further increases in O2 
demand or impaired O2 supply lead to tissue hypoxia [80], with subsequent 
anaerobic metabolism and lactate production [74].  
 
As a consequence, anaerobic metabolism will supplement energy provision with 
resulting lactacidosis either when DO2 falls below the DO2crit (as in heart failure, 
haemorrhage or hypoxaemia) or when O2 demand increases beyond the ability 
of O2 supply and tissue extraction (e.g. during heavy to severe exercise).  At 
worst, a reduced DO2 and impaired cellular utilisation of O2, which occurs across 
various circumstances such as severe anaemia can cause cellular hypoxia, cell 
death, organ failure and death [80]. The pathophysiological mechanisms 
underpinning the effects of anaemia are not yet fully understood and it may be 
the case that anaemia is associated with, rather than causative of unfavourable 
patient outcomes.  Regardless it is important to outline the physiological 
responses to anaemia that lead to adaptive mechanisms to prioritise tissue DO2 
[81] [82].  These responses include [83]: 
 
i) an increase in Q̇ that is proportional to the extent of anaemia. 
ii) anaemia stimulates an increase in minute ventilation as well as nitric 
oxide (NO)-mediated improvement in ventilation-perfusion matching, 
leading to an increase in the partial pressure of O2 in arterial blood 
and Hb oxygen saturation [84].  
iii) a reduction in systematic vascular resistance with preferential 
perfusion (through vasodilation) of vital organs (e.g. myocardium and 
brain).  At the micro-circulatory level, capillary blood flow is increased 
and pre-capillary O2 loss is reduced. 
iv) an increase in O2 extraction. 
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v) in chronic anaemia, 2,3-diphoshoglycerate (2,3-DPG) concentration 
increases, which promotes the offloading of O2 to the tissues via a 
rightward shift in the ODC.  
vi) activation of hypoxic cellular mechanisms including neuronal nitric 
oxide synthase (nNOS) and hypoxic inducible factors (HIFs), which 
act to maintain O2 homeostasis.   
 
2.3 Haematological variables 
 
This section initially pertains to definitions of haemoglobin content, blood 
volume and plasma volume.  Thereafter I discuss measurement techniques to 
quantify blood volume and its component parts with particular focus on the 
optimised carbon monoxide rebreathing method to measure total haemoglobin 
mass. 
 
2.3.1 Haematocrit and haemoglobin concentration 
 
Haematocrit (Hct) represents the fraction of the blood volume comprised of red 
blood cells (normally expressed as a percentage) and is a measure of 
erythrocyte fraction/packed cell volume (PCV).  Because Hct is based on whole 
blood it is dependent on PV [85] and therefore may not reveal accurate 
information pertaining to actual red cell volume (RCV), although it is often used 
as a surrogate marker of RCV.  Therefore, for a ‘true’ assessment of red 
cell/haemoglobin mass, an independent measurement technique must be 
performed (see Section 2.3.5 for possible methods).  Assuming a normal PV 
(which may not always be the case) in women, the normal reference range for 
Hct is 37-41% and 42-47% for males [86].  Therefore, Hct provides the 
volumetric relationship between red blood cells and plasma and importantly, Hct 
allows RCV or PV to be calculated once we have measured the quantity of the 
other [86]. 
 
The amount of O2-carrying protein Hb in whole blood is termed the 
haemoglobin concentration ([Hb]) and is now expressed in grams of Hb per litre 
(g.l-1), previously grams per decilitre (g.dl-1).  The change in units was bought in 
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by the Pathology Harmony Haematology Sub-group [87] for the terminology of 
the full blood count (FBC) to standardise units of measurement for both [Hb] 
and mean corpuscular haemoglobin concentration (MCHC) across all 
laboratories in the UK. There is some discrepancy in what normal reference 
ranges to use for [Hb], although typically for males between 130-180 g.l-1 and 
females 120-160 g.l-1 have been used [88].  Our local Haematology and Blood 
Transfusion User Handbook at University College Hospitals NHS Foundation 
Trust reports [Hb] reference ranges of between 115-155 g.l-1 for females and 
130-170 g.l-1 for males [89].  Similar to Hct, the measured [Hb] value is also 
based on whole blood and is therefore highly dependent on PV.  
 
2.3.2 Blood volume 
 
BV is simply the sum of RCV and PV given that other whole blood components, 
specifically white blood cells and platelets comprise less than 0.1% of BV [90]. 
Like with many measurements in clinical and sports medicine, our interpretation 
of BV and its component parts in dependent on what is deemed normal.  
Traditionally, BV has been expressed relative to body weight (ml.kg-1) with 
different ratios for males and females used although this adjustment may 
discriminate against obese and underweight individuals [90].  Alternative scaling 
techniques may be more appropriate such as relating blood volumes to lean 
body mass, although this is rarely carried out in practice.  A wide range of 
average normal BV values have been reported (62-86 ml.kg-1), which likely 
accommodates population variations in body weight to include underweight to 
overweight individuals [91].  The 1995 International Committee on 
Standardisation in Haematology [92] recommends a normal range of ± 25% 
from the predicted norm while others have categorised BV based on the extent 
of deviation from predicted normal values [91]. 
 
2.3.3 Plasma volume 
 
PV specifically relates to the intravascular portion of the extracellular fluid 
volume with the extravascular compartment characterised by fluid within the 
interstitial space [93].  Plasma is composed of around 92% water with additional 
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solutes such as plasma proteins, the most abundant of which being albumin 
[86].  Extracellular fluid volume is maintained within tight limits to maintain 
homeostasis in normal humans [94].  However, PV can be affected by body 
posture, exercise, hydration status and certain types of medication (e.g. 
diuretics) and PV regulation is underpinned by hormonal, neural, renal and 
cardiac mechanisms with the kidney playing a pivotal role [95] [90]. In this 
context, fluctuations in PV may cause haemoconcentration or haemodilution 
without any actual change in tHb-mass or RCV and therefore relying on [Hb] or 
Hct alone may not provide an accurate reflection of O2 carrying capacity.  
 
Indeed, data demonstrate that CHF leads to expanded PV without any 
reduction in RCV, so called ‘pseudoanaemia’ [96]. Similarly, others have 
reported that in patients with advanced CHF, haemodilution is common and is 
associated with worsened survival compared to patients with ‘true’ anaemia, 
suggesting that volume overload may be an important factor in anaemic CHF 
patients [97].  In contrast, PV has been shown to be contracted compared to 
controls in clinically stable patients with CHF receiving standard 
pharmacotherapy [98].  Fluctuations in PV have also been shown in patients 
with liver cirrhosis [99, 100], chronic severe anaemia [101], and patients during 
haemodialysis [102]. 
 
These studies highlight the importance of and justification for measuring tHb-
mass or RCV and PV in addition to [Hb] and Hct and why [Hb] may be a poor 
guide of blood O2 carrying capacity in several clinical circumstances.  Despite 
this, there is a dearth of research assessing how well [Hb] reflects actual red 
cell mass across different patient populations and disease states. 
 
2.3.4 Total haemoglobin mass 
 
The total amount of Hb within the body, independent of compartmental fluid 
volumes is termed the total haemoglobin mass (tHb-mass) and is closely 
associated with the O2 carrying capacity of blood given that each gram of Hb 
has the capacity to maximally transport 1.39 ml of O2 and a trivial amount of O2 
is transported in plasma.  tHb-mass, a component of red cell volume largely 
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determines arterial oxygen content (CaO2), although CaO2 is also influenced by; 
i) [Hb], ii) the arterial oxygen saturation of Hb, iii) the binding capacity of Hb, iv) 
the actual arterial pO2 and, v) the physical O2 solubility of plasma [78].  
 
2.3.5 Measurement of blood volume and its component parts 
 
Validity, reliability and sensitivity are essential components of any measurement 
tool within clinical and sports medicine [103].  This section provides an overview 
of procedures used for the measurement of blood volume and its component 
parts (red cell volume and plasma volume), before moving on to discuss 
techniques to determine tHb-mass with particular focus on the optimised carbon 
monoxide rebreathing method.  
 
The measurement of BV has been used in clinical medicine for the evaluation of 
anaemia, blood loss, polycythaemia, endocrine disorders and CHF [104, 105] 
as well as other applications in sports medicine such as among chronic 
exercisers [106], assessing adaptations to blood doping [107, 108] and 
altitude/hypoxic exposure [107, 109].  Measurement techniques to determine 
BV and its component parts have a long history, very much founded on the 
work by Haldane and Smith more than 110 years ago [110].  The underlying 
principle for the measurement of absolute blood volume is based on the 
indicator dilution technique [104]. It is important to state that the methods used 
to measure BV are indirect and are based on the observed dilution of a known 
amount of some appropriate substance or tracer entering the blood stream [90] 
that can be precisely and reliably measured. Equation 2-6 below underpins the 
methods that follow the indicator and dye-dilution principle.  At its most 
simplistic level, if a known quantity of indictor (represented as A below) is 
administered into the system and its concentration (C) can be measured, then 
the desired, unknown volume (V) can be calculated. 
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Equation 2-6. Formula underpinning the indicator and dye-dilution principle 
 
V= C/A 
Rearranged as A= V x C 
 
Importantly, the other factor to consider is allowing sufficient time for complete 
and homogenous mixing of the indicator/tracer within the unknown volume.  In 
this regard, the equation below is fundamental: 
  
Equation 2-7. Time dependent indicator and dye-dilution principle 
 
C1V1 = C2V2 
Where: 
 
C1 = the concentration of the solution at baseline, prior to dilution 
C2 = final concentration of the solution, post dilution 
V1 = volume to be diluted 
V2 = final volume after dilution 
 
Based on Equation 2-7, a known amount of tracer (A), contained in a known 
volume (V1) with a known concentration (C1), is administered in to a system 
whose volume (V2) is unknown.  A sample from V2 is taken (after allowing 
sufficient mixing time in the circulation), thereafter the concentration of the 
tracer (C2) can be sampled.  Because the amount of tracer remains the same 
before and after mixing within the unknown volume, Equation 2-7 can be 
applied and rearranged (as shown in Equation 2-8 below) to calculate the 
unknown volume: 
 
Equation 2-8. Rearranged formular for time dependent indicator and dye-
dilution principle with a known amount of tracer 
 
V2= C1V1/C2=A/C2 
 
Techniques to measure blood volume include the use of radioactively labelled 
RBCs with chromium (51Cr) for the quantification of RCV, human serum albumin 
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labelled with iodine isotopes (131I or 125I) for the measurement of PV [111] and 
the Evans Blue method [112], which utilises a dilutional technique that 
measures PV by staining plasma proteins with dye [113, 114] and so does not 
involve the use of radioactive isotopes.  The use of radioactive 51Cr is widely 
considered the gold standard method for determining RCV in terms of accuracy 
[115, 116] as outlined by the International Committee for Standardisation in 
Haematology [116].  It is a common inaccuracy to use the terms red cell mass 
and red cell volume interchangeably as the 51Cr method is a primary estimate of 
BV because counts in whole blood are compared with reference counts in the 
assay with subsequent measured red cell volume derived from BV using Hct 
[117, 118].  The use of 131I or 125I for the direct measurement of PV has been 
recommended [116], although its accuracy for the indirect measurement of RCV 
has been questioned [117].  In addition, using radioactive tracers in this manner 
are not without concerns over the health risks of using radioactivity as well as 
the time and costs involved with these techniques, which may to some extent 
limit their applicability and frequent use in the clinical setting given that they are 
restricted to the domain of the nuclear medicine laboratory.  
 
Similar to the radioactive techniques discussed above, the measurement of 
tHb-mass is reliant on the dilution of a tracer such as carbon monoxide (CO).  
Inhaled CO is used because of its high binding affinity (some 220 times greater 
than O2 [119]) with Hb that ensures it is absorbed and homogenously distributed 
throughout the circulation, providing sufficient time is allowed for this to occur.  
CO was first proposed in this context as early as 1882 by Grehant and 
Quinquard [120] and subsequently by Haldane and Smith in 1900 [110].  Much 
more recently, modified techniques using CO rebreathing have been developed 
and refined by Thomsen and colleagues in 1991 [121], and Burge and Skinner 
in 1995 [122].  The Burge and Skinner method, which requires at least 10 
minutes of rebreathing and venous blood sampling displays superior reliability 
to the Evan’s blue dye technique and a high degree of validity when compared 
to the gold standard 51Cr method [117, 122].   
 
However, further refinement and optimisation of the CO rebreathing technique 
was undertaken by Schmidt and Prommer in 2005 [19].  Distinct and improved 
changes to the technique included a redesigning of the rebreathing spirometer 
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greatly enhancing the portability of the equipment and thus widening the 
settings in which the test can be performed, both in the laboratory and in the 
field.  In addition, the use of a CO bolus to increase the rate of CO uptake into 
the circulation resulted in only 2 minutes of rebreathing being required to 
achieve complete CO distribution throughout the circulation, compared to 10 
minutes of rebreathing in the Burge and Skinner method.  This reduces the 
burden on the athlete or patient and lessens the time per test and therefore the 
optimised CO rebreathing method may be considered appropriate for more 
routine and regular use in the clinical and sporting arena.   
 
Importantly, any measurement technique used to routinely assess tHb-mass 
must not be harmful or dangerous and should have negligible effects on 
physical performance and well-being, it should be inexpensive, user friendly 
and of low inconvenience for the patient or athlete.  Previous techniques for 
measuring tHb-mass and blood volume compartments do not appear to have 
fully achieved these requirements.  However, the 2-minute optimised carbon 
monoxide (CO) rebreathing (oCOR) method [19] provides an accurate, reliable 
and safe technique by which to quantify tHb-mass.  This method is minimally 
invasive and has the lowest measurement error when compared to other blood 
volume techniques [117]. Despite this there is a dearth of research in the 
clinical setting that has utilised the oCOR technique, something this thesis will 
in part address through its use.  
 
2.4 Definitions, prevalence and burden of disease  
 
The following section provides a summary of definitions, prevalence and burden 
of the disease groups studied in this thesis.  In particular, chronic heart failure 
(CHF), chronic liver disease (CLD), inflammatory bowel disease (IBD) and 
surgical patients (surgical) will be focused on.  Finally, I will discuss anaemia in 
the context of specific disease states; CHF, CLD, IBD and surgery. 
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2.4.1 Chronic heart failure 
 
The recently published European Society of Cardiology Task Force Guidelines 
for the diagnosis of acute and CHF [123] defines HF as “a clinical syndrome 
caused by cardiac abnormality of structural and/or functional origin that results 
in raised intracardiac pressures or impaired cardiac output at rest or under 
stress”.  Therefore, the measurement of left ventricular ejection fraction (LVEF) 
either by echocardiogram or cardiac magnetic resonance imagining (cMRI) is 
the primary means of defining HF [123], although levels of B-type natriuretic 
(BNP) and/or N-terminal pro-B type natriuretic peptides (NT-proBNP) are used 
as an adjunct [124] for patients suspected of having HF and/or when HF is 
suspected in the absence left ventricular dysfunction [128].  In the non-acute 
setting, commonly used cut off values denoting the upper normal limits for BNP 
are 35 pg ml-1 and 125 pg ml-1 for NT-proBNP, with higher values applied in the 
acute setting [126].  In terms of LVEF (%), when < 40% the term HF with 
reduced ejection fraction (HFrEF) is used, when 40-49% HF with mid-range 
ejection fraction (HFmrEF) and when  50%, HF with preserved ejection 
fraction (HFpEF) is used [123].  
 
HF is characterised by symptoms such as breathlessness, fatigue and ankle 
swelling that may occur alongside indications of elevated jugular venous 
pressure, peripheral oedema and pulmonary crackles [125].  The New York 
Heart Association (NYHA) class system, originally devised in 1923 [126] is the 
most widely used grading system to classify patients based on the severity of 
symptoms and the extent of functional impairment, see Table 2-1 on the 
following page.  
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Table 2-1. New York Heart Association Classification of heart failure 
symptoms. 
Class Symptoms 
I No limitations. Ordinary physical activity does not cause fatigue, 
breathlessness or palpitation.  
(Asymptomatic left ventricular dysfunction is included in this class) 
 
II Slight limitation of physical activity. Patients are comfortable at rest but 
ordinary levels of physical activity result in breathlessness, fatigue, 
palpitation or angina.  Patients in this class are considered to have 
symptomatically “mild” heart failure. 
 
III Marked limitation of physical activity.  Patients are comfortable at rest 
but less than ordinary physical activities lead to symptoms.  Patients in 
this class are considered to have symptomatically “moderate” heart 
failure.  
 
IV Inability to carry out any physical activity without discomfort.  Symptoms 
of heart failure are present even at rest and with any level of physical 
activity discomfort is increased.  Patients in this class are considered to 
have symptomatically “severe” heart failure.  
Amended from the National Institute for Health and Care Excellence (NICE) 
clinical guidelines for chronic heart failure [128].  
 
HF occurs in the presence of several co morbidities that complicate and 
negatively affect patient outcomes [127].  Specifically, hypertension, coronary 
artery disease, atrial fibrillation, and chronic kidney disease demonstrate a 
direct causal relationship with HF while other common co-morbidities with 
varying clinical relevance include chronic obstructive pulmonary disease, 
diabetes, renal dysfunction, obesity and anaemia (with or without iron 
deficiency) [128]. It is outside the scope of this thesis to discuss all HF co-
morbidities in detail but HF in the context of anaemia will be discussed in more 
detail below (see section 2.5.1). 
 
HF is a significant public health burden and remains a rising global epidemic 
with prevalence of > 37 million individuals affected worldwide [129, 130]. In the 
United Kingdom around 900,000 people have HF [131, 132] with about 63,000 
new cases each year [132], with HF burden greatest among the elderly [130]. 
These figures are likely to increase owing to the aging population and better 
management of heart disease [129].  Perhaps unsurprisingly, HF is associated 
with increased morbidity and mortality and therefore poor prognosis, although 
there has been a trend towards an improved HF prognosis over the past 10 
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year [125] as highlighted by a reduction in age-standardised death rates in 
England from 130.6 to 51.8 per 100, 000 people between 1981 to 2010 [133].  
Despite this, as many as 30-40% of patients diagnosed with HF die within a 
year [134].  
 
2.4.2 Chronic liver disease 
 
Chronic liver disease (CLD) results from a progressive and chronic insult to liver 
parenchyma over an extended period of time leading to fibrosis and cirrhosis 
[135]. The strongest risk factor for liver cirrhosis is excessive alcohol 
consumption [136], with other leading causes of CLD being viral (hepatitis B 
and C), and non-alcoholic fatty liver disease (linked to obesity and diabetes).  
Other causes of CLD are genetic (haemachromatosis), autoimmune 
(autoimmune hepatitis), primary biliary cirrhosis and primary sclerosing 
cholangitis [137]. 
 
The global burden of LD is significant in terms of mortality and morbidity, with 
more than 1 million deaths and 31,027,000 disability adjusted life years 
(DALYs) due to liver cirrhosis alone [138].  In Europe, each year 170,000 
deaths are related to liver cirrhosis (1.8% of all deaths) [137] and now in the UK 
CLD is the 3rd commonest cause of premature death [139].  Common 
complications of CLD include ascites, variceal bleeding, encephalopathy and 
hepatorenal syndrome [140].  
 
2.4.3 Inflammatory bowel disease 
 
Inflammatory bowel disease (IBD) encompasses two main relapsing disorders 
that are uncontrolled immune-mediated chronic inflammatory intestinal 
conditions, specifically Crohn’s disease (CD) and Ulcerative colitis (UC) [141].  
UC is non-transmural and commonly limited to the large bowel, whereas CD is 
transmural and can afflict the whole gastrointestinal tract [142], although UC 
and CD have overlapping clinical and pathological features [141]. On a global 
level there is significant variation in the prevalence of IBD taking into account 
geography, environment, immigration trends and ethnicity [143]. Updated in 
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August 2015, the World Gastroenterology Organisation Global Guidelines on 
IBD reported a European prevalence of 505 and 322 per 100,000 persons with 
UC and CD, respectively with an annual incidence of 24.3 and 12.7 per 100,000 
person-years for UC and CD [141].  
 
2.4.4 Surgery 
 
The global volume of surgery is vast, with an estimated 234 million major 
surgical procedures undertaken every year worldwide [144].  In England 
between 2013-2014 there were 4.7 million surgical admissions, an increase of 
27% from 2003-2004 with general surgery, trauma, orthopaedic and urology 
specialties showing the highest activity [145].  Data of over 46,000 unselected 
patients derived from 28 European countries included in the European Surgical 
Outcomes Study suggest that the crude mortality rate across all nations for 
patients undergoing inpatient non-cardiac surgery is 4%, with a median length 
of hospital stay of 3 (IQR 1-7) days, although wide variations existed across 
individual countries [146].  For example, in the UK crude in hospital mortality 
was 3.6% with values ranging from as low as 1.2% in Iceland to 21.5% in 
Latvia.  In addition, data on over 4 million inpatient general surgical procedures 
in 94 NHS hospitals (spanning January 1999 and October 2000) obtained from 
the Intensive Care National Audit & Research Centre (ICNARC) and CHKS 
database supports the assumption that deaths are most common in older 
patients with pre-existing comorbidities.  It is this ‘high’ risk population that, 
although comprising a relatively small percentage of surgical procedures 
(12.5%) accounts for a very large percentage of deaths (more than 80% in this 
cohort) [147].   
 
This highlights the need for effective perioperative strategies to improve 
outcomes in high risk patients in particular, but also raises the importance of 
utilising effective and precise tools to assess perioperative risk in patients 
undergoing major surgery in general [148].  In addition, optimisation of patients 
preoperatively may offer an important opportunity to improve outcome.  This 
may take the form of improving the management and treatment of pre-existing 
co morbidities (e.g. hypertension, diabetes, cardiovascular or respiratory 
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disease), optimising haemoglobin levels [149], enhancing cardiorespiratory 
fitness (prehabilitation [150, 151]) and through the adoption of enhanced 
recovery pathways [152].    
 
2.5 Anaemia 
 
The following section discusses the prevalence, causes and importance of 
anaemia in certain disease groups, specifically those patient groups studied in 
this thesis; chronic heart failure, chronic liver disease, inflammatory bowel 
disease and in patients awaiting surgery.  
 
2.5.1 Anaemia and chronic heart failure 
 
The prevalence of anaemia in CHF varies widely, in part related to a lack of 
consensus on a uniform definition, as well as comorbidities such as chronic 
kidney disease that may cause or worsen anaemia [153] and the clinical setting 
being studied (e.g. hospitalised patients, community/outpatient setting or 
patients included in randomised controlled trials) [154].  Regardless of the 
definition used or clinical setting, anaemia is common in patients with CHF, is 
related to the severity of disease and is associated with worsened symptoms 
and adverse outcomes [14] such as increased hospitalisations [155] and 
mortality [156].  A meta-analysis of 34 studies, comprising over 150,000 HF 
patients revealed 37% as anaemic (using criteria in the original articles to define 
anaemia) [157], and were almost twice as likely to die compared to non-
anaemic patients even after adjustment for confounding factors such as age 
and renal dysfunction.  A similar prevalence of 34% (this increased to 40% in 
patients aged > 70 years) was found in The Study of Anemia in a Heart Failure 
Population (STAMINA-HFP), a prospective study of over 1000 unselected 
outpatients with HF [158].   
 
The most common cause of anaemia in CHF is iron deficiency, although many 
factors might independently contribute to the development of anaemia, 
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including but not exhaustively; chronic kidney disease (renal dysfunction) [159], 
chronic inflammation [160] also known as anaemia of chronic 
disease/inflammation (ACD/ACI), drug related (e.g. ACE inhibitors [161] and 
some beta blockers [162]), bone marrow dysfunction [163], and of particular 
interest to this thesis, haemodilution [97].  In addition, anaemia prevalence 
increases with age and is slightly higher in men than women in cohorts aged > 
65 years [164].  
 
2.5.2 Anaemia and chronic liver disease 
 
Anaemia is a very prevalent haematological abnormality affecting patients with 
chronic liver diseases with a prevalence ranging from 50-75% being reported 
[165, 166].  There is a varied aetiology of anaemia in chronic liver disease 
[167], although a major cause is gastrointestinal haemorrhage (either acute or 
chronic) and hypersplenism linked to portal hypertension.  In addition, a 
consequence of serious hepatocellular disease is a reduction in liver-producing 
clotting factors that would normally assist in lessening the effects of 
haemorrhage [168].  Given that the measured [Hb] is also dependent on plasma 
volume and that plasma volume is normally expanded/increased in patients with 
cirrhosis as a result of ascites and/or oedema, dilutional anaemia should also 
be considered as an aetiology of anaemia in chronic liver diseases [166, 169].   
 
2.5.3 Anaemia and inflammatory bowel disease 
 
A recent European meta-analysis of over 2000 patients with IBD reported an 
overall anaemia prevalence of 24%, which was higher in patients with CD (27% 
compared to UC (21%) [7].  An earlier systematic review found varying 
prevalence figures for anaemia in IBD with included studies reporting a 
prevalence ranging from 10 to 73% in CD and 9 to 67% in UC [170], perhaps 
related to different definitions of anaemia used and the clinical settings studied.  
For example, anaemia prevalence appears higher in hospitalised patients 
compared to the outpatients setting [171].  Overall these figures support the 
finding that anaemia represents a well known complication in IBD [172]. 
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The most important causes of anaemia in IBD are iron deficiency, vitamin B12 
deficiency and anaemia of chronic inflammation [172], which is closely linked to 
the regulation of iron homeostasis [173] and development of a functional iron 
deficiency [174, 175].  The predominant reasons for a high prevalence of iron 
deficiency in IBD (36 to 90% have been reported, depending on the definition 
used and cohort studied [171]) are chronic intestinal blood loss associated with 
the depletion of iron and iron stores [176] and impaired iron absorption caused 
by inflammation [177]. 
 
2.5.4 Preoperative anaemia 
 
Approximately 25-30% of patients will present with anaemia prior to non-cardiac 
surgery. Data of 227,425 patients retrospectively extracted from the United 
States’ National Surgery Quality Improvement Program (NSQIP) database 
demonstrates a prevalence of anaemia across all patients undergoing operation 
of 30.4%, equating to 69, 229 patients [13].  A similar prevalence (28.7%) was 
later confirmed by prospectively collected data from 28 European countries in 
patients undergoing non-cardiac and non-neurological surgery [6].  
Furthermore, undertaking a meta-analysis of 897, 658 patients from fourteen 
studies, Fowler and colleagues [178] revealed a slightly higher prevalence of 
preoperative anaemia (40.3%) prior to non-cardiac surgery of various surgical 
specialities; vascular, orthopaedic, spinal, and upper gastrointestinal.   
Importantly, existing co-morbities (e.g. diabetes, heart failure, kidney disease 
and infection) and the condition or disease for which patients are undergoing 
surgery affects the reported prevalence of anaemia.  For example, up to 75% of 
patients with Dukes Stage D colon cancer may be affected by anaemia [179].   
 
These figures highlight that preoperative anaemia is a common affliction in the 
surgical patient and more prevalent than reported in the general population.   
Despite this, preoperative anaemia is often an incidental finding during pre-
surgical workup and regularly an overlooked and under managed condition.  
This is in spite of considerable, albeit associative evidence of a relationship 
between preoperative anaemia and an increased risk of postoperative morbidity 
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and mortality following both non-cardiac [6, 13, 178, 180] and cardiac surgery 
[181-183].   
 
2.6 Cardiopulmonary exercise testing (CPET) 
 
Cardiopulmonary exercise testing, commonly abbreviated as CPX, CPEX or 
CPET is considered the gold standard assessment of cardiorespiratory fitness.  
CPET allows whole-body O2 transport and utilisation to be estimated through 
the direct measurement of exertional O2 consumption (V̇O2) [51], which is 
dependent on the integrated and dynamic function of the cardiovascular, 
pulmonary and musculoskeletal systems in response to increasing metabolic 
stress.  CPET is used in sports medicine to assess the aerobic capacity of 
athletes and to monitor the effects of training and intervention longitudinally.  In 
the clinical arena, CPET is routinely used in management of patients with heart 
failure [184, 185] as well as many other heart and lung diseases [186] such as 
cardiomyopathy [187], ischaemic heart disease [188, 189], chronic obstructive 
pulmonary disease [190] and pulmonary vascular disease [191, 192].  
 
In the context of surgery, CPET is conducted for the purposes of preoperative 
risk assessment prior to major surgery to determine objective physical fitness 
and to assist in guiding appropriate level of postoperative care [193, 194].  The 
main CPET outcomes are the peak or maximal exertional oxygen consumption 
(V̇O2 peak or V̇O2max), being the highest or maximal rate at which O2 can be 
utilised during exercise (typically averaged over the final 30 seconds of 
incremental exercise) and the exertional O2 consumption at anaerobic threshold 
(V̇O2 at AT), defined as the point during incremental exercise when anaerobic 
metabolism begins to make a significant contribution to overall metabolism.  
Impairments in both V̇O2 peak and V̇O2 at AT (and thus an impaired 
physiological reserve above the resting state) are associated with an increased 
risk of postoperative morbidity and mortality [56, 58, 195] following major non-
cardiac surgery.  Conversely, it is deduced that a higher level of physical fitness 
(as quantified by an elevated V̇O2 peak and/or V̇O2 at AT during CPET) 
provides benefit (greater physiological reserve) to withstand the physiological 
insult of undergoing major surgery [51].   
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The original work by Older and colleagues almost two decades ago was the first 
to highlight an association between low functional capacity quantified by CPET 
and adverse patient outcomes following non-cardiopulmonary surgery [195].  
Specifically, a reduced cardiorespiratory reserve, defined as an AT of less than 
11 ml.kg-1min-1 being associated with an increased risk of adverse postoperative 
outcome following major intra-cavity surgery [196].  Similarly, impaired V̇O2 
peak has been shown to predict worse postoperative outcomes following major 
lung resection (V̇O2 peak < 20 ml.kg-1min-1 [197], < 15 ml.kg-1min-1 [198]) and 
bariatric surgery (V̇O2 peak < 16 ml.kg-1min-1) [199].   
 
2.6.1 Preoperative cardiopulmonary exercise testing and major surgery 
 
Major surgery can be defined as any intervention occurring in a hospital 
operating theatre involving the incision, excision, manipulation, or suturing of 
tissue, usually requiring regional or general anaesthesia or sedation [144].  The 
determinants of surgical outcome (morbidity and mortality) are related to an 
interaction between the health and fitness of patients, the number and severity 
of existing comorbidities present [200], as well as patient age and surgery-
related factors (emergency or planned, mode, type and duration).  In addition, 
the systemic inflammatory response caused by hormonal, immunological and 
metabolic mediators [201] is essential for effective tissue repair and healing 
after surgery.  Effective O2 delivery to the tissues during the hypermetabolic 
postoperative period is thought to be a fundamental determinant of surgical 
outcome [17, 202] with patients who are unable to raise O2 delivery to meet the 
increased postoperative V̇O2 requirements more frequently developing 
complications [203, 204].  The cause of this uncoupling of O2 supply and O2 
demand is multifactorial but may be predominantly linked to the interaction 
between a patient’s existing comorbidities (e.g. cardiac disease, respiratory 
disease, or indeed any condition that impairs O2 delivery &/or cardiac output) 
and the degree of surgical insult [205]. 
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It is acknowledged that although the V̇O2 response from an exercise test is not 
directly comparable to that in a patient postoperatively, common with exercise, 
V̇O2 postoperatively following major surgery is high [206].  For example 
preoperative resting V̇O2 has been shown to increase from 110 ml.min-1.m-2 to 
approximately 170 ml.min-1.m-2 [207, 208] indicating a greater postoperative O2 
requirement and demand.  In this context, tHb-mass may be important to 
surgical outcome due to its role in determining O2 delivery.  This may be related 
to the close linear relationship that exists between tHb-mass, BV, Q̇ and aerobic 
capacity [209].  For example, a high BV is a prerequisite for a high tHb-mass, 
which in turn impacts upon Q̇ by elevating venous return and cardiac filling 
pressures [210, 211].  Because tHb-mass in combination with PV also governs 
[Hb] and therefore O2 carrying capacity, the effects of tHb-mass on determining 
O2 delivery are twofold. Given the association between markers of 
cardiorespiratory fitness (V̇O2 peak and AT) and surgical outcome, it would 
seem intuitive that a high tHb-mass may confer a survival advantage in the 
perioperative setting.  If this is the case, then strategies aimed at elevating tHb-
mass may improve outcome (morbidity and mortality) following surgery, but this 
remains to be confirmed in appropriately powered studies.  Given that anaemia 
is associated with an increased risk of adverse surgical outcome, it would be 
surprising if this relationship were not maintained for tHb-mass.   
 
2.7 Haemoglobin and physical function 
 
The following section reviews the effects of manipulating [Hb] on exercise 
capacity before discussing the association between changes in total 
haemoglobin mass and physical fitness.  
 
The manipulation of Hb has historically been achieved through the transfusion 
of packed RBCs or erythropoietin stimulating agents such as recombinant 
human erythropoietin (rhEPO).  rhEPO artificially stimulates erythropoiesis in 
addition to that which occurs naturally as a result of the glycoprotein hormone, 
erythropoietin (EPO) produced in the kidney [212].  Both methods, rhEPO and 
blood transfusion ultimately increase the numbers of circulating erythrocytes 
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and therefore the amount of O2 carried in whole blood.  This knowledge forms 
the physiological basis for the systematic and illegal practice of blood doping 
undertaken by an alarming number endurance athletes and coaches in the 
past.  The assertion is that elevated [Hb] increases arterial O2 content and 
systemic O2 transport (increasing DO2 relative to V̇O2) with the additional O2 
available to the working muscles resulting in an increased V̇O2max and athletic 
performance (e.g. faster running time, higher power output during cycling, etc) 
[213].  These same mechanisms (potential for increased DO2 and increased 
physiological reserve) may also play an important role in the perioperative 
period.   
 
2.7.1 Reductions in haemoglobin concentration and associations with exercise 
capacity 
 
A consistent finding in the following literature is that a reduction in [Hb] has a 
discernible effect on V̇O2max and to a greater extent on exercise endurance that 
is proportionate to the reduction in O2 carrying capacity.  Ekblom and 
colleagues [214] demonstrated in four participants a 13% reduction in [Hb] 
reduced V̇O2max (measured during maximal treadmill running) by 10% (from 
4.54 to 4.09 l.min-1), although a greater detriment was seen in submaximal 
cycling endurance time, which decreased by 30% from 5.77 to 4.04 minutes, 
following a single venesection of 800 ml of blood.  In the same study an extra 4 
participants underwent serial venesections of 400, 800, and 1200 ml of whole 
blood (4 days in between each) resulting in a fall in [Hb] of 10,15, and 18%, 
respectively.  These reductions were manifested by a similar impairment in 
V̇O2max (6, 10, and 16% reduction) and submaximal cycling endurance times 
(13, 21, and 30% reduction).   
 
Similarly, Ekblom and colleagues [215] aimed to investigate the effect of 
different levels of arterial O2 content on central circulation during both 
submaximal cycle ergometry and maximal treadmill exercise.  After venesection 
of 800 ml of whole blood, CaO2 was reduced by 10% and V̇O2max decreased 
from 4.27 to 4.03 l.min-1 (a 6% reduction).  CaO2 was reduced post venesection 
during both submaximal cycling (from 182 to 166 ml.l-1) and maximal running 
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performance (from 199 to 179 ml.l-1) and this was related to the change in [Hb] 
given that SaO2 remained unchanged.  Additionally, while exercising at higher 
submaximal workloads during cycle ergometry, blood lactate concentrations 
were lower in the “normal” state (5.9 mM) compared to the post venesection 
state (7.6 mM), which was inversely related to CaO2 and suggests a reduced 
anaerobic energy contribution in a situation where O2 availability is increased.  
This would suggest that one consequence of anaemia may be a greater lactate 
production during exercise [216].  
 
Other authors to have reported similar findings include Balke and colleagues 
[217] who showed a 9% decrease in V̇O2max 1 hour after a 500 ml blood 
donation, Woodson and colleagues [218] who showed V̇O2max decreased by 
16% after a 34% reduction in [Hb], and to a lesser extent Kanstrup and Ekblom 
[219] who demonstrated a 9% reduction in V̇O2max and 40% lower endurance 
time at the intensity eliciting V̇O2max after removing 900 ml of whole blood 
(resulting in an 11% reduction in [Hb]).  Finally, Rowell and colleagues [220] 
showed a modest 4% decrease in V̇O2max following a 14% decrease in [Hb] 
after repeated venesections equating to 700-1000 ml over a 5 day period.  The 
smaller detriment in observed V̇O2max (4%) by Rowell and colleagues may be 
explained by the use of the Astrand and Rhyming nomogram [221] as this has 
been shown to underestimate V̇O2max [220]. 
 
V̇O2max is the primary fitness outcome variable used in the majority of studies in 
this area, principally as it is the gold standard assessment of cardiorespiratory 
fitness and is largely considered to be constrained by the limits of the 
cardiovascular system.  However, V̇O2max does not reflect the submaximal step-
change metabolic demands encountered in every-day life such as when running 
for a bus or walking up stairs. Less is known about the impact of changes in 
[Hb] on submaximal markers of cardiorespiratory fitness, which the following 
section explores.  
 
Burnley and colleagues [222] investigated the influence of blood donation on 
V̇O2 uptake kinetics, V̇O2 peak and time to exhaustion during severe-intensity 
cycling.  The donation of approximately 450 ml of whole blood caused around a 
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5% decline in [Hb], from 15.4 to 14.7 g dl-1 and a reduction in haematocrit from 
44 to 41%.  This corresponded to a 54 second (14%) reduction in the time to 
exhaustion and around a 4% decline in measured V̇O2 peak.  Interestingly, the 
fall in [Hb] following blood donation was not related to the change in V̇O2 peak 
but was associated with the change in time to exhaustion (r= 0.57).  In contrast 
to previous studies, no differences were found in blood lactate values at the end 
of exercise after blood donation [218, 219].  In addition, blood donation had no 
effect on the speed of V̇O2 on-kinetics, a finding in keeping with previous 
investigations in this area [223].  This may suggest that the relatively small 
reduction in O2 delivery post blood withdrawal in this study was insufficient to 
affect V̇O2 kinetics or that adjustments in Q̇ (or its distribution to tissues) was 
sufficient to preserve muscle O2 delivery.  Nonetheless, this study confirms the 
importance of blood O2-carrying capacity as a determinant of V̇O2 peak and to a 
greater extent exercise endurance, the latter perhaps being a more valid marker 
of functional status than V̇O2 peak when relating to activities of daily living, 
which are in general not performed at a maximal level of physical exertion. 
 
Fritsch and colleagues [224] reported CPET data in 16 young healthy 
participants performing cycle ergometry before and two days post a single 
blood donation of 450 ml with resultant [Hb] falling from 14.5 to 13.0 g.dl-1.  The 
AT was reduced two days after blood donation when expressed as a 
percentage of V̇O2max (68.5 vs 52 %) and in absolute V̇O2 at the AT.  Similarly, 
data from Japan [225] suggest that the AT is lower in patients with iron 
deficiency anaemia compared to non-athletic controls (AT 15.9 ± 3.3 versus 
21.3 ± 1.3 ml kg-1 min-1, p< 0.01) and is susceptible to change following iron 
supplementation when [Hb] is increased ([Hb] 9.0 ± 1.8 to 12.1 ± 0.8 g.dL-1), AT 
(20.9 ± 6.3 to 25.0 ± 8.0 ml kg-1 min-1, p< 0.001). 
 
A reduction in [Hb] and thus in O2 carriage may impair exercise capacity in 
several ways.  Firstly, a lower arterial O2 content will reduce O2 availability to 
the skeletal muscle for the same muscle blood flow [222].  Secondly, muscle O2 
diffusing capacity is lower when Hb is reduced, in part related to changes in the 
spacing between capillaries of erythrocytes and/or slower O2 
dissociation/unloading of O2 from Hb [226].  Thirdly, a reduction in blood volume 
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as a result of acute blood withdrawal may impact upon aerobic capacity as 
changes in BV affect cardiac function, in particular ventricular preload via the 
frank-starling mechanism and thus influence the dispatch of O2 per beat by 
altering SV and Q̇ (both being important determinants of V̇O2 as described in 
the Fick equation) [227, 228]. 
 
Similar mechanisms may underpin the reduced AT observed when [Hb] falls but 
this is a much-debated and controversial concept [229, 230].   As previously 
eluded to, the AT represents the highest V̇O2 before the metabolic demands of 
tissues (mitochondria) outstrips O2 supply, and aerobic ATP resynthesis is 
supplemented by anaerobic metabolism leading to increased lactate production 
relative to the rate of glycolysis [231].  The AT is therefore an important marker 
of cardiorespiratory fitness as it provides an assessment of the ability of the 
cardiovascular system to supply O2 at a rate adequate to prevent muscle 
anaerobiosis [52].  If this is the case, then a reduced capacity to supply O2 to 
actively respiring tissues caused in part by low [Hb] or cardiovascular disease 
has the potential to reduce the AT. 
 
2.7.2 Increases in haemoglobin concentration and changes in exercise 
capacity 
 
Most published research studies discussed thus far have shown an association 
between a reduction in [Hb], impaired maximal exercise capacity and 
submaximal endurance.  Is the converse true when [Hb] is artificially elevated? 
The following section explores this question. 
 
Underpinned by the early work of Pace and colleagues in 1947 [232], a number 
of authors have reported data clearly showing that when [Hb] is elevated by the 
infusion of packed RBCs there is a reciprocal increase in V̇O2max [214, 215, 
233-239], see Figure 2-3 below.  Where studies failed to find such a relationship 
[240] between an elevated [Hb] and physical fitness this may in part be 
explained by the quantity of blood reinfused being insufficient, or there being 
inadequate time for the body to adapt to its normal [Hb] after venesection [216].  
When these factors are appropriately controlled for, elevating [Hb] increases 
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V̇O2max and endurance performance [233].  V̇O2max &/or exercise endurance has 
also been shown to increase in circumstances where [Hb] has been elevated by 
administering rhEPO in healthy individuals [241, 242], athletes [243], 
haemodialysis patients [244, 245] and patients with HF [246, 247] as well as 
following iron supplementation in young trained females [248]. 
 
 
Figure 2-3. Relationship between the % change in haemoglobin 
concentration ([Hb]) and % change in V̇O2max.  Each data point represents 
the mean of each study using data obtained during the first 48 h after 
haemoglobin manipulation.  Figure taken with permission from Calbet and 
colleagues [249] using data from 9 individual studies [214, 215, 217, 220, 
234-236, 250].  
 
In the clinical setting, the effects of blood transfusion on objectively measured 
cardiorespiratory fitness in adults is less well described, although the beneficial 
effects of blood transfusion on improving [Hb] and exercise capacity has been 
shown in children [251, 252] and young adults [253] with thalassemia.  In a 
small study of anaemic adult patients with stable haematological conditions, 
Wright and colleagues [254] aimed to address this by studying the effects of 
blood transfusion on exercise capacity measured objectively with CPET 
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performed prior to and 3-5 days post transfusion of allogeneic packed red blood 
cells.  Included patients were those aged over 18 years requiring transfusion for 
chronic anaemia as part of their routine hospital care.  In eighteen patients, the 
mean ± SD AT increased from 10.4 ± 2.4 to 11.6 ± 2.5 ml kg-1 min-1 following 
transfusion of a median (range) of 3 (1-4) units of packed red cells (mean ± SD 
increase in [Hb] from 83 ± 12 to 112 ± 14 g.l-1 after transfusion).  However, in 5 
patients the AT failed in increase following transfusion, perhaps related to a 
smaller increase in [Hb] in this group compared to patients in whom AT did 
significantly improve.  Improvements in V̇O2 peak [(mean difference post 
transfusion (95% CI) of 1.5 (0.3-2.7) ml kg-1 min-1)] and other CPET variables 
[(ventilatory equivalent for carbon dioxide (V̇E/V̇CO2) at AT, oxygen uptake 
efficiency slope and peak work rate)] were also noted.   
 
Although the increase in AT following transfusion was statistically and 
significantly different, the mean difference was only 1.2 (95% CI 0.2-2.2) ml kg-1 
min-1.  Whether this would constitute a meaningful and clinically significant 
change remains to be confirmed but is nonetheless an encouraging finding 
given the wider perioperative context in which this paper was conducted and 
written.  In the perioperative setting, optimising Hb and physical fitness 
(improving AT and V̇O2 peak) in patients prior to surgery may reduce 
perioperative risk and improve surgical outcome.  This is certainly the founding 
hypothesis underpinning ‘prehabilitation’ before major surgery, although 
improvements in patient outcomes remain to be confirmed with adequately 
powered, randomised controlled trials, something that the PREVENTT: 
preoperative intravenous iron to treat anaemia in major surgery trial [149] aims 
to address in the context of preoperative anaemia.  In the context of 
preoperative physical fitness, trials are planned to determine whether improving 
V̇O2 at AT following structured in-hospital exercise training leads to improved 
overall survival following major cancer surgery [255]. 
 
In the study by Wright and colleagues [254], it would also have been of interest 
to quantify the change in tHb-mass, blood and plasma volumes after transfusion 
in addition to the change in [Hb], as the measurement of tHb-mass may allow 
changes in Hb following intervention to be measured with greater precision than 
relying on [Hb] alone.  In addition, the relative contribution of tHb-mass and 
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plasma volume to the change in measured [Hb] post transfusion could also 
have been elucidated, which may have been of use in those patients where the 
change in [Hb] was small and in those where AT failed to increase.  Future 
studies may wish to use tHb-mass in this context as the primary haematological 
outcome variable.    
 
2.7.3  Are changes in total haemoglobin mass associated with alterations to 
aerobic capacity? 
 
A stronger relationship is consistently observed between markers of 
cardiorespiratory fitness and tHb-mass than with either blood volume or [Hb] 
[256] in athletes and healthy volunteers.  Procedures to increase tHb-mass 
result in elevated V̇O2max, whereas the opposite is true when tHb-mass is 
reduced [250].  
 
Karpovich and Millman in 1942 [257] were first to present data linking tHb-mass 
to exercise performance, specifically that a reduction in tHb-mass impaired 
athletic performance.  After blood donation of 500 ml, performance during cycle 
ergometry dropped considerably and remained depressed for 3 weeks before 
recovering to pre-donation performance levels.  The same authors [260] 
highlighted that this effect may be greatest in endurance athletes than in 
athletes performing shorter duration events (i.e. with a greater reliance on 
anaerobic energy systems).  For example, when blood donation occurred in a 
long-distance swimmer and cross-country runner their performance was 
markedly reduced whereas performance in two sprint-based athletes equalled 
their best within a few hours after blood donation.   
 
Similarly, another early study by Kjellberg and colleagues [258] described the 
relationship between BV, tHb-mass and aerobic performance in individuals of 
varying levels of training status. BV and tHb-mass were lower in untrained 
males (BV 75 ml.kg-1 and tHb-mass 11.5 g.kg-1) compared to moderately trained 
athletes (BV 90 ml.kg-1 and tHb-mass 13.6 g.kg-1) and elite athletes (BV 103 
ml.kg-1 and tHb-mass 15.7 g.kg-1), respectively.  The same trend was observed 
in females, albeit at an expected lower absolute level (approximately 10% in 
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this case). If tHb-mass is lowest in untrained individuals, who are otherwise 
healthy yet sedentary, would it be expected that in individuals with 
pathophysiology for tHb-mass to be lower still when compared to ‘normal’ 
individuals? 
 
Subsequently, a close association between tHb-mass and V̇O2max (r= 0.97) was 
observed in the early 1950’s by Astrand [259], where differences in maximal 
aerobic capacity between adults and children and between men and women 
were related to differences in total Hb (see Figure 2-4).  This initial investigation 
laid the foundation for much of the subsequent work in relation to total body Hb 
and aerobic capacity.  
 
 
Figure 2-4. Relationship between total body haemoglobin (between 100 to 
900 g) and absolute maximal oxygen consumption (V̇O2max) in 94 
individuals aged 7-30 years [259].  Figure taken from [260]. 
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In a study assessing BV and [Hb] as determinants of maximal aerobic power, 
Kanstrup and Ekblom [250] utilised the chromium (51Cr) labelled erythrocyte 
technique to quantify RCV in addition to measuring BV, PV, [Hb] and Hct.  
Results suggested that an elevation in V̇O2max and physical performance may 
be obtained by an increase in the product of [Hb] and BV, being the tHb-mass.  
Decreased [Hb] in the presence of an unchanged BV (lower O2 carrying 
capacity) reduces V̇O2max and exercise performance [215] and emphasises the 
importance of tHb-mass as a determinant of O2 carrying capacity and V̇O2max.   
 
A number of other cross-sectional studies have demonstrated a strong positive 
association between V̇O2max and tHb-mass including Gore and colleagues [29] 
who studied a cohort of trained athletes: female rowers (n= 17, r= 0.92, 
p<0.0001), male rowers (n= 12, r= 0.79, p < 0.005) and male runners (n= 33, r= 
0.48, p = 0.005), and Heinicke et al [261] who investigated BV and tHb-mass in 
elite athletes of different disciplines (downhill skiing, swimming, running, 
triathlon, junior and professional cycling).  V̇O2max was significantly related to 
tHb-mass not only in the whole group but also in all endurance disciplines.  
When tHb-mass has been increased through the use of rhEPO, reciprocal 
increases in  V̇O2max have been reported.  Specifically, V̇O2max increased by 6-
7% in 27 recreational athletes after an increase in tHb-mass of 7-12% after 
rhEPO use [262].  Similarly, a recent study in 19 trained men showed an 
improved 3,000 m running time trial performance (11:08 ± 1:15 min:sec to 10:30 
± 1:07 min:sec, p<0.001) following 4 weeks of rhEPO administration.  This 
improved performance coincided with a rhEPO-induced increase in V̇O2max 
(56.0 ± 6.2 ml.kg-1min-1 to 60.7 ± 5.8 ml.kg-1min-1, p<0.001) and tHb-mass (12.7 
± 1.2 g.kg-1 to 15.2 ± 1.5 g.kg-1, p<0.001) [263].  
 
Conversely, after a 550 ml venesection of whole blood in 9 moderately trained 
male and female athletes, tHb-mass was reduced by on average 77 ± 21 g 
[264].  This was significantly associated with a reduced absolute V̇O2max (255 ± 
130 ml.min-1 one day after phlebotomy) and was still decreased on day ten (197 
± 116 ml.min-1).  The authors also observed supressed endurance performance 
during this period of lower tHb-mass, although this was not objectively 
58 
quantified.  On a similar note, periods of inactivity or detraining have been 
shown to reduce tHb-mass with associated reductions in aerobic capacity [265].  
This finding could have important implications for individuals exposed to 
prolonged periods of bed rest or those recovering from surgery where levels of 
physical activity are in general very low. 
 
What can we expect a change in aerobic capacity to be from a given change in 
tHb-mass? This is an important question because we can predict likely 
improvements in functional capacity as a result of an intervention to enhance 
tHb-mass.  Schmidt and Colleagues [266] studied 144 male athletes from 
various specialities with absolute V̇O2max values ranging from 1010 to 6320 
ml.min-1 and tHb-mass from 242 g to 1453 g.  The authors found that V̇O2max 
was closely related to tHb-mass over the whole physiological range indicating 
that a change in tHb-mass of 1 g was associated with a change in V̇O2max of 4.4 
ml.min-1.  In addition, tHb-mass was most closely related to lean body mass 
(LBM) with 16.8 g of Hb per 1 kg LBM.  The value of 4.4 ml .min-1 is very close 
to that reported by Gore and colleagues [29] and to that recently reported by 
Schmidt and Prommer in an excellent review article in this area [209] whereby a 
change in tHb-mass of 1 g was associated with a change in V̇O2max of 
approximately 4 ml.min-1.   
 
Undertaking a meta-analysis to understand the dependency of V̇O2max on tHb-
mass and BV, Schmidt and Prommer [256] pooled data from 611 subjects.  
V̇O2max was determined using either incremental cycle ergometry or treadmill 
running, with values obtained from treadmill exercise reduced by 7% to account 
for the greater muscle mass utilised compared to cycling.  tHb-mass was 
measured in all subjects using the oCOR method (described in detail in Chapter 
3 of this thesis).  Results from linear regression revealed that a change in tHb-
mass by 1 g.kg-1 was associated with a change in V̇O2max of 4.4 ml.kg-1min-1 
(males 4.2 ml.kg-1min-1, females 4.6 ml.kg-1min-1), showing a strong relationship 
(r = 0.79). For BV, a similar close relationship (r = 0.76) was observed whereby 
a change in BV of 1 ml.kg-1 was related to a change in V̇O2max of 0.7 ml.kg-1min-
1, in keeping with previous work by Convertino that showed a similar 
relationship between BV and V̇O2max (r = 0.78) [267]. Interestingly, no significant 
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relationship between V̇O2max and [Hb] (males, r = 0.03, females, r = 0.12) or 
haematocrit (males, r = 0.08, females, r = 0.11) was observed.  The stronger 
relationship between tHb-mass and V̇O2max than other haematological markers 
highlights that fact that a high tHb-mass is an important determinant of a high 
aerobic capacity and that alterations in tHb-mass have the potential to change 
V̇O2max and potentially submaximal indices of physical fitness.  
 
2.7.4 Clinical applications of measuring total haemoglobin mass and 
associations with exercise capacity 
 
A dearth of literature exists at present that has measured tHb-mass in the 
clinical setting and investigated its association with markers of cardiorespiratory 
fitness.  Research studies that have quantified tHb-mass and markers of 
physical fitness have studied patients with renal failure [268, 269], type 1 
diabetes mellitus (T1DM) [49] and COPD [270].  The measurement of tHb-mass 
has also been reported in patients with CHF [96], polycythaemia [48] and 
patients with stable coronary artery disease [50], although not in relation to 
physical fitness.  I will briefly discuss those studies that have assessed tHb-
mass and objectively quantified physical fitness in the clinical context.  
 
Clyne and colleagues [268] prospectively studied 20 predialytic uraemic 
patients aged 43 ± 12 years.  Nine patients were tested on two occasions; the 
second testing being carried out after an average of 17 ± 5 months.  The study 
aimed to assess the factors limiting working capacity in this patient group.  
Exercise testing comprised two cycle ergometry tests; firstly, a test to measure 
maximal aerobic capacity using a stepwise increase in work rate (10-20 watts 
per minute) and secondly a series of steady state work rate increments (of 20-
50 watts) that increased every 4 minutes to facilitate the measurement of blood 
lactate levels in capillary blood.  tHb-mass was determined by the alveolar 
carbon monoxide method [271] and BV derived from tHb-mass and [Hb].  
Markers relating to chronic kidney disease were also measured and included 
the estimation of glomerular filtration rate (eGFR), serum calcium, phosphate, 
albumin and parathyroid hormone concentration (PTH).  Overall, maximal 
exercise capacity was impaired in patients with moderate to severe uraemia 
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compared to age and sex-matched healthy reference values.  Of particular 
interest in this study were those patients monitored longitudinally.  A decrease 
in steady state exercise capacity of almost 20% was observed between the first 
and second tests with this impairment being associated with an earlier blood 
lactate accumulation (indicative of an earlier reliance on anaerobic metabolism) 
and a reduction in tHb-mass as uraemia progressed.   
 
Similar findings were later reported by the same research group showing that a 
progressive decline in renal function induced a gradual decrease in tHb-mass 
and exercise capacity [269].  Specifically, 58 patients (45 ± 12 years) were 
studied with an eGFR ranging from 3 to 32 ml min-1, allowing the effects of a 
progressive decline in renal function on tHb-mass and exercise capacity to be 
studied.  tHb-mass and eGFR were partially correlated (adjusting for age and 
sex), r= 0.39, p <0.005; with maximal exercise capacity and tHb-mass showing 
a significant, albeit weak partial correlation (adjusting for age, sex and eGFR), 
r= 0.27, p < 0.05.  The authors commented that tHb-mass was measured rather 
than [Hb] or blood volume to avoid the possible effects of hypervolemia or 
diuretic therapy related hypovolemia.  Clyne and colleagues [269] concluded 
that anaemia appears to contribute towards the observed reduction in maximal 
exercise capacity in the cohort of patients studied.  
 
Kaponen and colleagues set out to answer two study questions in men with 
T1DM, firstly whether patients with T1DM (with normal kidney function) have 
similar blood O2 carrying capacity (defined by [Hb], tHb-mass and RCV) 
compared to controls, and secondly whether O2 carrying capacity influences 
V̇O2max similarly in diabetic patients compared to controls?  A similar [Hb] in 
patients with T1DM (14.4 g dl-1) and controls (14.5 g dl-1) was found, but lower 
tHb-mass (10 g.kg-1vs. 11 g.kg-1), BV (77 vs. 84 ml.kg-1) and V̇O2max (35 ml.kg-
1min-1 vs. 45 ml.kg-1min-1) in the T1DM group.  In patients with T1DM both tHb-
mass (51%) and blood volume (45%) explained a large proportion of the 
variance in V̇O2max and when compared to age- and leisure-time physical 
activity matched controls showed a shallower linear regression slope between 
V̇O2max and tHb-mass (2.4 ml.kg-1min-1 vs. 3.6 ml.kg-1min-1, respectively).  
Therefore, for a given tHb-mass and BV, patients with T1DM had a reduced 
V̇O2 compared to controls.  This study appears to confirm that the 
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measurement of tHb-mass may provide useful additional information as an 
early and sensitive marker of blood O2 carrying capacity than measuring [Hb] 
alone, given that there were no differences in [Hb] between the T1DM and 
control groups [49].   
 
In patients with COPD, repeated exposure to short-term hypoxia, termed 
‘interval hypoxia’ provides a potential therapeutic intervention to increase 
exercise tolerance.  Burtscher and colleagues [270] provided evidence that 
improvements in exercise tolerance may in part be related to changes in tHb-
mass following such intermittent hypoxic exposure.  In a double-blinded, 
randomised controlled trial in eighteen patients at risk of, or with mild COPD 
(aged 33-72 years), tHb-mass increased by 4%, and was positively related to a 
significant change in total exercise time (+10% increase, r= 0.59), time to reach 
AT during CPET (+13% increase) and the change in V̇O2 peak (r= 0.49) 
following a 3-week intervention of intermittent hypoxic exposure (totalling 15 
sessions).  Such hypoxic exposure is commonplace in endurance athletes who 
regularly attend altitude training camps and/or sleep in altitude tents to mimic 
the effects of hypoxia whilst the athlete remains at sea level.  The results of the 
study by Burtscher and colleagues [270] are promising and may have wider 
implications to a range of patient populations where increasing tHb-mass and 
physical fitness may be advantageous (e.g. prior to major surgery).  In addition, 
this study adds further evidence highlighting the benefits of measuring tHb-
mass in conjunction with more routine haematological markers of O2 carrying 
capacity such as [Hb] and Hct, which showed no significant change in either the 
hypoxic or normoxic group in this study following intervention.  
 
The result of Burtscher and colleagues [270] and also those of Kaponen et al 
[49] raise the following discussion.  If [Hb] alone had been used to define O2 
carrying capacity, then it would have been assumed unchanged ([Hb] of around 
145 g.l-1) in both patients with T1DM and healthy controls in the study by 
Koponen and colleagues and 145 g.l-1 vs 146 g.l-1 pre-and post-hypoxic 
exposure in the study by Burtscher and colleagues.  Thus, deficiencies in blood 
O2 carrying capacity may be masked if [Hb] is used in isolation due to 
compartmental fluid shifts confounding results.  [Hb] is determined by tHb-mass 
and circulating PV, thus a substantial reduction in O2 carrying capacity, related 
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to a low tHb-mass, may thus be masked if PV is contracted, as may be the case 
in many disease states.  Similarly, increases in PV may decrease [Hb] even in 
the context of a normal tHb-mass.  Therefore, without knowledge of tHb-mass 
and PV, our interpretation of [Hb] may be limited.    
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Chapter 3 
3 General methodology 
 
Chapter three outlines the methods I have used during this thesis.  Firstly, I 
begin with a thorough overview of the oCOR method, in particular the specific 
equipment required, the procedures involved, blood sampling and the 
subsequent calculation of tHb-mass.  Despite being the most widely used 
method to quantify tHb-mass in sports medicine, the oCOR method has been 
rarely applied in the clinical setting.  I use the oCOR method in Chapters 4, 5, 
and 6 which follow.  Secondly, I provide a detailed description of the methods 
relating to CPET, its conduct, equipment, calibration and key CPET variables 
(AT and V̇O2 peak).  I utilise CPET in Chapter 6 to quantify exertional V̇O2 at AT 
and V̇O2 peak as markers of cardiorespiratory fitness prior to surgery. 
 
3.1 Optimised carbon monoxide rebreathing method (oCOR) 
 
Total haemoglobin mass was determined using the optimised carbon monoxide 
rebreathing method described in detail by Schmidt and Prommer [19].   This 
method consists of a 2-minute rebreathing procedure of a known CO volume 
(0.5 to 0.9 ml of CO per kg of body mass in this thesis, depending on gender 
and clinical status, with some adjustment for [Hb], body mass index and the 
general status of the patient).  Each participant was seated for 15 minutes prior 
to testing to allow stabilisation of plasma volume, after which a mouthpiece 
containing approximately 10 g of soda lime (carbon dioxide scrubber) 
connected them to a spirometer (Spico-CO Respirations-Applikator, Blood Tec, 
Bayreuth, Germany) and a 3-litre anaesthetic bag pre-filled with pure medical 
grade oxygen (see  
Figure 3-1).  Thereafter the patient completely exhaled to residual volume and 
was then instructed to take a deep breath in through the spirometer as the CO 
dose was administered via a pre-filled 100 ml syringe.  Consequently, all the 
CO was inhaled in the first fraction of the breath and subsequently distributed 
within the alveoli.  Given that the affinity between Hb and CO is some 220- to 
240- times greater than that of Hb and O2 [119], the majority of CO will diffuse 
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into the bloodstream within the first few seconds after inhalation.  To further 
support the diffusion of CO into the bloodstream, patients held their breath for 
10 seconds after the first inspiration, after which they continued normal 
breathing from the spirometer for a further 1 minute 50 seconds.  The 
participant was disconnected after exhaling to residual volume, which is 
necessary to quantify the CO not absorbed into the bloodstream.  Finally, 
participants fully exhaled to residual volume into a CO gas analyser with parts 
per million sensitivity (Dräger Pac 7000, Drägerwerk AG & Co. KGaA, Bayreuth, 
Germany) before and at minute 4 after CO rebreathing to quantify the CO that 
was not taken up by the body.  In addition, to confirm that there was no gas 
leakage during rebreathing, the portable CO monitor was placed near the nose, 
mouth and spirometer throughout the 2-minute rebreathing phase.   
 
 6
4
 
 
 
 
Figure 3-1. Custom made spirometer developed for the optimised carbon monoxide rebreathing method by Schmidt and Prommer.  (A) 
oxygen (O2) tube, (B) O2 valve, (C) valve of the O2 reservoir, (D) prefilled CO syringe (100 ml capacity), (E) adapter to enable mouth 
piece connection, (F) netting bag of soda lime (CO2 scrubber), (G) sleeve, (H) mouth piece, (I) 3 litre anaesthetic bag (containing pure 
medical grade O2). Taken from the original paper by Schmidt and Prommer [19]. Patent numbers: US20050075552 A1; DE10222750C1. 
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3.1.1 Blood sampling 
 
At UCLH, [Hb] was collected (Hb 201 Microcuvette, Hemocue AB, Angelholm, 
Sweden) from a fingertip capillary blood sample and analysed immediately 
using a regularly calibrated (as per manufacturer’s instructions) HemoCue® Hb 
201+ (Hemocue AB, Angelholm, Sweden) when [Hb] could not be obtained 
from venous blood at the time of testing or was not available on the same day 
as the tHb-mass test on the hospital electronic blood records system.  At UCLH, 
fingertip capillary samples (200 μl) were collected before and 6- and 8-min after 
the start of CO rebreathing (Na-heparinized 200 μl RAPIDLyte Multicap 
Capillary tubes, Siemens Healthcare Diagnostics Inc, Deerfield, Il, USA), with 
samples analysed within 15 minutes for percent carboxyhaemoglobin (%COHb) 
using a blood gas analyser with 0.1% precision (Hemoximeter; Cobas b 221 
POC system, Roche Diagnostics Ltd, Rotkreuz, Switzerland). At Southampton, 
[Hb] was measured in venous blood. An intravenous cannula was inserted into 
the dorsal network of the hand prior to tHb-mass testing at Southampton, 
allowing venous blood samples (200 μl) to be collected before and at 6- and 8-
mins after CO rebreathing via a Na-heparinized blood gas syringe (RAPIDLyte, 
Siemens Healthcare Diagnostics Inc, Deerfield, Il, USA). Percent 
carboxyhaemoglobin was determined with 0.1 % precision at Southampton 
using the RAPIDPoint 500 Blood Gas System (Siemens Healthcare Diagnostics 
Inc, Deerfield, Il, USA).  Blood sampling from venous, arterial and capillary 
blood has been shown to yield an identical ∆%COHb and therefore identical 
tHb-mass values [272].  All blood samples for the determination of [Hb], Hct and 
%COHb were collected under the same conditions, from the same anatomical 
site, with patients in a seated position.  Blood samples were analysed within 10-
15 minutes of one another due to %COHb being analysed after the oCOR test 
using a blood gas machine (which takes 15 minutes). 
 
Venous blood samples were taken if there were no recent full blood test results 
on site specific hospital electronic records systems, and if patients provided 
additional (and optional) consent for venous blood samples to be collected.  
Where appropriate a butterfly needle (BD winged infusion set, Becton, 
Dickinson, Oxford, UK) was inserted into an antecubital, cephalic or vein 
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located in the dorsal network of the hand.  Blood samples (3-4 ml) were 
collected in two BD Vacutainers, drawn in the correct and specific order, which 
prevents the contamination of additives between different tubes; firstly, a 
serum-separating tube (SST, gold top) containing silica and polymer gel was 
filled, after which a vacutainer (purple top) containing 
ethylenediaminetetraacetic acid (EDTA 1.8 mg per ml of blood) was drawn.  
After blood samples were collected they were repeatedly inverted to ensure 
thorough mixing of additives and then allowed to clot at room temperature for 
20-30 minutes prior to centrifugation.  Thereafter, the SST Vacutainer was 
centrifuged at 4 degrees for 20 minutes at 2500 revolutions per minute using a 
refrigerated laboratory centrifuge (Rotofix 32 A, Hettich Zentrifugen, Tuttlingen, 
Germany). Subsequently, the resulting supernatant (designated as serum) was 
transferred immediately using a disposable pipette into appropriately labelled 
0.5-1.0 ml aliquots and stored in a -80°C freezer until future analysis. 
 
3.1.2 Calculation of tHb-mass 
 
tHb-mass was calculated using a specifically designed Excel spreadsheet 
(Microsoft Excel 2011 for Apple Macintosh) based on the formula below: 
 
tHb-mass (g) = K x MCO(ml) x 100 x (Δ%COHb x 1.39) 
 
K = current barometric pressure x 760-1 x [1(0.003661 x current temperature)] 
MCO = COadm – (COsystem + lung (after disconnection) + COexhaled (after disconnection) 
COadm = CO volume administered into the system 
COsystem + lung (after disconnection) = CO concentration in spirometer x (spirometer 
volume + remaining volume in the lung after rebreathing)  
COexhaled (after disconnection) = end-tidal CO concentration x alveolar ventilation x time 
Δ%COHb = difference between baseline %COHb and %COHb post CO 
administration (average of 6- and 8-min %COHb values) 
1.39 = Hüfners number (constant) (ml CO x g.Hb-1) 
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Where CO, carbon monoxide; %COHb, percent carboxyhaemoglobin; lung 
residual volume, 1500 ml in men, 1200 ml in women; alveolar ventilation, 5000 
ml.min-1. 
 
Blood volume (BV), plasma volume (PV) and red cell volume (RCV) were 
calculated from MCHC, [Hb] and tHb-mass, as follows: 
 
BV (ml) = tHb-mass (g)/[Hb] (g.dl-1) • 100 
 
RCV (ml) = tHb-mass (g)/MCHC • 100 
 
PV (ml) = BV – RCV 
 
When haematocrit and haemoglobin concentration values were obtained from 
capillary blood at UCLH these values were corrected to venous conditions using 
the following formulas [27, 273]: 
 
[Hb] (g.dl-1) = [Hbcapillary] • 0.8787 + 1.24 
 
Hct (%) = [Hctcapillary] • 0.8425 + 5.23 
 
Example: If 70 ml of CO is inhaled (based on a 70-kg athletic male, using the 1 
ml of CO per kg body mass ratio), per Hüfner’s constant this will bind to 50 g of 
Hb.  If the measured Δ%COHb following CO rebreathing is 6% (i.e. 6% of total 
haemoglobin is bound to CO), then 6% of tHb-mass is 50 g and tHb-mass is 
833 g or 11.9 g.kg-1.  This example is based on the volume of CO in the blood 
and the change in percent carboxyhaemoglobin in blood pre-and post-
rebreathing only, and does not consider the CO that is not absorbed into the 
blood stream as described in more detail in the methods and calculation of tHb-
mass above.   
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3.2 Cardiopulmonary exercise testing (CPET) 
 
Prior to undergoing CPET, I took a medical history for each patient to rule out 
contraindications to CPET (see 3.2.4) as well as recording current medications. 
Patients were instructed to take medications as usual on the day of testing.  In 
addition, spirometry was performed to measure forced vital capacity (FVC), 
forced expiratory volume in the first second (FEV1) and the FEV1/FVC ratio 
using an Easy on-PC spirometry device (New Diagnostic Design, Medical 
Technologies, Inc, Andover, MA, USA).  Pre CPET [Hb] was also was collected 
(Hb 201 Microcuvette, Hemocue AB, Angelholm, Sweden) from a fingertip 
capillary blood sample and analysed immediately (HemoCue® Hb 201+, 
Hemocue AB, Angelholm, Sweden) as per local standard operating procedures, 
if [Hb] was not available on electronic records systems on the same day as 
CPET.  
 
CPET was performed according to the American Thoracic Society/American 
College of Chest Physicians (ATS/ACCP) guidelines [274], under stable 
environmental conditions (temperature and barometric pressure), with 
continuous 12-lead electrocardiogram monitoring and in the presence of an 
experienced clinical exercise physiologist and clinician (where appropriate).  
Additionally, blood pressure was monitored once at rest and every two minutes 
during exercise with patients wearing a blood pressure cuff (Orbit-K cuff, 
SunTech Medical, Morrisville, USA) connected to a Multilyzer (Cortex 
Biophysik, Leipzig, Germany) with integrated fingertip pulse oximetry to monitor 
blood O2 saturation.  Patients were instructed to abstain from caffeine and 
nicotine on the day of CPET and be fasted for at least 1.5 hours prior to 
exercise. 
   
3.2.1 CPET equipment and calibration 
 
At UCLH, gas analysis was performed using the Metalyser 3B-R2 breath-by-
breath system (Cortex Biophysik, Leipzig, Germany), which allows the 
continuous measurement of volume and concomitantly determines inspired and 
expired O2 and CO2.  At Southampton, gas analysis was performed using the 
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Ergostik metabolic unit [(Geratherm Respiratory GmbH (Love Medical Ltd, 
Manchester, UK)]. Breath-by-breath oxygen uptake (V̇O2) and carbon dioxide 
output (V̇CO2) were recorded, together with respiratory rate, tidal volume, 
minute ventilation and end-tidal gas tensions. 
 
At both UCLH and Southampton, bi-daily calibration of the pressure analyser 
(am and pm) were performed on testing days using a digital barometer (GPB 
3300 Digital Barometer, GHM Messtechnik GmbH Standort Greisinger, 
Regenstauf, Germany).  Prior to every CPET, gas calibration of the O2 and CO2 
analyser and volume transducer calibration were performed. All calibration 
values were recorded in a calibration log.  Specific details of CPET calibration 
procedures are described below. 
 
3.2.2 Gas calibration   
 
The Cortex Metalyser 3B-R2 breath-by-breath metabolic cart was switched on 
at least 45 minutes prior to CPET to allow sufficient time for the equipment to 
warm up as per manufacturers recommendations.  Subsequently a two-point 
gas calibration was carried out using two gas mixtures; Gas 1 (ambient air: 
0.03% CO2, 20.93% O2) and Gas 2 (calibration/reference gas: 5% CO2, 15% 
O2), after which values were checked to ensure they were within an acceptable 
error range (ambient air: O2 20.93 ± 0.05%, CO2 0.03 ± 0.02%; calibration gas: 
O2 15 ± 0.05%, CO2 5 ± 0.05%) as set out in the ATS/ACCP guidelines [274].  If 
checked gas values fell outside of these limits the gas calibration procedure 
was re-run from the start until values fell within these accepted ranges of error.     
 
3.2.3 Triple V ML II Volume transducer calibration 
 
The Triple V volume transducer (Cortex Biophysik, Leipzig, Germany) was 
calibrated using a 3 litre syringe (Hans Rudolph, Inc, Shawnee, USA).  Five 
valid inspiratory and expiratory strokes were required for successful volume 
calibration.  Calibration values were checked to ensure they were within an 
acceptable range of error (3.0 ± 0.1 litres).  Volume calibration checks were 
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carried out at 3 different flow rates to mimic different rates of ventilation that 
occur during an incremental exercise test, specifically 0.5, 1.5 and 3 l.min-1.  
  
3.2.4 Contraindications for CPET 
  
Patients were screened prior to every CPET to rule out contraindications to 
undergoing testing.  Absolute and relative contraindications to CPET were 
based on those outlined in the American Thoracic Society/American College of 
Chest Physicians (ATS/ACCP) guidelines [274], described in detail below: 
 
3.2.4.1 Absolute Contraindications to CPET 
  
I. Acute MI (within 7-10 days of transmural infarct or within 5 days if minor 
and uncomplicated) 
II. Uncontrolled arrhythmias causing symptoms or haemodynamic 
compromise  
III. Severe left main stem stenotic lesions. 
IV. Uncontrolled hypertension (or systolic BP above 180 mmHg at rest) 
V. Pulmonary hypertension 
VI. Pulmonary oedema 
VII. Room air desaturation at rest (less than 85%)  
VIII. Acute inflammatory conditions (pericarditis, myocarditis)  
IX. Unstable angina (patient pain-free for 4 days before test) 
X. Dissecting aneurysm   
XI. Acute or recent pyrexial illness   
XII. Thyrotoxicosis   
XIII. Syncope 
XIV. Thrombosis of lower extremities  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3.2.4.2 Relative Contraindications to CPET   
 
I. Moderate stenotic valvular heart disease 
II. Left main coronary stenosis or its equivalent 
III. Frequent/fast atrial/ventricular rhythms  
IV. Hypertrophic obstructive cardiomyopathy  
V. Left ventricular failure/congestive cardiac failure   
VI. Complete heart block   
VII. Left ventricular hypertrophy   
VIII. Bundle branch block   
IX. Orthopaedic/neurological impairment  
X. Elderly, frail or disabled patients   
XI. Advanced or complicated pregnancy   
 
3.2.5 CPET protocol 
Patients pedalled an electromagnetically-braked cycle ergometer (UCLH, Lode 
Corival BV, Groningen, Netherlands; Southampton, Ergoline 2000, Ergoline 
GmbH, Bitz, Germany). 
A 3-minute rest period followed fitting of relevant equipment, after which 
unloaded cycling was performed at a cadence of 60 to 65 rpm for 3 minutes.  
Thereafter, patients performed a symptom-limited continuous incremental 
exercise ramp protocol, determined by the physiologist or clinician on the basis 
of predictive work rate algorithms and patient-reported activity levels [77].  
Ramp gradient was set to 10-25 W min-1 based on patient height, weight and 
age, with the aim being a test duration of between 8 to 12 minutes. Tests were 
terminated at patient exhaustion, or until the patient was unable to maintain a 
cadence of 40 rpm for more than 30 seconds despite verbal encouragement. 
The clinician stopped the test if the patient developed a sign or symptom listed 
in the ATS/ACCP CPET guidelines, which included: new arrhythmia; more than 
2 mm of ST elevation or depression on the ECG; an arterial blood pressure of 
more than 250 mm Hg systolic or 120 mm Hg diastolic (see 2003 ATS/ACCP 
statement on Cardiopulmonary Exercise Testing for an exhaustive list [274])   
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Following termination of CPET, patients were encouraged to perform a ‘cool-
down’ period of unloaded cycling for 3-5 minutes.  
 
3.2.6 Determination of primary CPET variables 
 
The two main variables measured during CPET to quantify cardiorespiratory 
fitness are the V̇O2 peak and V̇O2 at AT.  Below outlines in detail how both 
fitness markers were determined after CPET in each patient.   
 
3.2.6.1 Peak oxygen consumption (V̇O2 peak) 
 
Aerobic capacity was quantified by measuring the peak exertional oxygen 
consumption (V̇O2 peak, normalised for body weight and thus expressed in 
ml.kg-1min-1) achieved on a symptom limited, maximal incremental ramp test.  
Thus, V̇O2 peak reflects a patient’s limit of tolerance and providing sufficient 
volition/effort is closely reflective of V̇O2 max in the absence of a plateau in V̇O2 
as per the classical definition.  V̇O2 peak was recorded as the highest average 
V̇O2 over the final 30s of exercise [275] and is shown in Figure 3-2 (panel 3 of 
the nine panel plot) by the black arrow.   
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Figure 3-2. Oxygen consumption (blue line) and carbon dioxide output (red 
line) during incremental exercise. Dark green line represents the linear 
increase in work rate during the incremental ramp test. V̇O2 peak is shown 
by the black arrow. Screen shot taken from real patient test using Metasoft 
version 3.9 (Cortex Biophysik, Leipzig, Germany). 
 
3.2.6.2 Anaerobic threshold (AT) 
 
The V̇O2 at anaerobic threshold (ml.kg-1min-1) was determined by myself at 
UCLH and by an exercise physiologist at Southampton, both verified by a 
consultant physician with experience in conducting and interpreting CPET.  
Middle five of seven averaging of the breath-by-breath data was performed prior 
to determining the AT as per normal practice.  Specifically, AT was determined 
using a combination of the modified V-slope [276], ventilatory equivalents and 
end-tidal pressure methods shown in Figure 3-3 [277], which improves the rigor 
of AT detection [278].  In detail, the AT can be seen plotted in Figure 3-3 
represented by a vertical green line on panels 5, 6, 8 and 9.  Panel 5 shows the 
relationship between V̇O2 (x-axis) and CO2 output (V̇CO2) on the y-axis.  At the 
AT we see an excess CO2 output compared to ongoing V̇O2, which is illustrated 
by a break-away from the black dotted line (denotes a 1:1 relationship between 
V̇O2 and V̇CO2).  The excess CO2 reflects the additional CO2 released from 
bicarbonate (HCO3-) buffering of protons (H+) associated with the accumulation 
of lactate [279] with increasing exercise intensity.   
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Panel 6 shows the AT occurring at the nadir in V̇E/V̇O2 (blue line) before 
hyperventilation relative to O2 but not CO2 (red line, V̇E/V̇CO2) occurs.  This is 
also supported in panel 9 showing an increase in the end-tidal pressure for O2 
(PETO2, dark blue line), with no decrease in end-tidal pressure for CO2 (PETCO2, 
pink line) measured at the end of exhalation (representing alveolar ventilation). 
The AT can also be seen plotted in panel 8, which shows the profile of the 
respiratory exchange ratio (RER, black line) during incremental exercise.  As 
can be seen there is an increase in RER at the AT reflecting an excess V̇CO2 
relative to V̇O2 without evidence of hyperventilation (which can affect RER 
independently from excess V̇CO2 as a by-product of increased anaerobic 
metabolism.   
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Figure 3-3. Modified V-slope (panel 5), ventilatory equivalents (panel 6), 
and end-tidal pressure methods (panel 9) along with a plot of respiratory 
exchange ratio (panel 8) used for the detection of the anaerobic threshold 
(AT). The green line represents the AT in all panels and is reported as the 
oxygen consumption (ml.kg.min-1) at this point.  Screen shot taken from 
real patient test using Metasoft version 3.9 (Cortex Biophysik, Leipzig, 
Germany).  
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Chapter 4  
4 Test retest reliability of total haemoglobin mass using the optimised 
carbon monoxide rebreathing method 
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4.1 Abstract 
 
Background: Total haemoglobin mass (tHb-mass) represents the absolute 
mass of circulating haemoglobin, which determines the oxygen transport 
capacity of the blood, providing valuable information in the fields of clinical and 
sports medicine.  The optimised carbon monoxide rebreathing (oCOR) method 
allows precise, valid and reliable measurement of tHb-mass with low 
measurement error (≤ 2%) reported in many institutions.  However, it is 
important for every laboratory using the oCOR method to assess the site-
specific measurement error of tHb-mass.  As a result, the aim of this study was 
to assess the test retest measurement error of tHb-mass in our laboratory. 
Methods: Ten participants (50% female) volunteered to participate in the study 
(age 24 ± 5 years, weight 60.7 ± 12.4 kg).  Each subject performed two oCOR 
tests to determine tHb-mass separated by no less than 12 hours and no more 
than 7 days.  Typical error (TE) expressed as coefficient of variation (CV %) 
with 95% confidence intervals (95% CI) for tHb-mass were calculated according 
the methods of Hopkins [280].  Bland-Altman plots assessed differences in tHb-
mass between repeat tests [281]. 
Results: tHb-mass from test-1 (630 ± 190 g) and test-2 (631 ± 188 g) did not 
differ (p= 0.594) and were highly correlated (r= 1.000, p< 0.0001).  This was 
also the case for weight-adjusted tHb-mass (g.kg-1) between test1-2 (tHb-mass 
9.3 ± 1.6 g.kg-1 versus 9.3 ± 1.6 g.kg-1, p= 0.788).  TE as CV % (95 % CI) for 
tHb-mass values between test1-2 for all patients (n= 10) was TE 1.9 % (95% CI 
1.3-3.4 %) or 9 g (95% CI 6-16 g).  Based on the mean tHb-mass of 630 g, this 
equates to a typical error of 12 g. Mean difference in tHb-mass between test-1 
and test-2 was 1 g with 95% limits of agreement of -4 to 6 g.   
Conclusions: The oCOR method to determine tHb-mass in our laboratory is 
reliable with a similarly low test retest measurement error compared to other 
established institutions.   
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4.2 Introduction 
 
The oCOR method allows tHb-mass to be quantified and shows comparable 
measurement error to the gold standard technique (51Cr labelled RBCs), but 
without the associated risks of using radioactive isotopes [117].  Previous 
studies have reported excellent reliability when using the oCOR method with an 
error of measurement (expressed as typical error, TE) of ~2% commonly being 
reported [44, 46, 282, 283].  A meta-analysis of studies using the oCOR method 
reported a mean measurement error of 2.2% for tHb-mass, although values 
ranged from 1.4-3.5% across different laboratories [117].  In addition, 
determination of tHb-mass by the oCOR method is dependent on the 
repeatable measurement of percent carboxygenhaemoglobin (%COHb) in 
blood by a hemoximeter [284], with previous studies typically using the 
Radiometer OSM3 or ABL-80 devices (Radiometer Medical ApS, Denmark) [19, 
284-286], whilst I used a Cobas b 221 POC Hemoximeter (Roche Diagnostics, 
Switzerland) as this was the analyser in use at our institution.  Analyser error of 
≤ 1% is essential for the accurate measurement of %COHb and subsequent 
tHb-mass calculation.   
 
If there is an intention or justification for the oCOR method to be used more 
widely in the clinical setting as both a research and clinical tool, then an 
appreciation of population distribution norms and what a patient’s normal 
physiological variation is also important to establish. Given that a test cannot be 
valid without first meeting the criteria of reliability, it is essential for any 
institution implementing the oCOR method to quantify laboratory-specific 
measurement error in tHb-mass in the first instance.  Without knowledge of 
measurement error (of any test or physiological variable in fact), it is often 
assumed that tHb-mass has been reliably determined so that if the test was 
repeated a few days later, a similar value would be obtained.  Chapter 4 tested 
this assumption.  
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4.2.1 Study aims 
 
i) To quantify the test-retest typical error of total haemoglobin mass 
determined by the 2-minute optimised carbon monoxide rebreathing 
method in our institution, and 
 
ii) To quantify the repeatability of %COHb measurements using the 
Cobas b 221 POC Hemoximeter (Roche Diagnostics, Rotkreuz, 
Switzerland) used in our institution. 
 
4.3 Methods 
 
4.3.1 Ethics 
 
The study protocol and procedures were approved by the University College 
London (UCL) Research Ethics Committee (Project ID: 6654/001), and 
conformed to the standards set by the Declaration of Helsinki.  Participants 
were provided with an information sheet prior to written informed consent being 
obtained (see Appendix A and B, respectively).   
 
4.3.2 Inclusion criteria 
 
I. Male or female adults (age > 18 years) 
II. Free from chronic disease   
 
4.3.3 Exclusion criteria 
 
i) Smokers 
ii) Baseline %COHb > 5 % 
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4.3.4 Participants 
 
Participants were employees from either University College London or 
University College Hospitals NHS Foundation Trust who were recruited through 
word of mouth and following advertisement via email correspondence.  Ten 
healthy individuals (50% female) volunteered to participate in the study (age 24 
± 5 years, height 154.6 ± 9.5 cm, weight 60.7 ± 12.4 kg).  All participants were 
non-smokers, and informed to refrain from strenuous activity, alcohol and 
caffeine intake for 24 hours before each oCOR test.   
 
4.3.5 Study design 
 
Twenty oCOR procedures were carried out in total with each participant 
performing two oCOR tests separated by no less than 12 hours and no longer 
than 7 days apart to allow a comparison of tHb-mass measurements.  Where 
possible both tests were carried out at a similar time of day on an individual 
participant basis to minimise the effect of diurnal variations [287].   
 
4.3.6 Statistics 
 
Statistical analysis was performed using Statistical Package for the Social 
Sciences (SPSS) (Version 23.0 for Apple Macintosh, Chicago, IL, USA).  
Values are presented as mean ± standard deviation (SD), unless otherwise 
stated.  Repeatability of %COHb was assessed from five capillary blood 
samples for the Cobas b 221 POC blood gas machine (Hemoximeter) using the 
coefficient of repeatability (CR).  CR is calculated by multiplying the within-
subject SD by 2.77 (√2 x 1.96) [288], which quantifies absolute reliability of 
measurement error in the same units as the measurement tool.  The typical 
error (TE) expressed as coefficient of variance (CV %) with corresponding 95% 
confidence intervals (95% CI) for tHb-mass were calculated according to the 
methods described by Hopkins [280], where TE is calculated from the standard 
deviation of difference scores ÷ √2.  To assess differences in tHb-mass 
between repeat tests, limits of agreement (LoA) and 95% CI were calculated by 
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the Bland-Altman method [281] using a specifically developed Excel 
spreadsheet [289]. Correlation analyses were performed using either Pearson’s 
correlation coefficient or intraclass correlation coefficient (ICC) where 
appropriate.  Paired t-tests were performed to assess differences in %COHb, 
total haemoglobin mass, blood volume, red cell volume and plasma volume 
between tests1-2.  Significance was accepted as a p-value < 0.05.  
 
4.4 Results 
 
4.4.1 Repeatability of the Cobas b 221 POC Hemoximeter (Roche 
Diagnostics, Rotkreuz Switzerland) 
 
The coefficient of repeatability (CR) of baseline %COHb for 5 capillary blood 
samples measured by the Cobas b 221 POC Hemoximeter (Roche Diagnostics, 
Rotkreuz, Switzerland) was ± 0.14 %, see Table 4-1. 
 
Table 4-1. Mean, standard deviation and coefficient of repeatability of 
percent carboxyhaemoglobin from five consecutive capillary blood samples 
taken from the same participant. 
 
Sample  %COHb 
1 0.80 
2 0.70 
3 0.70 
4 0.80 
5 0.70 
Mean 0.74 
SD 0.05 
CR ± 0.14 
%COHb, percent carboxyhaemoglobin; CR, coefficient of repeatability. 
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4.4.2 Reliability of haemoglobin concentration and haematocrit 
 
Table 4-2. Test retest reliability of haemoglobin concentration and 
haematocrit. 
ID number [Hb] (g.l-1) T1 [Hb] (g.l-1) T2 Hct (%) T1 Hct (%) T2 
TRT01 (M) 141.6 144.2 42.9 41.0 
TRT02 (M) 137.2 138.1 42.3 43.4 
TRT03 (F) 100.3 106.4 35.2 34.8 
TRT04 (F) 115.2 122.2 39.2 39.6 
TRT05 (M) 146.0 155.6 44.3 41.8 
TRT06 (F) 113.5 123.1 38.1 37.2 
TRT07 (F) 109.9 112.6 36.4 35.9 
TRT08 (F) 128.4 123.1 38.5 38.8 
TRT09 (M) 145.1 133.7 42.0 42.9 
TRT10 (M) 148.6 146.8 45.9 44.9 
Mean 128.6 130.6 40.5 40.0 
SD 17.6 15.7 3.5 3.4 
 
 
There were no differences in either [Hb] or Hct (%) between oCOR test1-2, see 
Table 4-2.  Repeat [Hb] and Hct (%) values were strongly correlated (([Hb] ICC 
r= 0.94 (95% CI 0.77-0.98), p< 0.0001; Hct (%) ICC r= 0.96 (95% CI 0.84-0.99), 
p< 0.0001)).  Typical error for Hct (%) between test1-2 was TE 4.0% (95% CI 
2.7-7.3) and for [Hb] TE 7.5 % (95% CI 5.1-13.9). The mean difference (SD) for 
[Hb] and Hct (%) between tests was 2.0 ± 6.7 g.l-1 and -0.46 ± 1.7%, 
respectively.  
 
4.4.3 Percent carboxyhaemoglobin 
 
Baseline %COHb from test-1 and test-2 did not differ (%COHb test-1 0.87 versus 
test-2 0.87 %, p= 0.912).  In addition, %COHb measured at min-6 (5.8 % test-1 
versus 5.8 % test-2, p= 0.347) and min-8 (5.7 % test-1 versus 5.7 % test-2, p= 
0.594) post CO rebreathing did not differ between test-1 and test-2, see Figure 
4-1 and Table 4-6 below. 
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Figure 4-1. Percent carboxyhaemoglobin (%COHb) at baseline and at 6- 
and 8-min after CO rebreathing during oCOR test-1 (open circles) and 
oCOR test-2 (black rectangles).  Error bars represent standard deviation 
(SD). 
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Table 4-3. Absolute total haemoglobin mass, red cell volume, blood volume and plasma volume from repeat optimised carbon 
monoxide rebreathing tests. 
ID Number 
tHb-mass (g) 
T1 
tHb-mass (g) 
T2 
RCV (ml) 
T1 
RCV (ml) 
T2 
BV (ml) 
T1 
BV (ml) 
T2 
PV (ml) 
T1 
PV (ml) 
T2 
TRT01 (M) 733 730 2222 2078 5692 5566 3470 3487 
TRT02 (M) 778 774 2401 2432 6230 6157 3829 3726 
TRT03 (F) 448 452 1574 1478 4910 4667 3336 3189 
TRT04 (F) 439 455 1491 1475 4183 4094 2691 2618 
TRT05 (M) 908 906 2757 2434 6836 6399 4079 3965 
TRT06 (F) 373 371 1251 1120 3610 3311 2359 2192 
TRT07 (F) 535 532 1771 1696 5350 5197 3579 3502 
TRT08 (F) 505 505 1516 1594 4323 4510 2807 2915 
TRT09 (M) 737 735 2131 2360 5581 6046 3450 3686 
TRT10 (M) 841 846 2600 2585 6222 6330 3622 3745 
Mean 630 631 1971 1925 5294 5228 3322 3303 
SD 190 188 521 514 1028 1055 539 568 
oCOR, 2-minute optimised carbon monoxide rebreathing test; (M), male; (F), female; T1, test 1; T2, test 2; tHb-mass, total 
haemoglobin mass (grams, g), RCV, red cell volume (millilitres, ml); BV, blood volume (millilitres, ml), PV, plasma volume 
(millilitres, ml). 
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Table 4-4. Weight adjusted total haemoglobin mass, red cell volume, blood volume and plasma volume from repeat optimised 
carbon monoxide rebreathing tests. 
ID Number 
tHb-mass 
(g.kg-1) T1 
tHb-mass 
(g.kg-1) T2 
RCV 
(ml.kg-1) T1 
RCV 
(ml.kg-1) T2 
BV 
(ml.kg-1) T1 
BV 
(ml.kg-1) T2 
PV 
(ml.kg-1) T1 
PV 
(ml.kg-1) T2 
TRT01 (M) 11.3 11.2 34.2 32.0 87.6 85.6 53.4 53.6 
TRT02 (M) 10.3 10.3 31.7 32.5 82.3 82.2 50.6 49.7 
TRT03 (F) 6.8 6.7 23.9 22.1 74.6 69.7 50.7 47.6 
TRT04 (F) 8.3 8.6 28.2 28.0 79.2 77.7 51.0 49.7 
TRT05 (M) 10.2 10.2 30.8 27.3 76.5 71.9 45.6 44.6 
TRT06 (F) 7.1 7.0 23.8 21.0 68.6 62.2 44.8 41.2 
TRT07 (F) 8.3 8.3 27.5 26.3 83.1 80.7 55.6 54.4 
TRT08 (F) 9.6 9.7 28.8 30.7 82.2 86.7 53.4 56.1 
TRT09 (M) 10.6 10.6 30.8 34.1 80.6 87.4 49.9 53.3 
TRT10 (M) 10.5 10.5 32.4 32.1 77.6 78.7 45.2 46.6 
Mean 9.3 9.3 29.2 28.6 79.2 78.3 50.0 49.7 
SD 1.6 1.6 3.5 4.5 5.3 8.2 3.7 4.8 
oCOR, 2-minute optimised carbon monoxide rebreathing test; (M), male; (F), female; T1, test 1; T2, test 2; tHb-mass, total 
haemoglobin mass (grams per kilogram, g.kg-1), RCV, red cell volume (millilitres per kilogram, ml.kg-1); BV, blood volume (millilitres 
per kilogram, ml.kg-1), PV, plasma volume (millilitres per kilogram, ml.kg-1).
8
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There were no differences in tHb-mass (g or g.kg-1), RCV (ml or ml.kg-1), 
BV (ml or ml.kg-1), or PV (ml or ml.kg-1) measured from repeat tHb-mass 
tests (p> 0.05).  All repeat values were highly statistically significantly 
correlated [(tHb-mass, g & g.kg-1 (r= 1.000, p< 0.0001; r= 0.999, p< 0.0001 
respectively); RCV, ml & ml.kg-1 (r= 0.955, p< 0.0001; r= 0.888, p= 0.001 
respectively); BV, ml & ml.kg-1 (r= 0.964, p< 0.0001; r= 0.898, p= 0.001 
respectively); PV ml & ml.kg-1 (r= 0.966, p< 0.0001; r= 0.884, p= 0.002 
respectively). See preceding Table 4-3 and Table 4-4 for raw data in 
participants and Figure 4-3 showing the relationship between tHb-mass (g) 
measured from repeat oCOR tests.  
 
4.4.4 Comparison of tHb-mass determined by the oCOR method 
 
Figure 4-4 shows differences in tHb-mass between test-1 and test-2 in the Bland-
Altman plot.  The mean difference and SD in tHb-mass between test1-2 was 1 ± 
6 grams, with a very strong relationship between the two tHb-mass values (r= 
1.00, p<0.0001), see Figure 4-3.  There were no differences in tHb-mass values 
from test-1 and test-2 (630 ± 190 g versus 631 ± 188 g, p= 0.594), see Table 4-5 
(the same was the case for weight adjusted tHb-mass).  The TE and 95 % 
confidence intervals (95 % CI) for tHb-mass values between test1-2 for all 
patients (n= 10) was TE 1.9 % (95% CI 1.3-3.4 %).  Based on the mean tHb-
mass of 630 g from both tests, this would equate to a TE of 12 g (95% CI 8-22 
g).   
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Table 4-5. Total haemoglobin mass for individual participants. 
Participant tHb-mass1 tHb-mass2  Mean tHb-mass1-2 Difference 
1 (M) 733 730 732 3 
2 (M) 778 774 776 4 
3 (F) 448 452 450 -4 
4* (F) 439 455 447 -17 
5 (M) 908 906 907 2 
6 (F) 373 371 372 2 
7 (F) 535 532 534 3 
8 (F) 505 505 505 0 
9 (M) 737 735 736 1 
10 (M) 841 846 844 -4 
Mean 630 631 630 -1 
SD 190 188 189 6 
* tHb-mass value measured for participant 4 during test number 2 was 
affected by a major mouthpiece leak during CO rebreathing leading to 
overestimation of tHb-mass. Total haemoglobin mass, tHb-mass 
expressed in grams (g); (M), male; (F), female. 
 
 
Table 4-6. Baseline percent carboxyhaemoglobin from test1 for each 
participant. 
Participant %COHb1 %COHb2 Mean %COHb Difference 
1 0.9 0.8 0.85 0.1 
2 0.8 0.9 0.85 -0.1 
3 0.8 0.8 0.80 0.0 
4 0.8 0.8 0.80 0.0 
5 1.0 0.9 0.95 0.1 
6 0.8 0.7 0.75 0.1 
7 0.8 0.9 0.85 -0.1 
8 0.7 0.7 0.70 0.0 
9 1.0 1.1 1.05 -0.1 
10 1.0 1.0 1.00 0.0 
Mean 0.9 0.9 0.86 0.0 
SD 0.11 0.13 0.11 0.08 
%COHb, percent carboxyhaemoglobin.  Data at baseline pre-CO rebreathing 
from oCOR test1. 
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Figure 4-2. Individual total haemoglobin mass for each participant. Data 
expressed in grams (g). Red, females; blue, males.  
 
Figure 4-3. Correlation between total haemoglobin mass (tHb-mass) from 
test-1 (tHb-mass1) and test-2 (tHb-mass2).  Data expressed in grams (g). 
Red, female; Blue, male. 
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Figure 4-4. Bland-Altman plot for tHb-mass from test-1 and test-2 
(expressed in grams of haemoglobin).  The middle horizontal dashed line 
represents the overall mean difference (1 g) between test-1 and test-2 and 
the two solid lines represent the 95% limits of agreement (-4 to 6 g). 
Patient highlighted in red displayed evidence of a mouthpiece leak during 
testing but remains in the analysis for completeness. 
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4.5 Discussion 
 
Test-retest reliability refers to the reproducibility of observed values when the 
measurement is repeated [290].  A test with better retest reliability indicates 
improved precision of single measurements and enhanced ability to track 
changes of measurements longitudinally over time [290].  Importantly any test 
cannot be valid (the ability of a measurement tool to reflect what it is designed 
to measure) unless it is reliable [291].  The main aim of this study was to 
quantify the test-retest measurement error (test-retest reliability) of total 
haemoglobin mass using the 2-minute optimised carbon monoxide rebreathing 
method in our testing institution at University College London Hospital.  In 
addition, as tHb-mass determined by the oCOR method is dependent on the 
precision of %COHb measured in blood by a Hemoximeter [117], I assessed 
the repeatability of %COHb values obtained from the Cobas b 221 POC 
Hemoximeter used in this study. 
 
The most important finding from this study was that the test-retest typical error 
of tHb-mass was 1.9 % or expressed in raw units was 9 grams of Hb, which 
demonstrates a level of reliability that is comparable to most previous studies 
(see Table 4-7 for a non-exhaustive list) that have utilised the 2-minute oCOR 
method.  In addition, it is very similar to the 2.2% typical error associated with 
the oCOR method reported by Gore and colleagues [117], who performed a 
meta-analysis of errors of measurement in blood volume indices from the 
available literature.  The original paper by Schmidt and Prommer in 2005 [19] 
(who developed, refined and patented the 2-minute oCOR method) reported a 
TE of 1.7 %.  Subsequent studies have reported TE values ranging from 1.2 % 
[283] in 6 recreationally active adults to 3.3 % in national-level cyclists  [27].  
The pooled (average) TE % from all studies in Table 4-7 is 1.8%.  The 
coefficient of repeatability (CR) of baseline %COHb derived from 5 capillary 
blood samples measured by the Cobas b 221 POC Hemoximeter was 0.14 %.   
This is low and is below the analyser error of ≤ 1% essential for the accurate 
measurement of %COHb for subsequent tHb-mass calculation [284].
 9
1
 
 
 
 
 
Table 4-7. Typical error of total haemoglobin mass measured using the 2-minute optimised carbon monoxide rebreathing method. 
Authors Sample size Cohort TE % (95% CI) 
Schmidt and Prommer 2005 [19] N= 11 (8 male) Moderately trained adults 1.7 (3.3 %) 
Gore et al. 2006 [283] N= 6 (3 male) Healthy, recreationally active adults 1.2 (0.8-2.5 %) 
Garvican et al. 2010 [292] N= 11 (all male) 6 male professional cyclists, 5 recreationally active controls 1.3 (0.9-2.5 %) 
Eastwood et al. 2008 [282] N= 6 (all male) Active male adults 2.1 (1.7-2.6 %) 
Eastwood et al. 2009 [293] N= 23 (12 male) Adolescents 2.3 (1.7-3.6 %) 
Prommer et al. 2008 [44] N= 24 (20 male) Trained athletes 1.4 (1.1-1.7 %) 
Schumacher et al. 2008 [27] N= 7 (all male) German national under-23 cyclists 3.3 %b 
Pottgiesser et al. 2008 [46] N= 29 (all male) Healthy male adults 1.5 %a b 
Clark et al. 2009 [36] N= 12 (all male) Endurance-trained cyclists 1.9 (1.5-3.0 %) 
Robertson et al. 2010 [294] N= 16 (11 male) Highly trained runners 2.0 (1.6-2.6 %) 
Naef et al. 2015 [295] N= 18 (all male) Healthy male adults 1.4 (1.0-2.1 %)c 
All participants performed the 2-minute optimised carbon monoxide rebreathing method [19] to determine total haemoglobin mass 
(tHb-mass).  TE % (95% CI), Typical error (95% confidence interval). aTE derived from 11 participants, b95% CI not provided, ctHb-
mass measured twice within 6 hours. Average TE for all studies is 1.8%.  
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The data obtained from the current study on the reliability of tHb-mass allows 
the quantification of the precision of a single, one-off measurement of tHb-mass 
in an individual.  Specifically, the observed within-subject typical error was 1.9 
% (95% CI 1.3-3.4 %).  Based on the mean tHb-mass of 630 grams (average 
tHb-mass from test1 and test2), and calculated TE (1.9 %), the 95% likely limits 
for this single tHb-mass measurement is between 604 to 657 grams (a range of 
54 grams).  In other words, we can be confident that in our hands, the 
probability of a one-off measurement of tHb-mass (g) falling outside these limits 
is 5%.  Conversely, the probability of a one-off measurement of tHb-mass falling 
within this range is 95%.   
 
The calculation of these likelihood limits can be used to calculate the probability 
that the ‘true’ tHb-mass for a subject or patient is greater (or less) than some 
predefined value or a value with clinical importance/significance.  This has 
important implications for interpreting data in future studies to qualify whether a 
‘true’, real-world change in tHb-mass has occurred.  In other words, is the 
change in tHb-mass greater than the error associated with the method of 
measurement.  If not, then any change could simply be a consequence of 
measurement error and our interpretation of results may be limited.  This 
underlying principle applies to all measurement techniques in sports and clinical 
medicine, although is perhaps overlooked.  
What criteria or threshold can we use when deciding whether a real-world 
change in tHb-mass has occurred?  Hopkins [290] suggests a realistic 
approach is to base such criteria on the TE of the test or method being used.  
Specifically, 1.5 to 2 times the typical error (i.e. greater than half the limits of 
agreement) has been advocated.  Accordingly, based on the mean tHb-mass 
(g) from the current study (630 g), limits of agreement (-4 to 6 g) and typical 
error of 1.9 % (equates to 9 g in raw units), the oCOR rebreathing method in 
our institution has the precision to detect a real-world change in tHb-mass of ≥ 
14 g (1.5 x TE) with sufficient confidence.  If we use 2 times the TE, this 
equates to a change in tHb-mass of 18 g.   
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In real terms this equates to an ability to detect a change in tHb-mass 
associated with reinfusion or withdrawal of one unit of packed red cells 
(containing ~ 60 g of Hb) [296] or changes in tHb-mass in the early phase of 
high-dose recombinant human erythropoietin administration, as shown by 
Parisotto and colleagues, where a mean increase in tHb-mass of between 58-
107 g was reported [262].  However, the oCOR rebreathing method may not 
have the ability to detect changes in tHb-mass during periods of micro-dosing or 
‘maintenance’ with recombinant human erythropoietin administration [297].  
This may be related to such changes being close to the natural oscillations in 
tHb-mass that have been reported (4.6% average oscillation in tHb-mass 
recoded over a one year period in endurance-trained athletes [298].  The 
stability of tHb-mass in clinical populations has been little studied and what 
would be considered a normal oscillation in tHb-mass in this context remains to 
be explored in different patient and disease populations. 
 
4.5.1 Study limitations 
 
The small sample size in this study was a potential limitation, although 10 
participants is in keeping with 6 of the studies outlined in Table 4-7 that have 
utilised the 2-minute oCOR method to determine tHb-mass and reported TE 
values that are similar to that reported in the current study (i.e. 2 %).  
Furthermore, as Hopkins suggests [290], when the typical error has the same or 
very similar magnitude as the smallest worthwhile effect, a sample size of 10 
provides sufficient precision in a simple test-retest study without a control 
group. This is based on Equation 4-1 below.  
 
Equation 4-1. Sample size formula based on typical error and smallest 
worthwhile effect. 
 
𝑛 =  2(𝑡 ×  𝑠/𝑑)2
 
 8𝑠2/𝑑2 
 
Where 𝑛 is the estimated sample size; 𝑡 is the test statistic; 𝑠 is the typical error 
and 𝑑 is the smallest worthwhile effect. 
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If we use the calculated typical error for tHb-mass of 1.9 % derived from the 
current study and an assumed smallest worthwhile effect of 1.8 % (pooled TE 
from studies reported in Table 4-7, a sample of 9 participants gives adequate 
precision in a simple test retest experiment.  Given that sample size is 
proportional to the square of the typical error, a high level of reliability is 
extremely important in any research experiment [290].  In Chapter 4 I have 
shown a low TE in the repeat measurement of tHb-mass using the oCOR 
method in our institution. 
 
4.6 Conclusion 
 
This study demonstrates that tHb-mass measured using the 2-minute optimised 
carbon monoxide rebreathing method is of sufficient reliability in our testing 
institution compared to previous studies using this technique.  In addition, the 
analyser error of the Cobas b 221 POC Hemoximeter was low and less than 
that essential (≤ 1%) for the accurate measurement of %COHb for subsequent 
calculation of tHb-mass.  Finally, the measurement error in tHb-mass using the 
oCOR method suggests that clinically important changes in tHb-mass can be 
detected following targeted intervention, such as for example following infusion 
of packed RBCs, use of rhEPO and intravenous iron supplementation. 
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Chapter 5 
 
5 Haemoglobin concentration, total haemoglobin mass and plasma volume 
in patients: implications for anaemia 
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5.1  Abstract 
 
Background. Anaemia is a common haematological disorder encountered 
in many clinical settings and is defined when [Hb] is < 120 g.l-1 in females 
and < 130 g.l-1 in males, according to World Health Organisation criteria. 
Because [Hb] is based on whole blood, it is dependent on both PV and the 
total amount of circulating haemoglobin (tHb-mass), which may both affect 
[Hb] independently of one another, but are rarely independently measured 
in clinical medicine.  Thus, anaemia may result not only from a fall in tHb-
mass, but from a simple rise in PV.  Therefore, reliance on [Hb] values may 
be misleading.  We sought to explore the relationship between tHb-mass 
and [Hb] in healthy volunteers and in different exemplar patient populations 
to test the hypothesis that tHb-mass is poorly correlated with [Hb]. 
Methods. Healthy volunteers (HV) and patients from the following disease 
groups were studied; chronic liver disease (CLD), chronic heart failure (CHF), 
inflammatory bowel disease (IBD) and those awaiting elective surgery 
(surgical).  tHb-mass was quantified using the optimised carbon-monoxide 
(oCOR) rebreathing method and circulating [Hb] determined.  
Results. One hundred and nine participants (61% male), mean (IQR) age 52 
(36-64) years were enrolled and successfully completed the oCOR test, of 
which 36% were anaemic.  Mean ± SD [Hb] and tHb-mass (g & g.kg-1) were 
128.4 ± 18.1 g.l-1, 669 ± 181 g and 8.5 ± 1.9 g.kg-1, respectively. There was no 
difference in tHb-mass (g or g.kg-1) between sub-groups, although [Hb] and Hct 
(%) were significantly lower in CLD patients compared to all other groups, 
owing to expanded plasma volume.  In all participants tHb-mass was correlated 
with [Hb] (r= 0.50, p< 0.0001) but this relationship varied across sub-groups 
(HV r= 0.87, p< 0.0001; surgical r= 0.787, p< 0.0001; IBD r= 0.687, p< 0.0001), 
although tHb-mass and [Hb] were not correlated in CLD (r= 0.410, p= 0.114) or 
CHF (r= 0.312, p= 0.157).  tHb-mass did not explain variance in [Hb] in CLD 
(adjusted R2= 0.109, p= 0.114) or CHF (adjusted R2= 0.052, p= 0.157) with PV 
independently accounting for a greater proportion of the variance in [Hb] over 
and above tHb-mass in these group (R2 change= 0.724 in CHF and 0.805 in 
CLD). 
Conclusions. The relationship between tHb-mass and [Hb] varies considerably 
in different disease states with plasma volume a key confounding variable 
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showing wide variability on an individual patient level.  Knowledge of tHb-mass, 
PV and [Hb] provides a more comprehensive assessment of haematological 
and volume status in patients compared to relying on [Hb].  This study raises 
the question as to whether the concept of ‘anaemia’ needs readdressing and if 
we should be defining volume excess and tHb-mass deficit separately instead?   
 
5.2 Introduction  
 
Anaemia is a common haematological disorder encountered in many clinical 
settings and disease states such as cancer [299], IBD [7], CHF [300], chronic 
kidney disease [301, 302], chronic liver disease (LD) [8] and in patients 
preoperatively [303, 304]. Anaemia regardless of aetiology is associated with 
reduced quality of life [305], chronic fatigue [306, 307] and poor prognosis 
across a range of diseases from CHF [308, 309] to various malignancies [15] as 
well as poor postoperative outcomes in cardiac [181, 182] and non-cardiac [6, 
13] surgery.  For all these reasons, circulating haemoglobin concentrations 
([Hb]) are routinely measured in clinical practice. Once identified, the cause of 
impaired haemoglobin synthesis or erythrocytosis, or of increased red cell 
destruction, is often sought and treatment (either of the underlying cause, or 
through the administration of packed red cells) instigated.  
 
It is becoming clear that our understanding of the pathogenesis of anaemia, and 
thus of investigations and treatment responses, may have been somewhat 
simplistic.  Traditionally anaemia has been considered the result of a reduced 
tHb-mass (impaired O2 carriage) but also, given that measured [Hb] is based on 
whole blood, it is dependent on PV, which may affect [Hb] independently- a 
factor rarely considered in clinical practice.  But a low [Hb] might also be found 
when haemoglobin synthesis and erythrocytosis are normal, and when tHb-
mass is normal (or even high), if plasma volume is disproportionately expanded.  
For example, disease-related changes in global water balance or distribution of 
body water or the use of diuretic therapy may disturb PV.  Thus, patients with 
IBD might face intestinal blood loss, suppressed haemoglobin synthesis 
(anaemia of chronic inflammation) or hypoalbuminaemia, causing fluid shifts 
relating to altered plasma oncotic pressure [310].  In CLD, patients may 
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similarly experience blood loss and fluid shifts as a result of raised portal 
venous pressure [99, 311], hypoalbuminaemia and the use of diuretic therapy 
[312].  Patients with CHF may suffer disturbances in circulating blood volumes 
due to raised central venous pressure, increased renin-angiotensin-aldosterone 
activity, and the use of diuretics [93, 95].  Indeed, PV expansion resulting in 
haemodilution is a recognised feature of HF [96, 97].  In contrast, contractions 
in PV caused by pharmacotherapy may mask a fall in tHb-mass by maintaining 
[Hb] [98].  
 
Why may this be of clinical relevance? [Hb] is used as a trigger for further 
investigations and treatment in a number of settings from anaemia 
management to transfusion requirements in surgery.  If a reduced [Hb] is not a 
result of a ‘true’ deficit in tHb-mass, is a patient’s O2 carrying capacity impaired 
and is Hb optimisation necessary?  In contrast, a patient may have a reduced 
[Hb] as a result of hypervolaemia (i.e. PV expansion) without any deficit in tHb-
mass.  The clinical management of these two scenarios may be vastly different.  
For example, in a patient with CHF, optimisation of Hb may be required in the 
first scenario whereas appropriate management of volume status may be 
appropriate in the second.  Therefore, knowledge of tHb-mass, PV and [Hb] 
may provide a more comprehensive assessment of haematological and volume 
status compared to relying on [Hb] alone.  Furthermore do we need to 
readdress ‘anaemia’ as a concept and should we be defining volume excess 
and tHb-mass deficit separately? 
 
Previous techniques used to quantify red cell mass (actually a measurement of 
red cell volume, ml) have involved radiolabelling of red blood cells with 
chromium (51Cr) and are therefore tools limited to nuclear medicine 
departments.  The use of isotopes for the measurement of blood volume 
compartments are not without associated risks to the patient, are costly and 
place a burden on the patient in terms of the time and procedures required to 
perform, and are thus not routinely performed unless for special circumstances 
(such as the management of excessive erythrocytosis in polycythaemia).  
These barriers may have limited the applicability of such techniques for more 
routine and regular use in clinical medicine.  In contrast, such barriers may be 
overcome through use of the 2-minute oCOR method, refined by Schmidt and 
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Prommer [19], which offers a less invasive, safe, precise and reliable technique 
to measure tHb-mass.  In addition, the 2-minute oCOR method has comparable 
if not lower measurement error when compared to previous blood volume 
techniques.  Despite these advantages it has rarely been applied in the clinical 
setting. Thus, the relative contributions of PV and tHb-mass to measured [Hb] 
across disease states has not been well described.  I sought to address this 
issue, studying patients suffering IBD, CLD and CHF, I also studied healthy 
volunteers (HV), as well as a preoperative patient cohort.  
 
5.2.1 Study aim 
 
i) To explore the relationship between total haemoglobin mass and 
haemoglobin concentration in different disease states. 
ii) To assess the feasibility of using the optimised carbon monoxide 
rebreathing method in patients. 
 
5.2.2 Study hypothesis 
 
Total haemoglobin mass will be poorly correlated with haemoglobin 
concentration. 
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5.3 Methods  
 
Ethical approval was granted by the London- Camden and Kings Cross 
Research Ethics Committee (REC reference: 13/LO/1902).  We fully adhered to 
Caldicott guidelines and conformed to the standards set by the Declaration of 
Helsinki. Patients were given a participant information sheet (see Appendix C) 
at least 24 hours prior to written informed consent being obtained from all 
participants willing to take part (see Appendix D). 
 
5.3.1 Patients 
 
Adult (> 18 years) healthy volunteers and patients at University College 
Hospital (University College London Hospitals NHS Foundation Trust, UCLH), 
Southampton General Hospital (University Hospital Southampton NHS 
Foundation Trust) and the Royal Free Hospital (Royal Free London NHS 
Foundation Trust, RFH) were prospectively studied between February 2015 and 
May 2016.  Age, gender, height, weight, diagnosis, planned surgical procedure, 
comorbidities (such as diagnosis of diabetes, respiratory or cardiovascular 
disease) and current medications were also documented.  
 
5.3.2 Inclusion criteria 
5.3.2.1 Healthy volunteers (HV) 
 
i) Male or female adults (age > 18 years) 
ii) Free from chronic disease   
 
5.3.2.2 Chronic heart failure (CHF) 
 
i) Heart failure confirmed with B-type natriuretic peptide (BNP) > 200 
pg.ml-1 (if available) 
ii) Echocardiogram or cardiac magnetic resonance imaging (cMRI) 
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evidence of left ventricular (LV) impairment as defined by a left 
ventricular ejection fraction of less than 50% 
iii) New York Heart Association (NYHA) class II-IV 
iv) Not fully stabilised heart failure, i.e. still symptomatic with shortness 
of breath and/or peripheral oedema and/or clinical signs of bibasal 
crepitations or peripheral oedema 
 
5.3.2.3 Chronic liver disease of mixed aetiology (CLD) 
 
i) Alcoholic liver disease 
ii) Primary sclerosing cholangitis 
iii) Hepatitis C related liver cirrhosis 
iv) Cryptogenic cirrhosis 
 
5.3.2.4 Gastrointestinal disease 
 
i) Confirmed diagnosis of Inflammatory bowel disease (IBD) 
a. Crohn’s disease 
b. Ulcerative colitis 
 
5.3.2.5 Surgical patients (Surgical) 
 
i) Patients scheduled to undergo elective surgery regardless of 
specialty 
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5.3.3 Exclusion criteria 
 
i) Adults with known underlying history of learning disabilities, or adults 
who do not have mental capacity to consent for themselves. 
ii) Prisoners 
iii) Unable to comply with basic breath-holding instructions. 
iv) Baseline %COHb is greater than 5% (as commonly occurs in 
smokers). 
v) Haemoglobinopathies (e.g. Sickle cell anaemia). 
 
5.3.4 Statistics 
 
Statistical analysis was performed using SPSS Statistics (Version 23.0 for 
Apple Macintosh, Chicago, IL, USA).  Values are presented as mean ± 
standard deviation (SD), unless otherwise stated.  Median and interquartile 
range (IQR) are reported when variables are not normally distributed and when 
data transformation (logarithmic, square root or reciprocal) did not result in a 
normally distributed variable.  Categorical variables are presented as frequency 
(%).  Normal (Gaussian) distribution was assessed using a combination of the 
Kolmogorov-Smirnov test, visual inspection of histogram charts and normal Q-Q 
plots for each variable.  Pearson’s correlation coefficient assessed the 
relationship between [Hb] and tHb-mass, allowing adjustment for PV (ml).  
Linear regression assessed the proportion of variance in tHb-mass explained by 
[Hb], allowing adjustment for PV (ml). In both correlation and regression 
analyses [Hb] and tHb-mass are expressed in g.l-1 and grams, respectively and 
PV in ml, unless otherwise stated.  This is also the case elsewhere, unless 
otherwise stated. 
 
Differences across sub-groups were assessed by one-way analysis of variance 
(ANOVA), prior to which the assumption of normality was tested by the 
Levene’s test for homogeneity of variances.  Where homogeneity of variance 
was verified, being the case for [Hb], Hct, tHb-mass (g), RCV (ml & ml.kg-1), PV 
(%) and weight, a one-way ANOVA, with post hoc comparisons by Gabriel’s 
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test (due to the slightly different sample sizes across sub-groups) was 
performed. When homogeneity of variance was violated, as was the case for 
BV (ml & ml.kg-1), PV (ml & ml.kg-1), age and tHb-mass (g.kg-1), a Welch 
ANOVA [313] was performed with subsequent post hoc comparisons made by 
the Games-Howell test as this post hoc test does not rely on the assumption of 
equal variances [314].  All tests were two-sided with statistical significance 
being accepted as a p-value of < 0.05. 
 
5.3.5 Equations 
 
Body surface area (BSA) was derived from height (H) and body weight (W) 
using the formula of Du Bois and Du Bois [316]: 
Equation 5-1. Du Bois and Du Bois body surface area formula 
 
BSA[m2]= 0.007184 × H[cm]0.725 × W[kg]0.425 
 
Estimation of normal adult values for RCV and PV were calculated using the 
formulas from the 1995 Expert Panel on Radionuclides of the International 
Council for Standardisation in Haematology [92]: 
 
Equation 5-2. Estimation of normal male adult red cell volume and plasma 
volume 
Mean normal RCV (ml)=(1486 × S)-825 
Mean normal PV (ml)=1578 × S 
 
Equation 5-3. Estimation of normal female adult red cell volume and 
plasma volume 
Mean normal RCV (ml)=(1.06 × age)+(822 × S) 
Mean normal PV (ml)=1395 × S 
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where 𝑆 = body surface area (m2) calculated using the formula of Du Bois and 
Du Bois [316] (see equation 5-1 above). 
 
Equation 5-4. Calculation of mean normal blood volume 
 
Mean normal BV (ml)= mean normal RCV + mean normal PV 
 
BV and PV values were adjusted for age, sex, weight, and height using a 
published formula to calculate normal volumes as derived from >100,000 
measurements of height and weight from Metropolitan Life tables [91].  Normal 
BV, PV and RCV were classified as measured volumes within ± 8% of the 
expected normal volume on an individual level. Mild to moderate volume 
expansion was considered >8% to <25% deviation from expected norms, and 
severe as >25% of the expected normal volume [91].   
 
5.3.6 Power calculation 
 
The power calculation was based on available literature, specifically using the 
study by Hinrichs and colleagues [24] and was performed using G*3 Power 
version 3.1.9.2 [316].  According to Hinrichs and colleagues, the relationship 
(expressed as Pearson’s correlation coefficient) between haemoglobin 
concentration ([Hb]) and total haemoglobin mass (tHb-mass) was r= 0.59, p< 
0.05).  Based on this, the number of patients using a two-tailed correlation: 
bivariate normal model, for 80% power with a significance of 0.05 is estimated 
at 21 per group.  Given that five groups were studied (patient populations; IBD, 
surgical, liver disease and chronic heart failure) and healthy volunteers, a total 
of 105 participants were required.  
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5.4 Results 
 
One hundred and nine participants (61 % male), mean (IQR) age 52 (36-64) 
years consented to take part in the study.  Sixteen patient were tested at 
Southampton General Hospital, ninety at University College London Hospital 
(inclusive of all healthy volunteers) and three at the Royal Free Hospital.  
Surgical specialities of planned procedures are shown in Table 5-1 with patient 
characteristics and aetiology of disease of inflammatory bowel disease patients 
in Table 5-2.  Patient characteristics, medications and aetiology of liver disease 
and chronic heart failure are shown in Table 5-3 and Table 5-4, respectively.  
There were no differences in weight between sub-groups.  HV were younger 
compared to all patient groups (p< 0.0001) with CHF patients being older than 
IBD (p= 0.001), surgical (p= 0.008) and LD patients (p= 0.002).  In the whole 
group 36% were anaemic according to WHO criteria (< 120 g.l-1 in females and 
< 130 g.l-1 in males).  The prevalence of anaemia in sub-groups were as follow: 
IBD (9%), HV (24%), surgical (18%), HF (55%) and LD (94%). 
 
Table 5-5 shows haematological variables in male and female participants.  
Males displayed elevated [Hb], tHb-mass (g, g.kg-1 & g.m2) as well as BV and 
PV (ml & ml.m2) but not when adjusted for measured body weight.  RCV (ml & 
ml.kg-1 & ml.m2) were also higher in males compared to females.  Table 5-6 
shows haematological variables in anaemic and non-anaemic participants.  
Anaemic subjects displayed lower [Hb], Hct (%), RCV (ml & ml.kg-1 & ml.m2) and 
tHb-mass (g, g.kg-1 & g.m2) compared to non-anaemics.  In contrast, BV (ml.kg-1 
only) and PV (ml, ml.kg-1, ml.m2 & %) were higher in anaemic participants.  Also, 
participants classified as anaemic displayed reduced MCV and elevated RDW 
compared to non-anaemic subjects. 
 
Table 5-7 shows haematological variables for the whole study cohort, healthy 
volunteers and in different disease sub-groups.  These values for Hct, [Hb] and 
tHb-mass are also displayed graphically in Figure 5-1 (A-D) and for BV and PV 
in Figure 5-2 (A-D), respectively.  tHb-mass, RCV, BV and PV expressed 
relative to BSA (m2) are expressed in Figure 5-3 (A-D).  LD patients had lower 
[Hb] and Hct compared to healthy volunteers and other disease groups (p< 
0.0001). tHb-mass (g, g.kg-1 & g.m2) did not differ between sub-groups nor did 
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RCV (ml).  However, RCV (ml.kg-1) in LD patients was lower than HV (p= 0.006) 
and HF (p= 0.006) and when expressed relative to BSA, RCV (ml.m2) was lower 
in LD compared to patients with HF (p= 0.047).   
 
BV (ml) was expanded in LD patients compared to IBD (p= 0.038), surgical 
patients (p= 0.037) but was not different from CHF patients or HV.  Weight 
adjusted BV (ml.kg-1) was greater in HF (p= 0.016) and HV (0.008) compared to 
surgical patients.  BV (ml.m2) was higher in LD compared to surgical patients 
(p= 0.035), which was also the case for BV (ml.m2) in HF patients compared to 
IBD (p= 0.032) and surgical (p= 0.014).  In HV, BV (ml.m2) was higher 
compared to surgical patients (p= 0.046).   
 
PV (ml) was expanded in LD compared to HV (p= 0.006), IBD and surgical 
patients (p= 0.002) but not patients with HF (p= 0.100). PV expressed relative 
to body weight (ml.kg-1) was expanded in LD patients compared to IBD (p= 
0.007) and surgical patients (p= 0.003) but not HF (0.172) or HV (p= 0.191).  
HV demonstrated a larger PV (ml.kg-1) compared to IBD and surgical patients, 
respectively. PV (ml.m2) expressed relative to BSA was expanded in LD 
patients compared to IBD (p= 0.001), surgical (p= 0.001) and HV (p= 0.015) but 
not HF (p= 0.080). In HF patients PV (ml.m2) was elevated compared to IBD (p= 
0.014) and surgical (p= 0.008). Finally, HV displayed higher PV (ml.m2) 
compared to both IBD (p= 0.036) and surgical patients (p= 0.014). 
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Figure 5-1. Haematological variables in healthy volunteers and patient sub-
groups. Hct (%), haematocrit percentage (A); [Hb], haemoglobin 
concentration (B); tHb-mass, total haemoglobin mass (g & g.kg-1) (C & D). 
HV, healthy volunteers; IBD, inflammatory bowel disease; HF, heart failure; 
LD, liver disease. *p< 0.0001 for Hct and [Hb] in LD patients compared to all 
other groups.  No differences in tHb-mass (g or g.kg-1) between groups. 
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Figure 5-2. Blood and plasma volumes in healthy volunteers and patient 
sub-groups. BV, blood volume (ml & ml.kg-1) (A & B); PV, plasma volume (ml 
& ml.kg-1) (C & D). HV, healthy volunteers; IBD, inflammatory bowel disease; 
HF, heart failure; LD, liver disease. (A) BV (ml) between LD and IBD, *p= 
0.038, BV (ml) between LD and surgical, **p= 0.037; (B) BV (ml.kg-1) 
between HF and surgical, *p= 0.016, BV (ml.kg-1) between HV and surgical, 
**p= 0.008; (C) PV (ml) between LD and HV, *p= 0.006, PV (ml) between LD 
and IBD, **p= 0.002 and PV (ml) between LD and surgical patients, †p= 
0.002; (D) PV (ml.kg-1) between LD and IBD, *p= 0.007, PV between LD and 
surgical patients, **p= 0.003. 
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Figure 5-3. Total haemoglobin mass, blood, plasma and red cell volumes 
expressed relative to body surface area (m2) in healthy volunteers and 
patient sub-groups. tHb-mass, total haemoglobin mass (g.m2) (A); RCV, 
red cell volume (ml.m2) (B); BV, blood volume (ml.m2) (C); PV, plasma 
volume (ml.m2) (D). HV, healthy volunteers; IBD, inflammatory bowel 
disease; HF, heart failure; LD, liver disease.  No difference in tHb-mass 
(g.m2). (B) RCV (ml.m2) lower in LD than HF, *p= 0.047; (C) BV (ml.m2) in 
LD higher than surgical, *p= 0.035, BV (ml.m2) in HF higher than IBD, **p= 
0.032 and surgical, †p= 0.014, ***BV (ml.m2) in HV higher than surgical (p= 
0.046); (D) PV (ml.m2) higher in LD compared to IBD, *p= 0.001, surgical, 
**p= 0.001 and HV †p= 0.015 but not HF, p= 0.080,  PV (ml.m2) higher in 
HV compared to IBD, §p= 0.036 and surgical, ^p= 0.014.
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5.4.1 Relationships between haemoglobin concentration and absolute total 
haemoglobin mass 
 
In the whole population tHb-mass (g) correlated with [Hb] (g.l-1) (r= 0.500, p< 
0.0001, n= 109), which varied slightly by gender [(males (n= 66) r= 0.452, p< 
0.0001; female (n= 43) r= 0.462, p< 0.0001)].  In HV, IBD and surgical patients 
tHb-mass was strongly related with [Hb] (HV r= 0.871, p< 0.0001; IBD r= 0.687, 
p< 0.0001; surgical r= 0.787, p< 0.0001), see Figure 5-9.  However, this was 
not the case in patients with LD or CHF (LD r= 0.410, p= 0.114; CHF r= 0.312, 
p= 0.157).  After statistically adjusting for PV (ml), tHb-mass was strongly 
related to [Hb] in all groups (HV r= 0.965, p< 0.0001; IBD r= 0.976, p< 0.0001; 
surgical r= 0.985, p<0.0001; LD r= 0.984, p< 0.0001; CHF r= 0.905, p< 0.0001).   
 
In all anaemic patients (n= 39), tHb-mass did not significantly correlate with [Hb] 
(r= 0.301, p= 0.062) but did to a moderate extent in all patients without anaemia 
(r= 0.562, p< 0.0001).  Where analysis was possible due to very small sample 
sizes after patients were split by sub-group and anaemia status, tHb-mass was 
not significantly related to [Hb] in anaemic patients [(HV (n= 5) r= 0.204, p= 
0.742; surgical (n= 5) r= 0.669, p= 0.217; HF (n= 12) r= 0.462, p= 0.131; LD (n= 
15) r= 0.338, p= 0.218; IBD (n= 2).  In non-anaemic participants (n= 70), tHb-
mass was significantly correlated with [Hb] in HV (n= 16), r= 0.839, p< 0.0001; 
surgical (n= 23) r= 0.652, p= 0.001 and IBD (n= 20) r= 0.644, p= 0.002 but not 
HF (n= 10) r= 0.305, p= 0.391; LD (n= 1).  
 
When all patients were classified by volume status this altered the relationship 
between [Hb] & tHb-mass whereby the extent of volume expansion (BV and 
PV) reduced the association between [Hb] and tHb-mass. Specifically, 
hypovolemic patients (n= 5), r= 0.89, p= 0.041; normovolemic patients (n= 31), 
r= 0.89, p< 0.0001; mild to moderate BV hypervolemia (n= 37), r= 0.77, p< 
0.0001; severe BV hypervolemia (n= 36), r= 0.46, p= 0.004).  A similar trend 
was found for the extent of PV expansion, hypovolemic patients (n= 3), r= 0.99, 
p= 0.066; normovolemic patients (n= 24), r= 0.93, p< 0.0001; mild to moderate 
PV hypervolemia (n= 36), r= 0.88, p< 0.0001; severe PV hypervolemia (n= 46), 
r= 0.54, p< 0.0001).  Where possible (due to small numbers in each sub 
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category), sub-group analysis was performed across patient groups for 
completeness: normovolemic IBD patients (n= 10), r= 0.90, p< 0.0001; mild to 
moderate PV hypervolemia (n= 7), r= 0.92, p< 0.003; severe PV hypervolemia 
(n= 5), r= 0.54, p= 0.339).  Normovolemic surgical patients (n= 7), r= 0.95, p= 
0.001; mild to moderate PV hypervolemia (n= 14), r= 0.85, p< 0.0001; severe 
PV hypervolemia (n= 5), r= 0.824, p< 0.0001).  Normovolemic HF patients (n= 
4), r= 0.95, p= 0.046; mild to moderate PV hypervolemia (n= 6), r= 0.86, p< 
0.029; severe PV hypervolemia (n= 11), r= 0.59, p= 0.05). Mild to moderate PV 
hypervolemia in HV (n= 8), r= 0.91, p< 0.002; severe PV hypervolemia (n= 11), 
r= 0.89, p< 0.0001). 
 
5.4.2 Linear regression models 
 
In the whole population tHb-mass explained 25.0 % of the variance in [Hb] 
(adjusted R2 = 0.250, p< 0.0001).  PV independently accounted for 64.3 % of 
the variance in [Hb] over and above tHb-mass (R2 change= 0.624, p< 0.0001), 
in the whole population.  In sub-groups, tHb-mass explained different amounts 
of the variance in [Hb] (HV adjusted R2= 0.746, p< 0.0001; IBD adjusted R2= 
0.446, p< 0.0001; surgical adjusted R2= 0.605, p< 0.0001).  Of particular note, 
tHb-mass did not significantly explain variance in [Hb] in the two patient groups 
most likely to suffer expanded plasma volume and shifts in fluid- CLD (adjusted 
R2= 0.109, p= 0.114) or CHF patients (adjusted R2= 0.052, p= 0.157).  In 
keeping, PV independently accounted for a greater proportion of the variance in 
[Hb] over and above tHb-mass in these group (R2 change= 0.724 in CHF and 
0.805 in CLD) than in HV (R2 change= 0.192), surgical patients (R2 change= 
0.351) or IBD patients (R2 change= 0.422) (p<0.0001 in all cases).  Together, 
tHb-mass and PV explained 94.5 % of the variance in [Hb] in HV and IBD 
patients (adjusted R2 = 0.945, p< 0.0001), 96.9% in surgical patients (adjusted 
R2 = 0.969, p< 0.0001), 96.9% in LD patients (adjusted R2 = 0.969, p< 0.0001), 
and 80.3 % in patients with CHF (adjusted R2 = 0.803, p< 0.0001).  
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5.4.3 Haemoglobin concentration, plasma volume and total haemoglobin mass 
in individual participants  
 
Figure 5-4, Figure 5-5, Figure 5-6, Figure 5-7, and Figure 5-8 show individual 
participants ranked in order by weight adjusted total haemoglobin mass from 
smallest to largest with corresponding PV (ml.kg-1) and [Hb] (g.l-1) in HV, IBD, 
surgical, CHF and LD patients, respectively.  These figures show that on an 
individual level, patients may have the same or very similar tHb-mass values 
but different [Hb] and related PV values.  For example, in patients with IBD ( 
Figure 5-5), patient number 17 and 18 have very similar tHb-mass values (9.2 
g.kg-1 and 9.3 g.kg-1, respectively) but [Hb] of 161 g.l-1 and 107 g.l-1, respectively, 
with an elevated PV in patient number 18 compared to 17 (65.7 ml.kg-1 versus 
37.2 ml.kg-1).  Clinically these patients may be treated differently despite very 
minimal differences in O2 carrying capacity (tHb-mass).  Similarly, in LD 
patients (Figure 5-8), tHb-mass in patient number 2 and 3 are the same (5.2 
g.kg-1) but [Hb] is substantially lower in patient number 3 (severely anaemic) 
compared to patient number 2 (moderately anaemic), (69 g.l-1 versus 110 g.l-1; 
PV 67.8 versus 36.5 ml.kg-1, respectively).  
 
5.4.4 Blood, plasma and red cell volumes  
 
Derived BV, PV and RCVs were greater than expected normal values in all 
patients (BV, 5717 ± 1426 vs. 4789 ± 873 ml, p< 0.0001; PV, 3650 ± 1022 vs. 
2887 ± 464, p<0.0001; RCV, 2067 ± 582 vs. 1901 ± 410, p< 0.0001) and across 
all sub-groups for BV and PV but not for RCV in LD patients (see Table 5-8).  
Differences existed across sub-groups in the extent of deviation from expected 
normal PV.  Specifically, LD patients had the greatest deviation (+61 ± 38%) 
compared to IBD (+13 ± 16%, p= 0.002), surgical (+13 ± 16%, p= 0.002), and 
HV (+26 ± 15%, p= 0.022) but not HF (+30 ± 25%), although this was 
approaching significance (p= 0.062), see Table 5-8.  There were no significant 
differences across sub-groups in the extent of deviation from expected normal 
RCV (ml).   
 
117 
When all patients were categorised by the extent of PV expansion, defined as 
normal when derived PV was within ± 8% of the expected normal volume on an 
individual level, mild to moderate volume expansion was considered >8% to 
<25% deviation from expected norms, and severe as >25% of the expected 
normal volume, differences in [Hb] and Hct were found, as shown in Figure 5-10 
(A-B). Specifically, in patients with severe PV expansion, [Hb] was significantly 
lower (119.3 ± 17.9 g.l-1) than patients with mild to moderate PV expansion 
(131.9 ± 14.3 g.l-1, p= 0.005), normal PV (140.3 ± 17.6 g.l-1,p< 0.0001) and PV 
contraction (151.9 ± 9.7 g.l-1, p= 0.001), see Figure 5-10 (A).  Similarly, Hct (%) 
was significantly reduced in patients with severe PV expansion (37.2 ± 6.4 %) 
compared to patients with mild to moderate PV expansion (40.8 ± 3.9 %, p= 
0.014) and normal PV (42.7 ± 4.1 %, p< 0.0001).  Patients with PV contraction 
(n=3) had numerically elevated Hct (46.0 ± 3.5%) compared to severe PV 
expansion group, although this was not statistically significant (p= 0.086), 
Figure 5-10 (B). 
 
 
 
 
 
 
 
 
  
1
1
8
 
 
 
 
 
 
 
Figure 5-4. Individual participants ranked by tHb-mass (g.kg-1) (dark grey bars) with corresponding PV (ml.kg-1) (light grey bars) and 
[Hb] (g.l-1) (black circles) in healthy controls (n= 21). tHb-mass, total haemoglobin mass; PV, plasma volume; [Hb], haemoglobin 
concentration. 
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Figure 5-5. Individual IBD patients (n= 22) ranked by tHb-mass (g.kg-1) (dark grey bars) with corresponding PV (ml.kg-1) (light grey 
bars) and [Hb] (g.l-1) (black circles). tHb-mass, total haemoglobin mass; PV, plasma volume; [Hb], haemoglobin concentration. 
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Figure 5-6. Individual surgical patients (n= 28) ranked by tHb-mass (g.kg-1) (dark grey bars) with corresponding PV (ml.kg-1) (light 
grey bars) and [Hb] (g.l-1) (black circles). tHb-mass, total haemoglobin mass; PV, plasma volume; [Hb], haemoglobin concentration. 
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Figure 5-7. Individual chronic heart failure patients (n= 22) ranked by tHb-mass (g.kg-1) (dark grey bars) with corresponding PV 
(ml.kg-1) (light grey bars) and [Hb] (g.l-1) (black circles). tHb-mass, total haemoglobin mass; PV, plasma volume; [Hb], haemoglobin 
concentration. 
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Figure 5-8. Individual chronic liver disease patients (n= 16) ranked by tHb-mass (g.kg-1) (dark grey bars) with corresponding PV 
(ml.kg-1) (light grey bars) and [Hb] (g.l-1) (black circles). tHb-mass, total haemoglobin mass; PV, plasma volume; [Hb], haemoglobin 
concentration. 
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Figure 5-9. Unadjusted relationship between [Hb] (g.l-1) and tHb-mass (g) 
in healthy controls (A, n= 21), patients with IBD (B, n= 22), surgical 
patients (C, n= 28), liver disease (D, n= 16) and CHF (E, n= 22). tHb-mass, 
total haemoglobin mass; [Hb], haemoglobin concentration; IBD, 
inflammatory bowel disease; CHF, chronic heart failure. 
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Figure 5-10. Haemoglobin concentration (A) and haematocrit (B) in all patients categorised by plasma volume (PV) status.  PV 
contraction (n= 3) was classified as > minus 8% from expected norm. Normal PV (n= 24) was classified as derived PV within ± 8%   
of the expected normal volume on an individual level. Mild to moderate volume expansion (n= 36) was considered >8% to <25% 
deviation from expected norms, and severe PV expansion (n= 46) as >25% of the expected normal volume. 
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Table 5-1. Surgical specialty of planned surgical procedure. 
Surgical specialty Frequency N (%) 
Upper gastrointestinal 8 (28.5%) 
Lower gastrointestinal 8 (28.5%) 
Orthopaedic 7 (25%) 
Other 3 (10.7%) 
Urology 2 (7.1%) 
 
 
 
Table 5-2. Characteristics and aetiology of inflammatory bowel disease 
patients. 
Variable IBD (n= 22)   
Gender    
  Male (%) 50%   
Age (yr) 50 (33-62)   
Height (cm) 170.2 ± 7.3   
Weight (kg) 77.7 ± 18.1   
Aetiology of IBD    
Crohn’s disease 4 (18%)    
  Small bowel CD 2 (9%)   
  Terminal ileal CD 1 (4.5%   
Ulcerative colitis 9 (41%)   
  Ulcerative proctitis 3 (14%)   
  Pan UC 2 (9%)   
Collagenous colitis 1 (4.5%)   
IBD, Inflammatory bowel disease; CD, Crohn’s disease; UC, Ulcerative colitis 
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Table 5-3. Characteristics, medications and aetiology of liver disease 
patients. 
Variable LD (n= 16)   
Gender    
  Male (%) 75%   
Age (yr) 51 (48-55)   
Height (cm) 174.8 ± 8.9   
Weight (kg) 85.3 ± 18.5   
Primary aetiology of liver disease    
Hepatitis 3 (19%)   
ALD 8 (50%)   
Cryptogenic cirrhosis 2 (12%)   
Sclerosing cholangitis 2 (12%)   
Other 1 (6%)   
Hypertension 1 (6%)   
Medication    
  Beta blocker 3 (19%)   
  ACE inhibitor 0 (0%)   
  Statin 0 (0%)   
  Diuretic 5 (31%)   
Diuretic times per day    
  None 11 (69 %)   
  Once 5 (31 %)   
  Bi daily 0   
ALD, decompensated alcoholic liver disease; ACE inhibitor,    
angiotensin-converting-enzyme inhibitor. 
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Table 5-4. Characteristics, medications and aetiology of chronic heart 
failure patients. 
Variable CHF (n= 22)   
Gender    
  Male (%) 82%   
Age (yr) 68 (61-75)   
Height (cm) 173.5 ± 8.1   
Weight (kg) 80.4 ± 15.9   
Aetiology of heart failure    
Ischaemic heart disease 7 (32%)   
  Cardiomyopathy 10 (45%)   
  Ischaemic  5 (22%)   
  Non-ischaemic 5 (22%)   
Other 5 (22%)   
Hypertension 7 (32%)   
NHYA class    
  I 2 (9%)   
  II 14 (64%)   
  III 4 (18%)   
  IV 2 (9%)   
LVEF (%) 33.2 ± 11.4   
Medication    
  Beta blocker 19 (86%)   
  ACE inhibitor 20 (91%)   
  Statin 16 (73%)   
  Diuretic 17 (77%)   
  Diuretic dose (mg) 25 ± 29   
Diuretic times per day    
  None 5 (22%)   
  Once 14 (64%)   
  Bi daily 3 (14 %)   
NYHA, New York Heart Association Class; LVEF (%), left ventricular ejection 
fraction; ACE inhibitor, angiotensin-converting-enzyme inhibitor. 
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  Table 5-5. Haematological variables in males and females.   
Variable Whole group 
(n= 109) 
Males 
(n= 66) 
Females 
(n= 43) 
P-value 
[Hb] (g.l-1) 128.9 ± 18.8 132.8 ± 20.9 123.0 ± 13.1 0.003 
Anaemia (%) 36% 35% 37%  
Hct (%) 39.8 ± 5.6 40.5 ± 6.6 38.7 ± 3.4 0.057 
tHb-mass (g) 669 ± 181 758 ± 152 533 ± 132 < 0.0001 
tHb-mass (g.kg-1) 8.5 ± 1.9 8.9 ± 1.8 7.9 ± 2.0 0.006 
tHb-mass (g.m2) 348 ± 74 375 ± 67  305 ± 65 < 0.0001 
BV (ml) 5717 ± 1426 6346 ± 1325 4754 ± 970 < 0.0001 
BV (ml.kg-1) 73.4 ± 15.7 74.9 ± 14.5 71.1 ± 17.2 0.222 
BV(ml.m2) 2980 ± 570 3140 ± 552 2733 ± 511 < 0.0001 
PV (ml) 3650 ± 1022 4021 ± 1053 3080 ± 649 < 0.0001 
PV (ml.kg-1) 46.9 ± 11.4 47.4 ± 11.5 46.1 ± 11.5 0.556 
PV (ml.m2) 1902 ± 427 1988 ± 455 1771 ± 347 0.009 
PV (%) 64% 63% 65% 0.057 
RCV (ml) 2067 ± 582 2324 ± 552 1673 ± 368 < 0.0001 
RCV (ml.kg-1) 26.5 ± 6.3 27.4 ± 6.2 25.0 ± 6.3 0.049 
RCV (ml.m2) 1077 ± 244 1151 ± 246 962 ± 192 < 0.0001 
[Hb], Haemoglobin concentration; Hct, haematocrit; tHb-mass, total 
haemoglobin mass; BV, blood volume; PV, plasma volume; RCV, red cell 
volume. Data are presented as mean ± SD, or frequency (%). 
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Table 5-6. Haematological variables in anaemic and non-anaemic 
participants.  
Variable Whole group 
(n= 109) 
Anaemic  
(n= 39) 
Non-anaemic 
(n= 70) 
P-value 
[Hb] (g.l-1) 128.9 ± 18.8 109.6 ± 12.5 138.9 ± 10.6 < 0.0001 
Anaemia (%) 36%    
Hct (%) 39.8 ± 5.6 34.9 ± 5.9 42.4 ± 3.0 < 0.0001 
tHb-mass (g) 669 ± 181 594 ± 192 711 ± 162 0.001 
tHb-mass (g.kg-1) 8.5 ± 1.9 7.7 ± 1.9 9.0 ± 1.8 0.001 
tHb-mass (g.m2) 348 ± 74 311 ± 76 368 ± 65 < 0.0001 
BV (ml) 5717 ± 1426 5977 ± 1837 5606 ± 1146 0.217 
BV (ml.kg-1) 73.4 ± 15.7 77.3 ± 16.7 71.6 ± 14.8 0.051 
BV(ml.m2) 2980 ± 570 3123 ± 692 2900 ± 476 0.078 
PV (ml) 3650 ± 1022 4083 ± 1351 3434 ± 686 0.005 
PV (ml.kg-1) 46.9 ± 11.4 52.6 ± 12.2 44.0 ± 9.6 < 0.0001 
PV (ml.m2) 1902 ± 427 2130 ± 517 1776 ± 305 < 0.0001 
PV (%) 64% 68% 61% < 0.0001 
RCV (ml) 2067 ± 582 1894 ± 692 2171 ± 501 0.018 
RCV (ml.kg-1) 26.5 ± 6.3 24.7 ± 7.1 27.5 ± 5.6 0.023 
RCV (ml.m2) 1077 ± 244 993 ± 293 1123 ± 199 0.007 
MCV (fl) 89.8 ± 6.5 88.0 ± 6.2 91.0 ± 6.6 0.038 
MCH (pg) 29.8 ± 2.5 29.3 ± 2.9 30.1 ± 2.2 0.218 
MCHC (g.l-1) 331.6 ± 14.7 333.1 ± 18.0 330.5 ± 12.2 0.477 
RDW (%) 13.9 ± 1.4 14.5 ± 1.7 13.7 ± 1.1 0.024 
Creatinine (mol.l-1) 96.7 ± 87.8 114.9 ± 117.4 84.3 ± 58.2 0.166 
Albumin (g.l-1) 41.1 ± 7.4 37.4 ± 8.7 43.7 ± 4.9 0.001 
[Hb], Haemoglobin concentration; Hct, haematocrit; tHb-mass, total haemoglobin 
mass; BV, blood volume; PV, plasma volume; RCV, red cell volume; MCV, mean 
corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean 
corpuscular haemoglobin concentration; RDW, red cell distribution width.  
Anaemia defined according to World Health Organisation criteria ([Hb] <130 g.l-1 
in men and <120 g.l-1 in women.  Data are presented as mean ± SD, or frequency 
(%). 
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Table 5-7. Haematological indices for the whole population and in patient sub-groups. 
Variable Whole group 
(n= 109) 
HV 
(n= 21) 
IBD 
(n= 22) 
Surgical 
(n= 28) 
LD 
(n= 16) 
CHF 
(n= 22) 
[Hb] (g.l-1) 128.9 ± 18.8 132.2 ± 14.4 137.5 ± 15.7 136.6 ± 17.3 103.6 ± 14.9 126.1 ± 12.9 
Anaemia (%) 36% 24% 9% 18% 94% 54% 
Hct (%) 39.8 ± 5.6 41 ± 3.2 42.3 ± 3.4 41.6 ± 4.1 30.0 ± 4.8 41.2 ± 4 
tHb-mass (g) 669 ± 181 670 ± 175 657 ± 175 658 ± 174 640 ± 198 716 ± 197 
tHb-mass (g.kg-1) 8.5 ± 1.9 9.5 ± 2.1 8.4 ± 1.2 8.1 ± 1.6 7.7 ± 2.8 8.9 ± 1.6 
tHb-mass (g.m2) 348 ± 74 366 ± 77 344 ± 59 337 ± 66 321 ± 98 367 ± 74 
BV (ml) 5717 ± 1426 5496 ± 990 5208 ± 1078 5239 ± 1007 6811 ± 1860 6252 ± 1659 
BV (ml.kg-1) 73.4 ± 15.7 78.5 ± 13.4 68.2 ± 10.3 65.4 ± 12 81.6 ± 23.1 77.9 ± 14.3 
BV (ml.m2) 2980 ± 570 3025 ± 397 2749 ± 345 2703 ± 371 3401 ± 829 3213 ± 618 
PV (ml) 3650 ± 1022 3429 ± 538 3189 ± 635 3249 ± 571 4965 ± 1447 3883 ± 953 
PV (ml.kg-1) 46.9 ± 11.4 49.1 ± 7.9 42 ± 7.7 40.7 ± 8.2 59.1 ± 16.0 48.6 ± 9.2 
PV (ml.m2) 1902 ± 427 1890 ± 207 1688 ± 234 1678 ± 236 2471 ± 615 2001 ± 362 
PV (%) 64% 63% 61% 62% 73% 62% 
RCV (ml) 2067 ± 582 2067 ± 487 2018 ± 487 1997 ± 495 1845 ± 565 2368 ± 770 
RCV (ml.kg-1) 26.5 ± 6.3 29.4 ± 6.2 26.1 ± 3.5 24.6 ± 4.8 22.5 ± 8.4 29.3 ± 6.5 
RCV (ml.m2) 1077 ± 244 1135 ± 214 1060 ± 155 1024 ± 185 930 ± 290 1212 ± 301 
[Hb], Haemoglobin concentration; Hct, haematocrit; tHb-mass, total haemoglobin mass; BV, blood volume; PV, plasma 
volume; RCV, red cell volume; HV, healthy volunteers; IBD, inflammatory bowel disease; LD, liver disease; CHF, chronic 
heart failure. Anaemia defined according to World Health Organisation criteria ([Hb] <130 g.l-1 in men and <120 g.l-1 in 
women.  Values are expressed as mean ± SD, or frequency (%). 
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Table 5-8. Derived blood, plasma and red cell volumes and expected norms in all participants and patient sub-groups. 
Variable Whole group 
(n= 109) 
HV 
(n= 21) 
IBD 
(n= 22) 
Surgical 
(n= 28) 
LD 
(n= 16) 
CHF 
(n= 22) 
Derived BV (ml) 5717 ± 1426a 5496 ± 990 a 5208 ± 1078 a 5239 ± 1007 a 6811 ± 1860c 6252 ± 1659d 
Expected normal BV (ml) 4789 ± 873 4487 ± 797 4666 ± 939 4749 ± 884 5164 ± 920 4979 ± 752 
Deviation from expected normal BV (%) +19 ± 21% +23 ± 15% +12 ± 12% +11 ± 14% +33 ± 33% +25 ± 25% 
Derived PV (ml) 3650 ± 1022a 3429 ± 538a 3189 ± 635a 3249 ± 571a 4965 ± 1447b 3883 ± 953e 
Expected normal PV (ml) 2887 ± 464 2730 ± 432 2818 ± 502 2874 ± 471 3079 ± 483 2985 ± 399 
Deviation from expected normal PV (%) +26 ± 27% +26 ± 15% +13 ± 16% +13 ± 16% +61 ± 38% +30 ± 25% 
Derived RCV (ml) 2067 ± 582 a 2067 ± 487 a 2018 ± 487d 1997 ± 495b 1845 ± 565 2368 ± 770f 
Expected normal RCV (ml) 1901 ± 410 1757 ± 367 1847 ± 439 1875 ± 416 2085 ± 437 1994 ± 354 
Deviation from expected normal RCV (%) +9 ± 23% +18 ± 17% +9 ± 11% +6 ± 15% -8 ± 34% +18 ± 27% 
Data expressed as mean ± SD.  Blood volume (BV) derived from quantified total haemoglobin mass using the formula: tHb-mass (g)/[Hb] 
(g.dl-1) • 100.  Plasma volume (PV) calculated using the formula: PV (ml) = BV – RCV. Red cell volume (RCV) calculated using the 
formula: RCV (ml) = tHbmass (g) /MCHC (g.dl-1) • 100. ap< 0.0001, bp= 0.022, cp= 0.041, dp= 0.001, ep= 0.002, fp= 0.007 derived vs. 
expected volumes. MCHC, mean corpuscular haemoglobin concentration.  
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Table 5-9. Anaemia based on haemoglobin concentration, red cell and plasma volume status in all participants (n= 109). 
Anaemia 
status 
 Normal PV Mild to moderate PV 
expansion 
Severe PV 
expansion 
PV 
contraction 
Total 
Non-anaemic Normal RCV 12 8 1 1 22 
 RCV deficit 4 1 0 2 7 
 RCV excess 5 17 19 0 41 
 Total 21 26 20 3 70 
Anaemic Normal RCV 1 5 5 0 11 
 RCV deficit 2 4 8 0 15 
 RCV excess 0 1 13 0 14 
 Total 3 10 26 0 39 
Normal BV, PV and RCV were classified as derived volumes from measured tHb-mass within ± 8% of the expected normal volumes on    
an individual level. Mild to moderate volume expansion was considered >8% to <25% deviation from expected norms, and severe as 
>25% of the expected normal volume.  BV, blood volume, PV, plasma volume, RCV, red cell volume. Anaemia defined according to 
World Health Organisation criteria ([Hb] <130 g.l-1 in men and <120 g.l-1 in women.  Values are expressed as counts. 
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5.5 Discussion 
 
To my knowledge this is one of the largest studies to have measured total 
haemoglobin mass in the clinical setting through the novel application of the 
optimised carbon monoxide rebreathing method.  The aim of this study was to 
explore the relationship between total haemoglobin mass and haemoglobin 
concentration in different patient populations to ascertain the degree to which 
tHb-mass correlated with [Hb] and the contribution of tHb-mass and PV to 
measured [Hb].  It was hypothesised that tHb-mass and [Hb] would be poorly 
correlated and therefore [Hb] a poor index of O2 carrying capacity. 
 
I found a prevalence of anaemia of 36% (using WHO criteria) in all participants, 
although this varied considerably across sub-groups, ranging from 9% in IBD 
patients to 94% in patients with chronic LD.  The key findings from this study 
were as follows; there was a moderate relationship between tHb-mass and [Hb] 
in all participants (r= 0.500, p< 0.0001, n= 109) but this varied considerably 
across sub-groups and appeared to degrade with disease severity in so much 
that tHb-mass was strongly related to [Hb] in HV (r= 0.871, p< 0.0001), surgical 
(r= 0.787, p< 0.0001) and IBD (r= 0.687, p< 0.0001) patients.  However, in CHF 
and LD patients tHb-mass did not correlate with [Hb], and tHb-mass explained 
no significant variance in [Hb]. 
 
In the whole population, PV independently accounted for 64% of the variance in 
[Hb] over and above that attributable to tHb-mass, although again this varied 
considerably across sub-groups.  Specifically, the degree to which PV 
influenced [Hb] independently of tHb-mass was greatest in those patient groups 
most likely to suffer expanded plasma volume and shifts in fluid- CHF (72%) 
and CLD (80%) patients compared to 19% in HV.  No significant differences in 
tHb-mass (g, g.kg-1 or g.m2) between sub-groups were found, although this was 
not the case for [Hb] and Hct.  Specifically, [Hb] and Hct (%) were significantly 
lower in chronic LD patients compared to all other patient groups, related to 
differences in PV with wide inter-individual variability in PV observed.  Taken 
together, these results highlight that relying on [Hb] alone as a guide to O2 
carrying capacity without knowledge of PV and tHb-mass may be limited.  
 135 
 
Furthermore, it challenges the convention that [Hb] provides a good surrogate 
of tHb-mass.  For example, an abnormal [Hb] when reduced could primarily be 
related to a low tHb-mass (impaired O2 carrying capacity) in the setting of a 
‘normal’ and stable PV, but could also be reduced in the context of PV 
expansion without any deficit in tHb-mass.  I have shown a progressive 
decrease in [Hb] and Hct depending on the extent of PV expansion with PV 
exerting greatest effect on [Hb] in CHF and LD patients.  My results suggest 
that changes in plasma volume in patients with chronic heart failure or liver 
disease (but which might occur across a range of other disease states) may 
strongly influence [Hb], leading to diagnoses of severe anaemia in patients 
whose tHb-mass is quite normal. 
 
The overall prevalence of anaemia found in this study (36%) is similar to 
previous studies in non-cardiac surgical patients (30.4%) [13], CHF (34%) [158] 
but less than patients with chronic LD (50-75%) [166, 167].  In sub-groups, 9% 
of IBD patients suffered anaemia, which is less than has been reported across 
European Countries (24%) [7]. Some 54% of CHF patients suffered anaemia in 
the current study, somewhat more than has been previously reported in the 
Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (34%) 
[158] , and 30% in patients with advanced HF (NYHA class III or IV) [12].  
However, our results are in keeping with other studies that have reported the 
prevalence of anaemia in CHF of 55.6% [317] and 61% [97] respectively.  Of 
CLD patients, 94% suffered anaemia- a figure somewhat higher than that 
previously reported in some studies (50-75%) [166, 167], but is in keeping with 
data in decompensated CLD (86%) [318] or hepatitis C infection (75%) [165].  
Anaemia was also found in five female healthy volunteers (24%) in the current 
study, a surprising finding given that this group was free from known chronic 
disease or use of regular medications.  A possible explanation is menstruation 
leading to anaemia, although this cannot be confirmed in the current data. 
However, the menstrual cycle is the leading cause of iron deficiency, being the 
primary cause in approximately half of those with anaemia [319].  Such a figure 
is in keeping with the global prevalence of anaemia in the general population of 
non-pregnant females (30%) [1], but higher than 16% reported in non-pregnant 
women aged 15-49 years from high income regions and 22% in menstruating 
women from central and eastern Europe [320]. This may also be related to 
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volunteering bias in the current study whereby those who thought they might be 
anaemic preferentially applied to participate. 
 
The aetiology of anaemia was not studied in Chapter 5 but this would have 
been of interest to ascertain given the patient populations studied.  For 
example, anaemia of chronic inflammation, being inflammatory driven is the 
second most common cause of anaemia after iron deficiency [175] both of 
which are commonly encountered features of anaemia in IBD [321, 322], CHF 
[323, 324] and in patients preoperatively [304, 325].  In addition, anaemia is a 
common feature of chronic kidney disease (CKD) [326], with CKD a common 
comorbidity in CHF [327], being a strong independent risk factor for anaemia 
[300]. 
 
There appears to be a dearth of previous studies that have quantified tHb-mass 
in the clinical setting using the oCOR method [48, 49, 50]. Instead, previous 
research that has addressed whether [Hb] or Hct provides a good estimate of 
O2 carrying capacity have measured RCV either directly by radiolabelling RBCs 
or indirectly through the quantification of PV.  In 40 haematologically normal 
control subjects, Huber and colleagues [328] found a strong correlation 
between Hct (%) in the 20-50% range and RCV (r= 0.880, p< 0.001) 
determined by 51Cr labelling of RBCs.  However, this relationship was disturbed 
when Hct (%) was reduced (< 20%) and elevated above 50% in patients with 
polycythaemia.  The authors found that in polycythaemia, the correlation 
between Hct and RCV lessened owing to wider variability in PV and BV.  This 
suggests that direct measurement of RCV is required to provide sufficient 
accuracy in the diagnosis of polycythaemia, a finding supported by others using 
radiolabelled techniques [329, 330] and when applying the oCOR method [48].  
Ahlgrim and colleagues confirmed that BV in patients with polycythaemia vera 
is expanded not only through elevated RCV but also as a result of PV 
expansion when compared to healthy controls.  
 
The focus of such studies differed from mine: namely, they sought to address 
the degree to which variation in PV altered the accuracy of the diagnosis of 
polycythaemia, whilst I assessed the influence of variation in tHb-mass and PV 
on [Hb] per se and on the diagnosis of anaemia. Nor have any studies in this 
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field been comprehensive across disease states, or assessed tHb-mass (rather 
than RCV). 
 
Nonetheless, others have investigated whether peripheral Hct is an accurate 
surrogate of RCV in critically ill surgical patients [331] and the limitations of Hct 
to assess the need for RBC transfusion in hypovolemic anaemic patients [332].  
Takanishi and collegues studied patients admitted to a surgical intensive care 
unit.  PV was directly measured using I131 labelled albumin with RCV calculated 
from PV and peripheral Hct.  The key finding was that Hct did not reflect true 
RCV with values deviating by as much as 15 Hct percentage points.  Results 
may have been confounded by increased measurement error in Hct (which was 
not quantified in this study), given this is used to calculate RCV.  In addition, as 
only PV was directly measured, any error in this technique will affect 
subsequent estimation of RCV and BV.  Indeed, when I131 labelled albumin is 
used to measure PV, PV may be overestimated due to distribution into the 
extravascular space [333].  Nonetheless, knowledge of Hct, RCV and PV may 
offer additional information to allow a refined approach to transfusion therapy in 
surgical patients, although this remains to be confirmed.  
 
The other main setting in which haematological variables have been studied in 
the context of anaemia and volume status is CHF.  In a cohort of 100 patients, 
Adlbrecht and colleagues [96] showed no differences in quantified RCV 
determined by the 51Cr labelled RBC technique in anaemic and non-anaemic 
patients with a broad spectrum and severity of CHF.  However, [Hb] was 
reduced and PV expanded in anaemic patients, highlighting haemodilution as 
an important factor contributing to low Hb in CHF.  Abramov and colleagues 
[105] showed in a cohort of anaemic patients with low versus preserved left 
ventricular ejection fraction no correlation between [Hb] and RCV (r= 0.09, p= 
0.54), although this was not the case in patients with normal blood volumes 
where [Hb] and RCV were significantly related to a moderate extent (r= 0.55, p= 
0.02).  The authors also elucidated that dilutional anaemia (PV expansion 
without a RCV deficit) was more common in patients with low versus preserved 
ventricular ejection fraction.  In the study by Abramov and colleagues, RCV was 
not directly measured by derived from the quantification of PV, which has 
limitations as described previously in terms of measurement error, although 
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these may be small when comparing the validity between chromium and 
albumin dilution techniques [334].  I show a similar finding in the Chapter 5 
whereby the strength of the relationship between [Hb] and tHb-mass varied with 
the extent of PV disturbance. 
 
Decompensated CHF have also been studied in the context of volume status 
and anaemia.  In a cohort of 32 decompensated chronic HF patients (with 
systolic dysfunction) hospitalised for management of symptomatic volume 
overload, Miller and colleagues [335] quantified PV directly using the 
radiolabelled albumin dilution technique with RCV subsequently derived. 
Distinct variability in RBC profiles were seen in the context of defining anaemia.  
Interestingly, 19 of the 32 patients met WHO criteria for anaemia.  However, 
with the additional knowledge of RCV and PV, only 4/19 had a ‘true’ anaemia 
whereby both [Hb] and RCV were reduced.  In contrast, 15/19 demonstrated an 
expanded PV (dilutional anaemia) with the remaining patients (13/32) having a 
normal [Hb] (12 of these patients actually had RCV excess).   
 
Using the carbon monoxide rebreathing method, I extend such observations.  
To allow comparison I calculated RCV from BV and Hct, where BV is 
dependent on quantifying tHb-mass and [Hb].  I found a similar variability in 
RBC profiles in that 39 of the 109 participants were classified as anaemic based 
on WHO criteria, of which 15/39 had a RCV deficit and reduced [Hb].  However, 
only 2 (13.3 %) of these 15 patients had a RCV deficit, reduced [Hb] and normal 
PV (so called ‘true’ anaemia), with tHb-mass being 352 g and 449 g in these 
two patients.  The remaining 13 patients were hypervolemic to varying extents 
(n= 5 mild to moderate, tHb-mass 515 ± 80 g, and n= 8 severe, tHb-mass 539 ± 
105 g).  Interestingly, 14 of the 39 anaemic patients had a relatively raised tHb-
mass, with PV raised to a greater degree (n= 1 mild to moderate PV expansion, 
tHb-mass 610 g), n= 13 severe PV expansion, tHb-mass 758 ± 220 g. These 
data add further support to the argument that reliance on [Hb] can be 
misleading and provide a false view of a patients Hb status.  Therefore, 
knowledge of tHb-mass, PV and [Hb] provides a more complete assessment of 
Hb and volume profiles in patients and allows volume excess and tHb-mass 
deficit to be defined separately and questions whether the concept of ‘anaemia’ 
needs readdressing. 
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5.5.1 Strengths and weaknesses 
 
The strengths of this study include its prospective nature and use of the oCOR 
to quantify tHb-mass, as this shows comparable and likely lower measurement 
error compared to the gold standard (51Chromium radiolabelled RBCs) without 
any of the associated issues of handling radiolabelled blood.  In addition, the 
oCOR method is of little inconvenience to patients, minimally invasive (requiring 
three blood samples from the earlobe, fingertip or cannula) and is safe, despite 
being performed on patients with serious medical conditions and comorbidities.  
I have shown that most patients can perform the technique, despite there being 
a degree of patient compliance with the rebreathing procedure like that required 
in more complex pulmonary function tests.  This greatly widens the applicability 
of the oCOR test to measure tHb-mass and blood volume derivatives in the 
clinical setting, something I propose offers useful and additional information on 
the haematological status of patients compared to relying on more established 
and routine indices (e.g. [Hb], Hct) alone.  It is acknowledged that it will not be 
possible or perhaps justified to implement the oCOR method to routine clinical 
practice.  Instead, it may be an appropriate test in certain clinical contexts 
where further information on haematological and volume status is required.  
Indeed, certainly it would be justified to measure tHb-mass in cases where the 
aim of an intervention is to increase O2 carrying capacity such as in anaemic 
cases following blood transfusion or iron supplementation.  
 
Potential weaknesses of the current study include the relatively small sample 
size, although this study was adequately powered to explore the relationship 
between tHb-mass and [Hb] across sub-groups.  The sample size of patients 
with chronic LD (n= 16) is below the calculated 21 patients required based on 
the original a priori power calculation using the study by Hinrichs and 
colleagues [24] (see 5.3.6).  This was related to difficulty recruiting sufficient 
patients and conflicting time restrictions in being able test them, which although 
disappointing was out of my control.  However, it is unlikely that the addition of 
5 patients will have greatly altered the interpretation of results and subsequent 
narrative that tHb-mass is poorly related to [Hb] in CLD and CHF patients with 
PV being a key confounding factor. 
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The use of capillary and venous blood across testing sites (UCLH and 
Southampton) to quantify [Hb] is a weakness of this study, although blood 
sampling from venous, arterial and capillary blood have been shown to yield an 
identical ∆%COHb and therefore identical tHb-mass values [272].  [Hb] 
measured in capillary blood has been widely shown to be higher [336-338] than 
[Hb] measured in venous blood. Such differences may be related to differences 
in body posture at the time of sampling, as well as factors affecting fingertip 
capillary samples such as skin thickness and temperature [339]. Biological 
variability may also in part explain differences in [Hb] values obtained from 
capillary and venous blood.  All or some of these potential sources of error may 
have affected the measured [Hb] value and thus impacted upon the relationship 
between [Hb] and tHb-mass. To minimise such confounding factors, blood 
samples were taken by trained staff and [Hb] values obtained from capillary 
blood were corrected to venous conditions.  In addition, all blood samples for 
the determination of [Hb], Hct and %COHb were collected under the same 
conditions, from the same anatomical site, with patients in a seated position and 
analysed within 10-15 minutes of one another due to %COHb being analysed 
after the oCOR test using a blood gas machine (which takes 15 minutes).  The 
use of different blood gas machines and testing staff may have introduced error 
in the measurement of tHb-mass.  However, I have shown a low typical error 
(TE) of repeat tHb-mass measurements in Chapter 4 of 1.93% (95% CI 1.3-
3.4%) which is low and in keeping with other institutions [19, 285]. 
 
A method limitation in Chapter 5 (and Chapter 6) is that PV was not directly and 
independently measured, but was subsequently derived from BV once tHb-
mass and [Hb] had been determined.  Accordingly, PV values were dependent 
on the measurement of tHb-mass and [Hb].  Although the International 
Committee for Standardization in Haematology [116] suggest that human serum 
albumin labelled with iodine isotopes (131I or 125I) be used for the direct 
measurement of PV, in reality this was not feasible in this thesis given the time, 
costs and risks associated with techniques using radiolabelled isotopes, which 
precludes the widespread use of these techniques for routine and regular 
measurement of PV in the clinical setting.  Perhaps future studies may wish to 
perform an independent assessment of PV in a representative subset of the 
total study population to determine the agreement between measured and 
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derived PV.  Given that the primary aim of this Chapter was to explore the 
relationship between [Hb] and tHb-mass and that I have shown a low-test retest 
measurement error of the oCOR method in my hands to quantify tHb-mass, 
subsequently derived BV and PV may reflect this low level of error, although 
this cannot be confirmed in the current chapter. 
 
5.6 Conclusion and further research 
 
In conclusion, tHb-mass does not correlate with [Hb] in all patient groups and 
the relationship between tHb-mass and [Hb] appears to degrade as patients get 
sicker with PV a key confounding variable.  There also appears to be distinct 
variability in RBC profiles of anaemic and non-anaemic patients when tHb-mass 
and PV are quantified in addition to [Hb].  Knowledge of tHb-mass, PV and [Hb] 
may provide a more comprehensive assessment of haematological and volume 
status compared to relying on [Hb] alone. This appears especially true amongst 
those in whom plasma volume may change most as a result of specific disease 
states.  
 
Why may the findings from the current study be of clinical relevance? A low [Hb] 
is a trigger for a raft of further, perhaps unwarranted investigations (such as the 
assay of circulating haematinic factors) or treatments (such as the 
administration of packed red blood cells or iron supplementation), whilst 
denying the administration of agents to reduce plasma volume, which might 
sometimes be required.  However, the inability to readily measure PV and tHb-
mass means that patients are generally investigated or treated for a failure of 
Hb synthesis or of erythrocytosis. This may be inappropriate for a significant 
number of patients as I have shown in the current study. In other 
circumstances, contraction in plasma volume might offer false reassurance by 
maintaining [Hb], when tHb-mass is low.  Indeed, measured [Hb], and the 
diagnosis of anaemia, can be strongly influenced by (or can largely depend 
upon) changes in plasma volume in so much that tHb-mass can be normal or 
elevated in anaemia.  Therefore, if a reduced [Hb] is not a result of a ‘true’ 
deficit in tHb-mass, does this mean oxygen carrying capacity is impaired and 
that Hb optimisation is the appropriate treatment? In this case, a reduced [Hb] 
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may be the result of hypervolaemia (PV expansion) without any deficit in tHb-
mass, and therefore alternative clinical management of volume status may be 
appropriate through diuretic therapy.  I have shown in the current study that 
patients may have the same tHb-mass but vastly different [Hb], related to the 
extent of PV disturbance.  Therefore, knowledge of tHb-mass, PV and [Hb] may 
provide a more comprehensive assessment of haematological status compared 
to relying on [Hb] alone and raises the question whether we need to readdress 
‘anaemia’ as a concept in clinical practice and should we be defining volume 
excess and tHb-mass deficit separately instead? 
 
I have demonstrated that the oCOR method is well tolerated by patients of 
varying ages with chronic diseases of mixed aetiology and severity.  This, in 
addition to the previously highlighted advantages of using the oCOR technique 
over other methods greatly widens the potential applicability of using this 
technique in the clinical setting, which others may wish to adopt.  Future studies 
may wish to investigate how best to normalise tHb-mass and derived blood 
volume compartments to allow adequate anthropometric reference values to be 
established.  For example, body weight, lean body mass, body surface area or 
using allometric scaling techniques may be appropriate.  In addition, the use of 
tHb-mass as a primary outcome when longitudinally monitoring the 
haematological status of patients following intervention is proposed given the 
larger variability in other haematological variables that I and others have shown.  
For example, using tHb-mass to assess the haematological status of patients 
throughout the perioperative period or quantifying changes in tHb-mass 
following iron supplementation or blood transfusion may be warranted.  
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Chapter 6 
6 Total haemoglobin mass is an important determinant of preoperative 
exercise capacity measured by cardiopulmonary exercise testing 
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6.1 Abstract 
 
Background. Impaired physical fitness, assessed by cardiopulmonary exercise 
testing (CPET) is associated with postoperative morbidity and mortality.  
Haemoglobin is the blood’s oxygen-carrying pigment and anaemia, defined as a 
haemoglobin concentration ([Hb]) of <130 g.l-1 in men and <120 g.l-1 in women, 
is thus associated with such reduced fitness.  However, anaemia may result not 
only from a fall in the absolute mass of haemoglobin (tHb-mass), but from a 
simple rise in the volume of plasma in which that haemoglobin is carried.  
Therefore, tHb-mass may correlate better with CPET-derived physical fitness in 
preoperative patients, than does [Hb]. I tested this hypothesis by exploring the 
relationship between [Hb], tHb-mass and preoperative CPET. 
Methods.  Patients awaiting major elective surgery underwent CPET. tHb-mass 
was quantified using the optimised carbon-monoxide (oCOR) rebreathing 
method and circulating [Hb] determined. 
Results.  Forty-two patients (83% male) were enrolled and successfully 
completed CPET and the oCOR test, of which 26% were anaemic.  Mean ± SD 
peak oxygen consumption (V̇O2 peak) and oxygen consumption at anaerobic 
threshold (V̇O2 at AT- the point at which anaerobic metabolism significantly 
supplements aerobic metabolism) were 15.7 ± 5.9 and 10.2 ± 2.3 ml.kg-1min-1, 
respectively.  Haemoglobin concentration was unrelated to V̇O2 at AT (r= 0.023, 
p= 0.892) or V̇O2 peak (r= 0.041, p= 0.796) expressed in ml.kg-1min-1.  In 
contrast, tHb-mass (g.kg-1) was related to V̇O2 peak (r= 0.483, p= 0.001), and 
more so to V̇O2 at AT (r= 0.661, p< 0.0001) expressed in ml.kg-1min-1. tHb-mass 
(g.kg-1) explained 43.7% of V̇O2 at AT (p< 0.0001) and 23.3% of V̇O2 peak (p= 
0.001) ml.kg-1min-1.  [Hb] did not explain any variance in either measure.  A 1 
g.kg-1 increase in tHb-mass was associated with a 1.0 ml.kg-1min-1 increase in 
AT (p< 0.0001) and a 2.0 ml.kg-1min-1 increase in V̇O2 peak (p= 0.01), after 
adjusting for age, sex, smoking status, diabetes and the presence of 
cardiovascular disease. 
Conclusions.  Unlike [Hb], tHb-mass is an important determinant of preoperative 
patient physical fitness associated with exertional oxygen consumption.  It is 
both measurable and manipulable (through targeted transfusion of red blood 
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cells) and therefore trials of targeted increases in tHb-mass to enhance physical 
fitness and improve surgical outcome thus appear warranted. 
 
6.2  Introduction  
 
Cardiopulmonary exercise testing (CPET) measures the integrated function of 
the cardiovascular, pulmonary and musculoskeletal systems and provides an 
objective assessment of physical fitness.  CPET is routinely used for the 
purposes of preoperative assessment and risk stratification prior to major 
surgery and to guide care postoperatively [193, 194] with the aim of improving 
patient outcomes.  CPET measures exertional oxygen consumption (V̇O2) at 
peak exercise (the peak exertional oxygen consumption, V̇O2 peak), and at the 
anaerobic threshold (V̇O2 at AT), being a submaximal marker of physiological 
reserve.  When reduced, V̇O2 peak and V̇O2 at AT are associated with an 
increased risk of morbidity and mortality [56, 58, 195] following major surgery. 
 
Haemoglobin (Hb) is the blood’s O2 carrying pigment carried in circulating red 
blood cells (RBCs). Accordingly, the availability of Hb may influence 
cardiorespiratory fitness. Preoperative anaemia is defined using whole blood as 
a circulating haemoglobin concentration ([Hb]) <130 g.l-1 in men and <120 g.l-1 in 
women [2].  Preoperative anaemia is common and affects around one third of 
cases [6], is associated with decreased exercise capacity [11, 60] and an 
increased incidence of postoperative morbidity and mortality [6, 13].  However, 
because the measured [Hb] is based on whole blood it reflects both the mass of 
circulating Hb (tHb-mass), and the volume status of patients, specifically the 
volume of plasma in which erythrocytes are suspended.  The 2-minute 
optimised carbon monoxide rebreathing (oCOR) method developed by Schmidt 
and Prommer [19] provides a precise, safe and reliable technique to quantify 
tHb-mass, although this method has rarely been applied in the clinical setting 
despite its many advantages over previous techniques.  
 
Because the proportion of O2 carried in plasma is trivial (0.3 ml O2 per 100 ml-1 
blood), the relationship between exercise capacity and tHb-mass might be 
stronger than that with [Hb]. Indeed, a close relationship between tHb-mass and 
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aerobic capacity has been demonstrated in healthy volunteers and athletes 
[250, 340] but whether this applies to patient populations is less certain.  
Indeed, no studies have measured tHb-mass in patients awaiting major surgery 
and investigated associations with CPET-derived exertional oxygen 
consumption.  In Chapter 6 I tested this hypothesis. 
 
6.2.1 Study aim 
 
To explore the relationship between both [Hb] and tHb-mass and measures of 
patient physical fitness, determined by cardiopulmonary exercise testing 
(CPET). 
 
6.2.2  Study hypothesis 
 
tHb-mass will display a stronger relationship with exertional V̇O2 at AT and V̇O2 
peak than [Hb]. 
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6.3  Methods  
 
Ethical approval was granted by the London, Camden and Kings Cross 
Research Ethics Committee (REC reference: 13/LO/1901).  We fully adhered to 
Caldicott guidelines and conformed to the standards set by the Declaration of 
Helsinki. Patients were given a participant information sheet (see Appendix E) 
prior to written informed consent being obtained from all participants willing to 
participate (see Appendix F). 
 
6.3.1 Patients 
 
Adult (> 18 years) elective (non-cardiac) surgical patients at University College 
Hospital (University College London Hospitals NHS Foundation Trust) and 
Southampton General Hospital (University Hospital Southampton NHS 
Foundation Trust) were prospectively studied between February and August 
2015.  Patients were either receiving CPET as part of their routine preoperative 
assessment, or were co-recruits to the ‘METS’ study of the role of CPET in 
altering surgical outcome [341].  Patients were sent a participant information 
sheet by a member the CPET team enclosed with their routine CPET 
appointment letter.  Subsequently, patients were contacted regarding their 
voluntary participation in the study. Age, gender, height, weight, diagnosis, 
planned surgical procedure, comorbidities (such as diagnosis of diabetes, 
respiratory or cardiovascular disease) and current medications were 
documented.  
 
6.3.1.1 Inclusion criteria 
 
i) Male or female adults (> 18 years) 
ii) Able to perform CPET 
iii) Able to perform oCOR technique 
iv) Able to consent 
v) Awaiting major surgery 
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6.3.1.2 Exclusion criteria 
 
i) Adults with known underlying history of learning disabilities, or adults 
who do not have mental capacity to consent for themselves.  
ii) Prisoners. 
iii) Have contraindication to CPET as outlined in ATS/ACCP guidelines. 
iv) Baseline %COHb greater than 5% (as commonly occurs in smokers). 
v) Haemoglobinopathies (e.g. Sickle cell anaemia). 
 
6.3.2 Cardiopulmonary Exercise Testing 
 
CPET was performed according to the established and widely used American 
Thoracic Society/American College of Chest Physicians (ATS/ACCP) guidelines 
on CPET [274], see methods section 3.2 for full details. 
 
6.3.3 Statistics 
 
Statistical analysis was performed using SPSS Statistics (Version 23.0 for 
Apple Macintosh, Chicago, IL, USA).  Values are presented as mean ± 
standard deviation (SD), unless otherwise stated.  Median and interquartile 
range (IQR) are reported when variables are not normally distributed and when 
data transformation (logarithmic, square root or reciprocal) did not result in a 
normally distributed variable.  Categorical variables are presented as frequency 
(%).  Normal (Gaussian) distribution was assessed using a combination of the 
Kolmogorov-Smirnov test, visual inspection of histogram charts and normal Q-Q 
plots for each variable.  Independent samples t-test and Mann-Whitney U tests 
assessed the differences in haematological variables in anaemic and non-
anaemic patients, depending on normality of data distribution.  Pearson’s 
correlation coefficient assessed the relationship between [Hb], tHb-mass and 
exertional V̇O2 allowing adjustment for confounding.  Linear regression models 
assessed the associations between V̇O2 and haematological variables ([Hb] 
and tHb-mass) and the proportion of variance in V̇O2 explained by [Hb] and 
tHb-mass, allowing adjustment for confounding. Specifically, age, gender, 
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smoking status, diabetes and the presence of cardiovascular disease (defined if 
a patient had either ischaemic heart disease, heart failure of previous stroke) 
were included as confounders in both correlation and regression analyses. [Hb], 
tHb-mass, exertional V̇O2 at AT and V̇O2 peak were expressed in g.l-1, g.kg-1 
and ml .kg-1 min-1, respectively for both correlation and regression analysis.  
Elsewhere, V̇O2 is expressed in ml.kg-1 min-1 and tHb-mass in g.kg-1 unless 
otherwise stated.  All tests were two-sided with statistical significance accepted 
as a p-value of < 0.05.    
 
6.3.4 Power calculation  
 
The original a priori power calculation for this study was performed to be able 
detect significant differences in both exertional V̇O2 and tHb-mass between 
patients with and without postoperative morbidity on day-5.  Specifically, using 
data from West and colleagues [342] I anticipated that 50% of patients would 
have a post-operative morbidity by day-5 and the standard deviation of V̇O2 at 
AT to be 3.35 ml.kg-1min-1. For tHb-mass, based on the study by Koponen and 
colleagues [49] I assumed that the standard deviation of tHb-mass would be 
1.25 g.kg-1.  Allowing for a 10% loss to follow-up, 91 patients would provide 80% 
power at the 5% significance level to detect a minimum, clinically important 
difference in mean V̇O2 at AT of 2.1 ml.kg-1min-1 and a difference in mean total 
haemoglobin mass of 0.78 g.kg-1 between those patients with and without day-5 
postoperative morbidity. 
 
However, during patient recruitment and data collection it became clear that it 
was not going to be possible to recruit the 91 patients required to meet the 
original power calculation to look at postoperative outcome in this study. The 
main hypothesis of this study was that tHb-mass would display a stronger 
relationship with exertional V̇O2 than [Hb] and therefore to quantify these 
relationships was the primary aim of this study and while it would have been of 
interest to investigate links to postoperative outcome, at this stage it was not 
possible nor was it the primary aim.  Subsequently I performed a post hoc 
power calculation using G*3 Power version 3.1.9.2 [316] to establish an 
achieved power for this study of 0.91, based on the sample size of 42 patients, 
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an alpha value of 0.05 and observed correlation of r=0.48 between weight 
adjusted tHb-mass and V̇O2 peak (ml.kg-1min-1).  
 
6.4 Results 
 
Forty-three patients (19 from Southampton General Hospital and 24 from 
University College London Hospital) consented to take part in the study, of 
whom 10 were co-recruits of the ‘METS’ study participants [341].  One failed to 
successfully complete the oCOR protocol and so was excluded.  The patient 
characteristics, including surgical specialty are shown in Table 6-3. 
 
No major adverse clinical events occurred during CPET that resulted in 
premature exercise termination.  The mean ± SD V̇O2 peak and AT were 15.7 ± 
5.9 and 10.2 ± 2.3 ml.kg-1min-1.  AT was unable to be determined in 3 patients 
but these remain in any analysis containing V̇O2 peak. Mean ± SD [Hb] and 
tHb-mass were 135.6 ± 15.6 g.l-1 and 677 ± 146 g, respectively. Table 6-4 
shows haematological variables for all patients and categorised by anaemia 
classification.    
 
6.4.1  Anaemia and haematological variables 
 
Twenty-six percent of patients were anaemic preoperatively per WHO criteria.  
Thus, anaemic patients had lower [Hb] and Hct compared to non-anaemic 
patients (see Table 6-4).  There was no difference in tHb-mass between groups 
when expressed either in absolute grams of haemoglobin or when scaled to 
body mass (kg).  Anaemic patients displayed an expanded blood volume (ml.kg-
1) and plasma volume (ml & ml.kg-1) compared to non-anaemic patients (see 
Figure 6-1 B and D, respectively).   
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Figure 6-1. (A) Total haemoglobin mass (tHb-mass), (B) blood volume (BV), (C) haemoglobin concentration ([Hb]), (D) plasma volume 
(PV) in anaemic and non-anaemic CPET patients. *p< 0.05 
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6.4.2 Relationships between haematological variables and oxygen uptake 
 
[Hb] (g.l-1) was unrelated to either V̇O2 at AT (r= 0.023, p= 0.892) or V̇O2 peak 
(r= 0.041, p= 0.796) expressed in ml.kg-1min-1.  However, tHb-mass (g.kg-1) 
showed a moderate association with V̇O2 peak, (r= 0.483, p= 0.001) and, 
moreso, with V̇O2 at AT (r= 0.661, p< 0.0001), expressed in ml.kg-1min-1 (see 
Figure 6-2).  The relationships between tHb-mass (g) and V̇O2 at AT (ml.min-1) 
was r= 0.700, p< 0.0001 and between tHb-mass (g) and V̇O2 peak (ml.min-1), r= 
0.522, p< 0.0001.  After adjusting for age, gender, diabetes, smoking status, 
and the presence of cardiovascular disease, tHb-mass (g.kg-1) remained 
strongly correlated with V̇O2 at AT (r= 0.629, p< 0.0001) and to a lesser extent 
with V̇O2 peak (r= 0.412, p= 0.011) expressed in ml.kg-1min-1.   
 
6.4.3  Linear Regression Models 
 
[Hb] failed to significantly explain any of the variance in V̇O2 at AT (adjusted 
R2= -0.027, p= 0.892) or V̇O2 peak (adjusted R2= -0.023, p= 0.796) expressed 
in ml.kg-1min-1.  In contrast, tHb-mass (g.kg-1) explained 43.7% of the variance 
in V̇O2 at AT (ml.kg-1.min-1) p< 0.0001 and 23.3% in V̇O2 peak (ml.kg-1.min-1) p= 
0.001.  After adjusting for age, gender, smoking status, diabetes, and the 
presence of cardiovascular disease, only tHb-mass (g.kg-1) was associated with 
V̇O2 at AT (ml.kg-1min-1) with a 1 g.kg-1 increase in tHb-mass associated with a 
1.0 ml.kg-1min-1 increase in AT (p< 0.0001).  Similarly, after adjustment for age, 
gender, smoking status, diabetes, and the presence of cardiovascular disease, 
only tHb-mass (g.kg-1) was associated with V̇O2 peak (ml.kg-1min-1) with a 1 
g.kg-1 increase in tHb-mass associated with a 2.0 ml.kg-1min-1 increase in V̇O2 
peak (p= 0.01).  See Table 6-1 and Table 6-2 for multiple linear regression 
coefficients for factors assessed in the prediction of V̇O2 at AT and V̇O2 peak, 
respectively. 
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Table 6-1. Multiple linear regression coefficients for factors assessed in the 
prediction of oxygen consumption at anaerobic threshold (V̇O2 AT, ml.kg-1 
min-1) 
 ß SE ß Standardised ß Sig 
Constant 1.95 3.39  0.569 
tHb-mass 1.09 0.24 0.64 <0.0001 
Age -0.02 0.03 -0.09 0.480 
Gender 0.98 0.84 0.16 0.252 
Diabetes -0.17 0.72 -0.03 0.811 
Smoking status -0.42 0.40 -0.13 0.300 
Cardiovascular disease -1.41 0.88 -0.21 0.121 
SE, standard error; tHb-mass (total haemoglobin mass, g.kg-1), age (yr), gender 
(male or female), cardiovascular disease (presence of either ischaemic heart 
disease, chronic heart failure or stroke), smoking status (current, former or non-
smoker), diabetes (present of absent).   
 
 
Table 6-2. Multiple linear regression coefficients for factors assessed in the 
prediction of peak oxygen consumption (V̇O2 peak, ml.kg-1 min-1) 
 ß SE ß Standardised ß Sig 
Constant 4.86 10.20  0.636 
tHb-mass 1.94 0.73 0.44 0.011 
Age -0.07 0.08 -0.13 0.353 
Gender 0.96 2.46 0.06 0.699 
Diabetes 0.57 2.16 0.04 0.791 
Smoking status -1.84 1.15 -0.23 0.117 
Cardiovascular disease -2.66 2.49 -0.16 0.292 
SE, standard error; tHb-mass (total haemoglobin mass, g.kg-1), age (yr), gender 
(male or female), cardiovascular disease (presence of either ischaemic heart 
disease, chronic heart failure or stroke), smoking status (current, former or non-
smoker), diabetes (present of absent).   
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Table 6-3. Patient characteristics and medications.  
Variable n= 42 
Gender  
  Male 35 (83%) 
  Female 7 (17%) 
Age (yr) 66 (58-71) 
Height (cm) 172 ± 9 
Weight (kg) 83 ± 16 
Surgical specialty  
  Urology 19 
  Hepatology 9 
  Maxillofacial 2 
  Upper gastrointestinal 3 
  Thoracic 4 
  Vascular 1 
  Gastrointestinal 4 
Ischaemic heart disease 5 (12%) 
Heart failure 1 (2%) 
Hypertension 19 (45%) 
Stroke  1 (2%) 
Diabetes 9 (21%) 
COPD 6 (14%) 
Smoking history  
  Current 6 (14%) 
  Former 12 (27%) 
  Never 24 (57%) 
Medication  
  Beta blocker 6 (14%) 
  Nitrate therapy 1 (2%) 
  ACE inhibitor 14 (33%) 
  Statin 13 (31%) 
COPD, chronic obstructive pulmonary disease; ACE 
inhibitor, angiotensin converting-enzyme inhibitor. Values 
are expressed as mean ± SD, median (IQR) or frequency 
(%). 
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Table 6-4. Haematological characteristics in anaemic and non-anaemic CPET patients. 
Variable All patients 
(n= 42) 
Anaemic 
(n= 11) 
Non-anaemic 
(n= 31) 
p-value 
[Hb] (g.l-1) 135.6 ±15.6 116.3 ± 11.7 142.5 ± 10.1 < 0.0001 
Hct (%) 41.4 ± 4.0 37.4 ± 4.2 42.7 ± 3.0 < 0.0001 
tHb-mass (g) 677 ± 146 610 ±119 700 ± 149 0.079 
tHb-mass (g.kg-1) 8.2 ± 1.3 7.8 ± 1.7 8.3 ± 1.2 0.316 
BV (ml) 5495 ± 1065 5753 ± 951 5404 ± 1102 0.356 
BV (ml.kg-1) 67.3 ± 12.2 74.7 ± 16.0 64.6 ± 9.6 0.016 
PV (ml) 3421 ± 678 3775 ± 560 3295 ± 680 0.043 
PV (ml.kg-1) 42.0 ± 8.2 49.0 ± 9.4 39.5 ± 6.3 0.001 
PV (%) 62.3 ± 3.7 65.9 ± 3.8 61.0 ± 2.7 < 0.0001 
RCV (ml) 2074 ± 462 1978 ± 466 2108 ± 464 0.431 
RCV (ml.kg-1) 25.3 ± 4.9 25.6 ± 7.4 25.1 ± 3.9 0.768 
MCV (fl) 90.5 ± 4.6 90.6 ± 4.3 89.4 ± 5.0 0.521 
MCH (pg) 30.3 ± 1.9 29.7 ±1.4 30.4 ± 2.1 0.370 
MCHC (g.l-1) 342 (321-349) 320 (314-347) 344 (331-350) 0.096 
Creatinine (µmol.l-1) 97 (65-102) 112 (67-188) 77 (65-97) 0.107 
Albumin (g.l-1) 42 (39-44) 36.0 (27-43) 43 (40-45) 0.042 
[Hb], Haemoglobin concentration; Hct, haematocrit; tHb-mass, total haemoglobin mass; BV, blood 
volume; PV, plasma volume; RCV, red cell volume; MCV, mean corpuscular volume; MCH, mean 
corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration. Anaemia 
defined per World Health Organisation criteria when ([Hb]) <130 g.l-1 in men and <120 g.l-1 in 
women.  Values are expressed as mean ± SD, median (interquartile range, IQR) or frequency (%). 
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Figure 6-2. (A) Unadjusted relationship between haematological variables 
and exertional oxygen consumption.  Relation of V̇O2 peak (ml.kg-1min-1) to 
tHb-mass (g.kg-1) (A) and [Hb] (g.l-1) (C) in 42 patients. Relation of V̇O2 at 
AT to tHb-mass (g.kg-1) (B) and [Hb] (g.l-1) (D) in 39 patients. tHb-mass, 
total haemoglobin mass; [Hb], haemoglobin concentration; AT, anaerobic 
threshold; V̇O2 peak, peak oxygen consumption. 
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6.5  Discussion 
 
To my knowledge this is the only study to have explored the relationship 
between total haemoglobin mass and physical fitness determined by 
cardiopulmonary exercise testing in patients awaiting major elective surgery.  
Whilst [Hb] was unrelated to exertional V̇O2 at either AT or V̇O2 peak (ml.kg-
1.min-1), total haemoglobin mass (g.kg-1) was associated with V̇O2 peak (r= 0.48) 
and to a greater extent with V̇O2 at AT (r= 0.66), even after adjusting for 
measured confounding variables.  These relationships strengthened when 
comparing absolute tHb-mass (g) with V̇O2 at AT (ml.min-1) (r= 0.700 p< 
0.0001) and V̇O2 peak (ml.min-1), r= 0.522, p< 0.0001.  Some 44% of the 
variance in a patient’s V̇O2 at AT (ml.kg-1.min-1) was attributable to measured 
tHb-mass (g.kg-1), which may be of particular importance in the perioperative 
setting, given the consistent link between V̇O2 at AT and surgical outcome. 
 
There is limited research in the clinical setting with which to compare my 
results.  However, one study by Koponen and colleagues [49] measured total 
haemoglobin mass using the oCOR method and aerobic capacity (V̇O2 peak) 
quantified by CPET in 12 men with type 1 diabetes (T1DM) and healthy controls 
(n= 23). [Hb] was not associated with V̇O2 peak either in patients with T1DM or 
controls, in keeping with results from the current study.  In patients with T1DM, 
body mass-normalised tHb-mass was strongly related with V̇O2 peak (ml.kg-
1.min-1), r= 0.71; p< 0.01 and tHb-mass explained 51% of the variance in V̇O2 
peak.  This study did not report the relationship between tHb-mass and AT 
however.  The strength of correlation between tHb-mass (g.kg-1) and V̇O2 peak 
(ml.kg-1.min-1), r= 0.71 reported by Koponen and colleagues [49] is stronger 
than results from the current study (r= 0.48).  This may in part be explained by 
differences in relatively small sample sizes, differences (albeit small) in 
measurement error inherent in both oCOR test and CPET measurement and 
perhaps to a greater extent related to V̇O2 peak being dependent upon 
patient/participant volition and motivation.  If this is the case then the 
relationships between V̇O2 peak and tHb-mass may be underestimated in the 
current study. This is one proposed advantage of using the AT to quantify 
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preoperative fitness as it is a non-volitional measure of physical fitness.  In 
general, the finding that tHb-mass displays a stronger relationship with V̇O2 
peak than [Hb] is consistent with previous reports in healthy volunteers and 
trained athletes (r= 0.79 in pooled data from 611 subjects, [340]; r = 0.48, 0.79 
and 0.92 in male runners, and male and female rowers, respectively [29]).    
 
Mean AT of 10 ml.kg-1min-1 and V̇O2 peak of 16 ml.kg-1min-1 are in keeping with 
previous studies quantifying preoperative exercise capacity using CPET ([58, 
59]).  Similarly, the prevalence of anaemia (26%) in the current study is in 
keeping with previously reported values of around 30% from large, retrospective 
datasets ([6, 13]), supporting anaemia as a common occurrence in patients 
awaiting major surgery.  The mean ± SD tHb-mass (g and g.kg-1) from the 
current study were 677 ± 146 g and 8.2 ± 1.3 g.kg-1, respectively.  These values 
are lower than those report by Koponen and colleagues [49] (tHb-mass 722 ± 
121 g and 10.1 ± 1.5 g.kg-1) in patients with T1DM and healthy controls (tHb-
mass 898 ± 96 g and 11.0 ± 1.1 g.kg-1).  Furthermore, values reported in the 
current study are substantially lower than those of endurance trained athletes 
(mean ± SD tHb-mass 1285 ± 123 g and 13.7 ± 0.5 g.kg-1) in elite rowers, [25]; 
tHb-mass 958 ± 123 g in trained cyclists, [27] and in excess of 14.5 g.kg-1 in 
elite marathon runners [261].   
 
Data from endurance-trained athletes suggest that such high tHb-mass values 
can only be reached by either years of intensive training or are strongly 
influenced by genetic factors [209], but may also be influenced by elicit use of 
erythropoietin and/or blood transfusion, previously common practice in many 
endurance sports.  However, data from untrained subjects also suggests that 
improvements in V̇O2 peak following only 6 weeks of endurance training can 
also be achieved, with increases in peak Q̇ and O2 carrying capacity (quantified 
by RCV and tHb-mass) being the primary underlying mechanisms [344].  
Indeed, as Schmidt and Prommer hypothesise [209], tHb-mass governs aerobic 
exercise capacity via two mechanisms through which V̇O2max can be enhanced 
as a result of i) a balanced increase in both tHb-mass and PV (thus increasing 
Q̇) and ii) by elevating [Hb] in the context of reduced or unaltered PV, which 
augments the arteriovenous oxygen content difference (oxygen extraction).  It is 
 160 
this dual role which may explain the observed stronger relationship between 
tHb-mass and exertional V̇O2 in the current study.   
 
Given that prolonged endurance training is not feasible in patients awaiting 
major surgery, and genetics are predetermined, alternative interventions to 
increase tHb-mass preoperatively (and thus aerobic fitness and related surgical 
outcome) are worthy of exploration.  In addition, preoperative anaemia is 
associated with an increased risk of postoperative morbidity and mortality [6, 
13] and it would thus perhaps be surprising if a similar relationship was lacking 
for tHb-mass.  Furthermore, as I have shown a close relationship between tHb-
mass and preoperative fitness, and given the link between exertional V̇O2 and 
surgical outcome, it would seem logical to purport that a high tHb-mass may be 
advantageous to patient outcomes in the perioperative setting, although this 
remains to be confirmed.  It should be highlighted that aerobic exercise training 
causes many other important physiological adaptations, such as altered cardiac 
structure and function [344] and changes within skeletal muscle [345, 346] that 
may lead to enhanced functional capacity in patients independently of changes 
in tHb-mass, with even small gains potentially of clinical significance, 
particularly in the perioperative period.  Indeed, this is an area of growing 
research in patients awaiting major surgery to optimise physical fitness 
preoperatively (termed prehabilitation), with the aim of improving postoperative 
outcome.  Optimisation of tHb-mass may also have a role to play in 
prehabilitation. 
 
The underlying causes of exercise intolerance are multifactorial, especially in 
patients with multiple co-morbidities commonly encountered preoperatively.  
However, and although subject to much debate [229], it is widely considered 
that reduced V̇O2 peak and V̇O2 at AT are related to an impairment in systemic 
DO2 relative to metabolic demands [230, 277], although muscle fibre type 
recruitment and intramuscular enzymatic rate limitations have also been 
proposed as important limiting factors [347, 348].  Given that DO2 is dependent 
on Q̇ and arterial oxygen content, and that many patients are anaemic 
preoperatively (or at least may have lower haemoglobin values) this adds 
weight to the argument that increasing tHb-mass should be favourable as 
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purported above.  Certainly, the relationship of tHb-mass with exertional V̇O2 at 
AT and V̇O2 peak in Chapter 6 would hint towards this mechanism.  
 
Once tHb-mass has been quantified, other blood volume compartments (BV, 
RCV and PV) can be derived providing [Hb] and Hct (%) are measured.  In the 
context of anaemia, as I have also shown in Chapter 5, these variables offer 
additional insight into the haematological and volume status of patients given 
that the measured [Hb] can be affected by both changes in tHb-mass and PV, 
independently of one another.  As shown in Table 6-4, tHb-mass (g & g.kg-1) 
and RCV (ml & ml.kg-1) did not statistically significantly differ between anaemic 
and non-anaemic patients.  However, BV (ml.kg-1) and PV (ml & ml.kg-1) were 
expanded in anaemic patients, suggesting to some extent that anaemia in this 
small sample may in part be related to PV expansion rather than a deficit in O2 
carrying capacity as quantified by tHb-mass. Thus, dilutional anaemia may not 
have such negative effects on exercise capacity as ‘true’ anaemia, being 
characterised by a deficit in tHb-mass and impaired blood O2 carriage.  This 
may to some extent explain the lack of association between [Hb] and exertional 
V̇O2 I found in the current chapter.  In future studies the aetiology of anaemia 
should therefore also be evaluated.  Indeed, in the current study median 
creatinine concentrations were numerically (but not statistically significantly) 
higher in anaemic patients, suggesting chronic kidney disease as a potential 
underlying cause of anaemia.  However, it was not the aim of this study to 
elucidate the underlying aetiology of anaemia, and larger studies (with greater 
power) would be needed to determine if renal impairment contributed 
significantly to the prevalence of preoperative anaemia.  
 
6.5.1 Strengths and weaknesses 
 
Strengths of this study include its use of CPET to prospectively determine 
preoperative exercise capacity as it is considered the gold standard 
assessment of cardiorespiratory fitness, being both objective and precise.  As 
described previously in Chapter 5, the use of the oCOR method to quantify tHb-
mass is a strength.  Potential weaknesses of the current study include the 
relatively small sample size, although this study was adequately powered to 
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explore the relationship between tHb-mass and exertional V̇O2 (post hoc 
achieved power of 0.91, based on the sample size of 42, alpha value of 0.05 
and correlation of r=0.48 between weight adjusted tHb-mass and V̇O2 peak).  In 
addition, to my knowledge, the current study cohort is the largest in which the 
relationship between preoperative tHb-mass and CPET-derived physical fitness 
has been explored and is a larger sample size than the study by Koponen and 
colleagues [49].  As outlined in detail in Chapter 5 the use of capillary and 
venous blood across testing sites (UCLH and Southampton) to quantify [Hb] is 
a weakness of this study as is the use of different blood gas machines between 
sites.  I have already addressed in Chapter 5 how I minimised and/or controlled 
for these factors.  Finally, the use of different metabolic carts across sites may 
have impacted upon measured V̇O2, although both metabolic carts were 
calibrated prior to every CPET to reduce any measurement error in exertional 
V̇O2. 
 
6.6  Conclusion and further research 
 
In conclusion, in a cohort of patients awaiting major elective surgery, total 
haemoglobin mass was found to be an important determinant of preoperative 
cardiorespiratory fitness associated with exertional oxygen consumption, 
whereas haemoglobin concentration failed to show any significant relationship 
with exertional V̇O2.  Future studies may wish to address whether increasing 
tHb-mass preoperatively leads to improved fitness for surgery as quantified by 
CPET.  Subsequently, adequately powered and randomised controlled trials will 
be required to see if manipulation of tHb-mass affects surgical outcome, which 
the current Chapter 6 was not designed or powered to address. 
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7 Overall conclusion and future directions 
 
In this section I provide a general conclusion to my thesis and provide possible 
areas for future research based on my work to date.  At the end of this section I 
also provide a detailed abstract style overview for four future experiments. 
 
In this thesis, I have utilised the oCOR method to quantify tHb-mass in different 
patient populations and disease states and objectively measured 
cardiorespiratory fitness in patients awaiting surgery using the gold standard 
test, CPET.  In Chapter 4 I have shown that the oCOR method is reliable in my 
hands based on a low-test retest measurement error that is similar to other 
established institutions using the oCOR method.  In addition, the oCOR is well 
tolerated by patients of varying ages with chronic diseases of mixed aetiology 
and severity, is safe and minimally invasive.  This greatly widens the potential 
applicability of the oCOR test to measure tHb-mass and blood volume 
derivatives more routinely in the clinical setting, something I propose offers 
useful and additional information on the haematological and volume status of 
patients compared to relying on more routine RBC indices such as [Hb].  Thus, 
the oCOR method may provide better and more appropriate assessments of the 
factors influencing circulating [Hb].  Therefore, use of the oCOR method is 
advocated in the future.     
 
This thesis in part questions whether the concept of ‘anaemia’ needs 
readdressing, and whether we should be defining volume excess and tHb-mass 
deficit separately instead?  This is based on the findings of Chapter 5, which 
aimed to determine the degree to which tHb-mass was correlated with [Hb] in 
different patient populations and across disease states.  I have shown that tHb-
mass does not correlate with [Hb] in all disease states studied and that the 
relationship between [Hb] and tHb-mass appears to degrade as patients get 
sicker with PV a key confounding variable showing wide variability on an 
individual patient level.  Specifically, in disease states most likely to experience 
expanded plasma volume and shifts in fluid- CLD and CHF, tHb-mass does not 
correlate with [Hb] in these disease groups.  Furthermore, on an individual level, 
patients may have very similar or the same tHb-mass but vastly different [Hb] 
and PV.  Therefore, measured [Hb], and the diagnosis of anaemia, can be 
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strongly influenced by (or can largely depend upon) changes in plasma volume. 
Indeed, tHb-mass can be normal or elevated in anaemia.  Furthermore, the 
inability to readily measure PV and tHb-mass means that patients are generally 
investigated or treated for a failure of Hb synthesis or of erythrocytosis. This 
may be inappropriate for a significant number of patients.  In an era where 
personalised medicine is an emerging strategy, these findings may have 
important clinical implications that warrant further investigation.   
 
In Chapter 6 I explored the relationship between both [Hb] and tHb-mass with 
measures of objective patient physical fitness quantified by CPET.  In a cohort 
of patients awaiting major elective surgery, I found that tHb-mass was an 
important determinant of preoperative cardiorespiratory fitness, whereas [Hb] 
failed to show any significant relationship with physical fitness.  Given that tHb-
mass is measurable and manipulable, future studies may wish to address 
whether increasing tHb-mass preoperatively via targeted intervention using 
intravenous iron supplementation or blood transfusion leads to improved fitness 
for surgery as quantified by CPET (see future study 1 below).  The use of 
intravenous iron supplementation would also allow the relationship between 
changes in indices of iron status and tHb-mass to be explored as well as any 
independent relationship between iron indices and CPET variables to be 
elucidated.  The ongoing UK CAVIAR study, an observational study in patients 
undergoing cardiac and vascular surgery will address the effects of intravenous 
iron therapy (received as part of routine care) on changes in [Hb], biomarkers of 
iron deficiency (e.g ferritin, hepcidin, transferrin saturation) and in a sub-study, 
changes in total haemoglobin mass (via oCOR method) and functional capacity 
(assessed by CPET or 6-minute walk test, depending on study site).  
Additionally, adequately powered and randomised controlled trials are required 
to see if manipulation of tHb-mass affects surgical outcome, which my thesis 
was not designed or powered to address but is an interesting area for future 
research, and appears warranted. 
 
In this thesis PV was derived from the accurate measurement of tHb-mass and 
not directly quantified using an independent measurement technique.  
Therefore, future studies (see future study 2 below) may wish to perform an 
independent assessment of PV using the gold standard method (human serum 
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albumin labelled with radioactive iodine) to determine the agreement between 
measured and derived PV values.  This may be of importance in studies 
assessing the effects of treatment not only on red cell indices but also on 
volume status of patients.  For example, the effects of diuretic dose and timing 
on PV in patients with decompensated HF or ascites related to chronic LD may 
require a direct measurement of PV if the level of agreement between 
quantified and derived PV (using the oCOR method) is not of sufficient 
accuracy. This warrants further investigation. 
 
It is acknowledged that it may not be possible to implement the oCOR method 
into routine and widespread clinical practice.  Instead, it may be an appropriate 
test in certain clinical contexts where further information on haematological and 
volume status of patients is required.  This may be relevant to patients with 
anaemia and disease groups who are most likely to suffer expanded plasma 
volume and shifts in fluid (e,g, heart failure, chronic liver disease, chronic kidney 
disease), although I have shown that in other disease states such as IBD (not 
generally considered to commonly experience disturbances in PV) that tHb-
mass between individuals can be very similar but [Hb] substantially different.  In 
addition, it would appear justified to use the oCOR method to quantify changes 
in tHb-mass in cases where the aim of treatment is to optimise Hb and O2 
carrying capacity.  In this context, future research may wish to use tHb-mass as 
the primary haematological outcome variable, for example when longitudinally 
monitoring the haematological status of patients throughout the perioperative 
period (see future study 3 below) or during critical illness in patients on the 
intensive care unit.  In addition, how best to normalise tHb-mass and derived 
blood volume compartments (e.g. body weight, lean body mass, body surface 
area or using allometric scaling techniques) to allow adequate anthropometric 
reference values to be established also appears warranted.  This is important 
because if tHb-mass is to be used clinically in the future we need to know what 
constitutes a ‘normal’ tHb-mass and therefore what constitutes a tHb-mass 
deficit or excess.  For example, could we established an anaemia classification 
system based on tHb-mass alongside that for [Hb]?  This would require large, 
adequately powered studies to define such reference values.   
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Furthermore, in clinical practice if a patient is classified as anaemic based on 
[Hb] this routinely triggers a series of further investigations (mainly additional 
blood tests with associated costs to the NHS) to try and elucidate the underlying 
cause of anaemia and therefore an appropriate treatment to optimise Hb if 
necessary.  However, patients may be anaemic in the context of normal tHb-
mass but expanded plasma volume and I have shown that individual patients 
may have the same tHb-mass but vastly different [Hb] values and may therefore 
be treated differently if only [Hb] was used as an initial guide.  Therefore, could 
the oCOR method be used to quantify tHb-mass in anaemic patients as an 
initial screening test?  If there is no deficit in tHb-mass, is there a need for 
subsequent blood tests to be carried out? It would be interesting to find out the 
number of anaemic patients with electronic blood records at University College 
Hospital who had additional blood tests (e.g. iron studies, vitamin B12 and 
folate, thyroid function etc) to find out whether these subsequent results were 
normal or abnormal?  In addition, it would be of interest to elucidate how many 
patients were treated with a blood transfusion or iron supplementation (oral or 
intravenous).  Thereafter, one could calculate the costs incurred to the NHS 
from these additional (potentially unnecessary) tests and compare to the cost of 
performing an oCOR test.  In cases where additional blood tests failed to 
elucidate any abnormal results, would knowledge of a normal tHb-mass have 
prevented their conduct and/or provided useful additional information?  See 
future study 4 below.  This could further be studied prospectively by measuring 
tHb-mass using the oCOR method in anaemic patients and observing (not 
intervening) their subsequent standard, routine clinical care and investigations 
to highlight where tHb-mass would be most useful in this setting.  
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Future Study 1 
 
Long Title:   The effects of intravenous iron on total haemoglobin mass 
and exercise capacity determined by cardiopulmonary 
exercise testing in patients undergoing major surgery 
Short title:  Intravenous iron, tHb-mass and CPET prior to surgery 
Phase: Prospective observational study 
Population: Patients awaiting major surgery  
Number of sites: One 
Trial Medication: Non-randomised intravenous iron supplementation 
(received as routine care) 
Primary  
objectives:  1. Investigate the effect of intravenous iron 
supplementation on total haemoglobin mass 
2. Investigate the effect of intravenous iron 
supplementation on anaerobic threshold (AT) and peak 
oxygen consumption (V̇O2 peak).  
Secondary  
objectives:  1. Characterise the response of iron indices and hepcidin to 
intravenous iron treatment 
Outcome  
measures: 1. Change in total haemoglobin mass (g & g.kg-1) 
2. Change in anaerobic threshold (AT) and peak oxygen 
consumption (V̇O2 peak) 
3. Change in markers or iron metabolism and hepcidin 
Description of 
Study design: This would be a single centre, observational study in 
patients awaiting major elective surgery.  Patients would be 
tested pre-and post-intravenous iron treatment to 
determine changes in tHb-mass (measured using the 
optimised carbon monoxide rebreathing method), markers 
of iron metabolism and exercise capacity (determined by 
cardiopulmonary exercise testing (CPET) prior to 
undergoing operation. 
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Future Study 2 
 
Long Title:   Validity of derived plasma volume (PV) using the optimised 
carbon monoxide rebreathing method and directly 
measured PV using the radiolabelled albumin dilution 
technique. 
Short title:  Validity of PV using the oCOR and albumin methods 
Phase: Observational study 
Population: Healthy volunteers  
Number of sites: One 
Trial Medication: Nil 
Primary  
objectives:  1. To determine the level of agreement between derived 
PV using the optimised carbon monoxide rebreathing 
method and directly measured PV using the gold standard 
radiolabelled albumin dilution technique 
Secondary  
objectives:  1. To determine the validity of derived plasma volume using 
the oCOR method to detect acute PV expansion following 
intravenous infusion of saline solution compared to the gold 
standard albumin technique 
Outcome  
measures: 1. Plasma volume (ml & ml.kg-1) 
Description of 
Study design: This would be a single centre, observational study in 
healthy volunteers.  Participants would be tested six times 
in total is this study on two separate days.  In part 1, 
participants would perform the oCOR and albumin methods 
on the same day to assess the level of agreement between 
derived and directly measured PV.  In part 2, participants 
would perform both the oCOR and albumin methods pre-
and post PV expansion via infusion of saline solution to 
assess the validity of the oCOR method to detect changes 
in PV.  
 
 169 
Future Study 3 
 
Long Title:  Longitudinal assessment of haematological variables during 
the perioperative period 
Short title:  Haematological variables during the perioperative period 
Phase: Longitudinal observational study 
Population: Patients undergoing major surgery  
Number of sites: One 
Trial Medication: Nil 
Primary  
objectives:  1. Monitor total haemoglobin mass throughout the 
perioperative period 
2. Monitor blood volume and plasma volume throughout the 
perioperative period  
Secondary  
objectives:  1. Monitor routine haematological variables during the 
perioperative period 
Outcome  
measures: 1. Change in total haemoglobin mass 
2. Change in blood volume and plasma volume 
3. Change in haemoglobin concentration and haematocrit  
Description of 
Study design: This would be a single centre, observational and 
longitudinal study in patients awaiting major surgery.  
Patients would have their tHb-mass measured using the 
oCOR method on the day prior to surgery, the day after 
surgery and on postoperative days 3, 5, 8, 15, and 21, if 
the patient remained in hospital until discharge to 
characterise changes in tHb-mass, blood volume, plasma 
volume and routine haematological variables (e.g. 
haemoglobin concentration and haematocrit).  This study 
would allow the underlying causes of postoperative 
anaemia to be elucidated. 
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Future Study 4 
 
Long Title:  The prevalence and cost of anaemia in secondary care, a 
retrospective cohort study 
Short title:  Cost of anaemia in the secondary care setting 
Phase: Retrospective observational cohort study 
Population: Anaemic patients with electronic hospital blood records  
Number of sites: Two: University College Hospital and Southampton 
General Hospital 
Trial Medication: Nil 
Primary  
objectives:  1. To assess what is currently done in the hospital setting 
to detect and investigate anaemia 
2. To assess the economic implications of detecting and 
subsequently investigating anaemia in the secondary care 
setting  
Secondary  
objectives:  1. To determine the cost of measuring tHb-mass using the 
oCOR method and compare this to the economic costs of 
detecting and investigating anaemia 
Outcome  
measures: 1. Economic cost of detecting anaemia using [Hb], MCV, 
MCHC & RDW. 
2. Economic cost of investigating anaemia through 
additional tests (haematinics; total iron binding capacity, 
ferritin, iron, vitamin B12 and folate, thyroid function tests) 
3. Comparison of the economic cost of tHb-mass 
measurement versus cost of detecting, investigating and 
treating anaemia. 
Description of 
Study design: This would be a retrospective, multi-centre observational 
study using electronic patient records in all anaemic 
patients using anonymised data.  Patients would be 
excluded if they had known bone marrow malignancies.  
One would assess the prevalence of anaemia in individual 
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patients (no repeats) based on [Hb], MCV, MCHC, RDW in 
both the in-patient and outpatient setting with further 
refinement based on ICD10 diagnosis coding.  
Subsequently, one would determine how many patients 
underwent additional tests (e.g. haematinics; total iron 
binding capacity, ferritin, iron, vitamin B12 and folate, 
thyroid function) to elucidate the aetiology of anaemia and 
in how many patients were these results abnormal? Thus, 
one could work out the cost per positive finding and 
conversely the cost per negative finding.  In addition, this 
information could be used to refine current practice.  For 
example, if MCV and MCHC are normal then it is very 
unlikely that further investigations would be abnormal.  
Furthermore, if cases where a negative finding was 
elucidated would confirmation of a normal tHb-mass 
measurement have prevented their conduct?  
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Plumb, J.O.M., Otto, J. M., and Grocott, M. P. W. 'Blood doping' from 
Armstrong to prehabilitation: manipulation of blood to improve performance in 
athletes and physiological reserve in patients. Extrem Physiol Med, 2016. 5:5. 
 
Otto, J.M., Montgomery, H.E., and Richards, T. Haemoglobin concentration 
and mass as determinants of exercise performance and of surgical outcome. 
Extrem Physiol Med, 2013. 2(1):33.  
 
Otto, J. M., O'Doherty, A. F., Hennis, P. J., Cooper, J. A., Grocott, M. P. W., 
Snowdon, C., Carlisle, J. B., Swart, M., Richards, T., and Montgomery, H. E. 
Association between preoperative haemoglobin concentration and 
cardiopulmonary exercise variables: a multicentre study. Perioper Med (Lond), 
2013. 2(1):18. See appendix G. 
 
Otto, J.M., Plumb, J.O.M., Wakeham, D., Clissold, E., Loughney, L., Schmidt, 
W., Montgomery, H.E., Grocott, M.P.W., and Richards, T. Total haemoglobin 
mass, but not haemoglobin concentration, is associated with preoperative 
cardiopulmonary exercise testing (CPET) derived oxygen consumption 
variables. BJA (accepted for publication, 27th October 2016).  
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Other publications during PhD  
 
Burden, B. J., Pollock, N., Whyte, G. P., Richards, T., Moore, B., Busbridge, M., 
Srai, S, K., Otto, J. M., and Pedlar, C. R.  Impact of Intravenous Iron on Aerobic 
Capacity and Iron Metabolism in Elite Athletes. Med Sci Sports Exerc, 2015. 
47(7):1399-408. 
Nelson, A., Otto, J. M., Whittle, J., Stephens, C. M., Martin, D, S., Prowle, J. R., 
Ackland, G. L. Subclinical cardiopulmonary dysfunction in stage 3 chronic 
kidney disease. Open Heart, 2016;3:e000370. doi:10.1136/openhrt-2015- 
000370.  
Whittle, J., Nelson, A., Otto, J. M., Stephens, C. M., Martin, D, S., Sneyd, J. R., 
Struthers, R., Minto, G., and Ackland, G. L. Sympathetic autonomic dysfunction 
and impaired cardiovascular performance in higher risk surgical patients: 
implications for perioperative sympatholysis. Open Heart, 
2015;2:e000286.doi:10.1136/openhrt-2015-000268. 
Abstracts and posters  
 
Otto, J. M., O’Doherty, A. F., Moonesinghe, R. S., Stephens, C. M., Martin, D, 
S., Montgomery, H. E., and Richards, T.  Preoperative haemoglobin 
concentration, cardiopulmonary exercise testing and postoperative outcome. 
Network for the Advancement of Patient Blood Management, Haemostasis and 
Thrombosis. 16th Annual Symposium, April 2015.  
 
Otto, J.M., Plumb, J.O.M., Wakeham, D., Montgomery, H.E., Grocott, M.P.W., 
Richards, T. Assessment of blood oxygen carrying capacity in the clinical 
setting. Network for the Advancement of Patient Blood Management, 
Haemostasis and Thrombosis. 17th Annual Symposium, April 2016. 
 
Otto, J.M., Plumb, J.O.M., Wakeham, D., Montgomery, H.E., Grocott, M.P.W., 
Richards, T. Total haemoglobin mass is an important determinant of 
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preoperative exercise capacity measured by cardiopulmonary exercise testing 
in patients awaiting major surgery. Network for the Advancement of Patient 
Blood Management, Haemostasis and Thrombosis. 17th Annual Symposium, 
April 2016. 
 
Pedlar, C. R., Brown, M., Otto, J. M., Drane, A., Finch, J. M., Contursi, M., 
Shave, R., Wasfy, M., Hutter, A., and Baggish, A.  Temporal Sequence of 
Athlete’s Heart Regression During Prescribed Exercise Detraining: Diagnostic 
Implications. American College of Cardiology, December 2016.   
Presentations 
 
Otto, J. M., O'Doherty, A. F., Hennis, P. J., Cooper, J. A., Grocott, M. P. W., 
Snowdon, C., Carlisle, J. B., Swart, M., Richards, T., and Montgomery, H. E. 
Association between preoperative haemoglobin concentration and 
cardiopulmonary exercise variables: a multicentre study.  Invited presenter at 
the 6th National Perioperative Cardiopulmonary Exercise Testing (CPET) Forum 
as part of the Evidence Based-Perioperative Medicine Conference. June 2013. 
 
Otto, J.M. Haemoglobin mass, iron status and cardiorespiratory fitness.  
Presented to the Robbins Group, Department of Physiology, Anatomy and 
Genetics at the University of Oxford. November 2014. 
 
Otto, J.M. The importance of haemoglobin mass in the clinical setting. 
Presented to the Upper Gastrointestinal surgical research meeting at University 
College Hospital.  June 2015. 
 
Otto, J.M. Measurement of total haemoglobin mass in the clinical setting.  
Presented to the Anaesthetics Department at Papworth Hospital.  January 
2016.  
 
Otto, J.M., Plumb, J.O.M., Wakeham, D., Montgomery, H.E., Grocott, M.P.W., 
Richards, T. Total haemoglobin mass is an important determinant of 
preoperative exercise capacity measured by cardiopulmonary exercise testing 
in patients awaiting major surgery. Network for the Advancement of Patient 
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Blood Management, Haemostasis and Thrombosis. 17th Annual Symposium, 
April 2016.  Awarded third prize out of 84 accepted abstracts. The 14 best-rated 
abstracts were invited to present of which I was one. 
 
Otto, J.M. Total haemoglobin mass, but not haemoglobin concentration, is 
associated with preoperative cardiopulmonary exercise testing (CPET) derived 
oxygen consumption variables.  Presented at the Royal Marsden Anaesthesia 
and Surgery Education day. November 2016.  
Other work  
 
Bruinvels, G., Miles, L., Otto, J. M., Chau, M., and Richards, T.  Cochrane 
Protocol 0224: Iron therapy for iron deficient non-anaemic adults. Started June 
2015, work still on going.  
 
Pedlar, C. R., Brown, M., Otto, J. M., Drane, A., Finch, J. M., Contursi, M., 
Shave, R., Wasfy, M., Hutter, A., and Baggish, A.  Temporal Sequence of 
Athlete’s Heart Regression During Prescribed Exercise Detraining: Diagnostic 
Implications.  I was the invited expert on total haemoglobin mass and blood 
volume for this Boston Marathon Detraining Study.  This involved three 
separate visits to Boston Massachusetts (4-5 days each time) over a 3-month 
period to monitor the effects of detraining on cardiorespiratory fitness, cardiac 
structure and function, total haemoglobin mass and blood volume derivatives.  I 
conducted all optimised carbon monoxide rebreathing tests throughout this 
study.  
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Appendices 
 
Appendix A – Participant information sheet (Chapter 4) 
 
Information Sheet for Graduate Research Degree (PhD) 
                                                            
 
You will be given a copy of this information sheet. 
Title of Project: Test retest reliability of total haemoglobin mass using the optimised carbon monoxide rebreathing 
method 
This study has been approved by the UCL Research Ethics Committee (Project ID Number): 6654/001 
Name Mr James Otto 
Work Address Division of Surgery and Interventional Science, c/o Institute of Sport, Exercise and Health, 170 
Tottenham Court Road, London, W1T 7HA  
Contact Details  Email: james.otto@nhs.net, Mobile: 07949 340 801 
 
Introduction 
We would like to invite you to take part in a  research study. Before you decide whether you would  like to take part, 
it is important for you to understand why the research is being done and what it will involve. Please take time to 
read the following informat ion carefully and d iscuss it with friends, relatives and your GP if you wish. Ask us if 
there is anything that is not clear or if you would like more informat ion. Take time to decide whether or not you 
wish to take part. 
 
What is the purpose of the study? 
We wish to assess how reliable (accurate) a new technique is at measuring the total level of haemoglobin in the 
body, which reflects the capacity of the blood to carry oxygen.  
 
This study is being conducted to fulfil of the requirements of a Graduate Research Degree (PhD) being undertaken 
by Mr James Otto, Division of Surgery and Interventional Science at University College London (UCL). 
Haemoglobin concentration [Hb] is a routine and well-established parameter in medicine.  However, the 
measurement of [Hb] can be affected by many factors that may impact its accuracy.  A recently developed test 
measures the total amount of haemoglobin in the body (tHb-mass), which may p rovide a better, more sensitive 
marker of oxygen carry ing capacity and provide additional informat ion on the clin ical status of patients.  However, 
we do not know whether this new technique produces similar results when the same individual is measured on more 
than one occasion (reliability).  
 
Specifically, the aim of this study is: 
1. To assess tHb-mass on two separate occasions to see how similar the values are. 
 
Why have I been invited to take part in this study? 
We have chosen you because you are an adult aged 18 years or older and free from chronic medical conditions . 
Do I have to take part in the study? 
It is up to you to decide whether or not to take part. If you decide to take part you will be given a copy of this 
informat ion sheet and a signed copy of the consent form to keep and be asked to sign a consent form. If you wish to 
withdraw from the study you may do so at any time without giving a reason. If you decide not to take part in the 
study, this will not affect  the standard of care you receive. Furthermore, if you chose to withdraw from the study at 
any point in time your clin ical management in the hos pital will remain  unaffected and identifiab le data will be 
removed from the study database.  
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What will happen to me if I take part in the study? 
Measurement of total haemoglobin mass (tHb-mass) 
tHb-mass will be determined using the optimised carbon monoxide (CO) rebreathing method on two days separated 
by no more than 7 days.  You will be asked to rebreath a small volume of CO for 2 minutes through a mouthpiece.  
The mouthpiece is attached to specifically designed device for that measures the volume of air entering and leaving 
the lungs.  Before and at two t ime points after CO exposure, you will have a capillary blood sample taken.  In total 3 
blood samples are required per test (6 in total). 
 
What data will be collected? 
We will obtain a venous blood sample to allow the determination of haemoglobin concentration and haematocrit.  
To determine your tHb-mass we will collect three capillary blood samples from your earlobe or fingertip to measure 
carboxyhaemoglobin concentration.  The amount of b lood required in total is 5-10 ml or 1-2 teaspoons, which is 
analysed immediately and will not be stored.  In the unlikely event that an insufficient amount of blood is obtained 
by capillary  sampling, a venous sample maybe necessary and would require an addit ional needle  stick.  Samples 
will be taken by people experienced in taking blood samples. 
 
What are the benefits of taking part? 
It is unlikely that patients will benefit directly from this study.  
 
What are the disadvantages or risks of taking part? 
Side effects of carbon monoxide on health and wellbeing are very rare, especially at the very low dose used during 
our test.  However, a  very s mall number of indiv iduals have reported a headache or dizziness.  In the unlikely event 
of these symptoms occurring, a doctor will be consulted at hospital and if necessary will see you.  The dose used is 
less than would occur when in road traffic or after smoking a cigarette.  After having b lood taken, some very minor 
bruising sometimes occurs but every effort  will be made to prevent this from happening.  Samples will be taken by 
people experienced in taking blood samples. 
 
What will happen if I do not want to carry on with the study? 
You are free to  withdraw your consent for the study at any time, without giving  an y reason; this will in  no way 
affect your clinical treatment. If you do decide to withdraw from the study you will be asked to sign an ‘early  
termination’ form.  All identifiab le data will be withdrawn from the study but data that is not identifiable to th e 
research team will be retained and used in this research.   
In the (perhaps unlikely) event of a  loss of capacity to consent, the research team will retain tissue and personal data 
collected during this study and continue to use it confidentially  for res earch purposes.  This could include further 
research after the current project has ended.   
 
What if there is a problem? 
If you wish to complain, or have any concerns about any aspect of the way you have been approached or treated by 
members of staff you may have experienced due to your participation in the research, Nat ional Health Serv ice or 
UCL complaints mechanis ms are available to you. Please ask the researcher if you would like more informat ion on 
this.  
 
In the unlikely event that you are harmed by taking part in this study compensation may be available.  If you suspect 
that the harm is the result of the Sponsor’s (University College London) or the hospital's negligence then you may 
be able to claim compensation.   
 
After discussing with your research doctor, please make the claim in writing to the Mr Toby Richards who is the 
Chief Investigator for the research and is based at UCL Division of Surgery and Interventional Science, 9 th Floor, 
Royal Free Hospital, NW 3 2QG.  The Ch ief Investigator will then pass the claim to the Sponsor’s Insurers, via the 
Sponsor’s office. You may have to bear the costs of the legal action init ially, and you should consult a lawyer about 
this. 
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Harm: 
We will take every care in the course of this study. We have no reason to believe that you will come to any harm as 
a result of this research; if you are harmed due to someone’s negligence then you may have grounds for a legal 
action but you may have to pay for it. Regard less of this, if you wish to complain about any aspect of t he way you 
have been approached or treated during the course of this study, the normal National Health Serv ice complaints 
mechanisms are available to you. 
  
Will my taking part in this study be kept confidential?  
At point of entry to the research, each participant will be allocated a unique identification number for the purpose of 
sample and data storage.  Data will be pseudoanonymised; a register linking subject details and identification 
numbers will be kept to allow subject recall but will remain accessible only to the principal- and co-investigators 
and held on a password protected computer at University College London or NHS computer.  Identifiable data on 
the register will include name, date of birth and address.  Unique identifiers will be used fro m the time of data 
collection throughout the whole study duration. 
No data will be shared with third  parties.  A ll data will remain confidential throughout the whole study and will 
adhere to Caldicott guidelines.   
 
What if new information becomes available? 
Somet imes during the course of a research project, new information becomes available about the subject being 
studied. Should this happen a member of the research team will tell you about it and discuss with you whether you 
want to continue in the study.  
 
What will happen to the results of the research study? 
Following the completion of data collection from participants the research team will analyse the results. The results 
will be published in a medical/scientific journal as soon as possible after analysis has finished. You will not be 
identified in any report or publication. The study results can be sent to you if you wish to receive a report after 
complet ion of the study.  If so, please contact Mr James Otto via letter at University College London, Division of 
Surgery and Interventional Science, c/o Institute of Sport, Exercise and Health, 170 Tottenham Court  Road, 
London, W1T 7HA or email james.otto@nhs.net. 
 
Who is organising and funding the research? 
Mr James Otto (University College London and University College London Hospital) is organising the study.  
There is no direct external funding for this research project and therefore we are unable to reimburse any expenses 
relating to this study.   
 
Ethics Committee review 
All research using human subjects is reviewed before an ethics committee before they can proceed. The                     
University College London (UCL) Research Ethics Committee reviewed this proposal. 
Contact for further information. 
If you have any concerns or questions about the study or the way it has been carried out, you should contact: Mr 
James Otto, Email: james.otto@nhs.net, Mobile: 07949 340 801 
 
Please discuss the information above with others if you wish or ask us if there is anything that is not clear or if you 
would like more information.  
 
It is up to you to decide whether to take part or not; choosing not to take part will not disadvantage you in any way. 
If you do decide to take part you are still free to withdraw at any time and without giving a reason.   
 
All data will be collected and stored in accordance with the Data Protection Act 1998. 
 
Thank you for reading this information sheet and for considering take part in this research.  
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Sir Robert Naylor, chief executive  
 
             PIS University College Hospital, Version 1.4 13th February 2015                   www.uclh.org Page 1 of 5 
University College Hospital 
Department of Surgery 
235 Euston Road 
London 
NW1 2BU 
 
Direct line: 020 3447 5173  
Switchboard: 0845 155 5000/ 020 3456 7890 
Ext: 75173 
 
Email: toby.richards@uclh.nhs.uk 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
 
Participant Information Sheet 
Version 1.4 – 13th February 2015 
 
Title of Project: Assessment of oxygen carrying capacity in the clinical setting – a pilot 
Student’s research project 
 
 
Chief Investigator: Mr Toby Richards 
Student Researcher: Mr James Otto 
 
Introduction 
As a patient of University College London Hospitals NHS Trust you are being invited to take part in a research 
study. Before you decide whether you would like to take part, it is important for you to understand why 
the research is being done and what it will involve. Please take time to read the following information 
carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not you wish to take part.  
 
What is the purpose of the study? 
The purpose of this study is to assess the capacity of the blood to carry oxygen around the body.  To do 
this we wish to determine the total level of haemoglobin in the body using a new technique. 
 
This study is being conducted to fulfil of the requirements of a Graduate Research Degree (PhD) being 
undertaken by Mr James Otto, Division of Surgery and Interventional Science at University College London 
(UCL). 
Haemoglobin concentration [Hb] is a routine and well-established parameter in medicine.  However, the 
measurement of [Hb] can be affected by many factors that may impact its accuracy.  A recently developed 
test measures the total amount of haemoglobin in the body (tHb-mass), which may provide a better, more 
sensitive marker of oxygen carrying capacity and provide additional information on the clinical status of 
patients.  Despite this, there is limited information on total haemoglobin mass  in the clinical setting and 
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therefore this research aims to investigate the usefulness of total haemoglobin mass in different patient 
groups. 
 
Specifically, the aims of this study are: 
1. To assess [Hb] and tHb-mass in patients to see how well they match each other. 
2. To determine whether tHb-mass provides a better assessment of blood oxygen carrying capacity.  
 
Why have I been invited to take part in this study? 
We have chosen you because you are a patient at University College London Hospitals NHS Foundation 
Trust and have one of the following chronic medical conditions; chronic heart failure, liver disease, renal 
disease or gastrointestinal disease or are due to undergo surgery.  
Do I have to take part in the study? 
It is up to you to decide whether or not to take part. If you decide to take part you will be given a copy of 
this information sheet and a signed copy of the consent form to keep and be asked to sign a consent form. 
If you wish to withdraw from the study you may do so at any time without giving a reason. If you decide 
not to take part in the study, this will not affect the standard of care you receive. Furthermore, if you chose 
to withdraw from the study at any point in time your clinical management in the hospital will remain 
unaffected and identifiable data will be removed from the study database.  
 
What will happen to me if I take part in the study? 
Measurement of total haemoglobin mass (tHb-mass) 
tHb-mass will be determined using the optimised carbon monoxide (CO) rebreathing method.  You will be 
asked to re breath a small volume of CO for 2 minutes through a mouthpiece.  The mouthpiece is attached 
to specifically designed device for that measures the volume of air entering and leaving the lungs .  Before 
and at two time points after CO exposure, you will have a blood sample taken.  In total 3 blood samples are 
required. 
 
What data will be collected? 
We will collect information from you to help establish your health status, including but not exclusively, your  
diagnosis, medical history and current medications.  Where information is missing, your medical notes will 
be looked at to obtain this information. To determine your tHb-mass we will collect three blood samples 
from you to measure carboxyhaemoglobin concentration.  The amount of blood required in total is 
approximately 5-10mls or 1-2 teaspoons, which is analysed immediately and will not be stored. People 
experienced in taking blood samples will take the samples. 
 
In addition, we wish to collect a urine sample (20-30 ml, 5-6 teaspoons) and venous blood sample (10-15 
ml, 3-4 teaspoons), from one needle stick for the purposes of current and future research.  These samples 
will be obtained at the same appointment that your tHb-mass is measured and are additional to routine 
care.  Samples will be labelled with a unique ID number and so will be stored anonymised for personal 
identifiers.  However, members of the research team who have legitimate access to the samples will be 
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able to link the ID numbers with corresponding personal information.  This is known as a 
pseudoanonymised system.  Samples will be stored in UCL research freezers in the Division of Surgery and 
Interventional Science in accordance with legislation in the Human Tissue Act (HTA) and UCL policy.  We 
wish to store samples for future research as in recent years, as new technologies and approaches are 
developed, the analysis of stored samples can contribute substantially to the clinical relevance of research 
and maximise its value.  This research will involve the analysis and use of human DNA in the samples 
(genetic testing), and proteomic (study of protein structure and function) and metabolomic (study of 
chemical processes involving metabolites) analyses.   
 
What are the benefits of taking part? 
It is unlikely that patients will benefit directly from this study.  
What are the disadvantages or risks of taking part? 
Side effects of carbon monoxide on health and wellbeing are very rare at the low dose used during our test.  
However, a very small number of individuals have reported a headache or dizziness.  In the unlikely event 
of these symptoms occurring, a doctor will be consulted at hospital and if necessary will see you.  The dose 
used is less than would occur when in road traffic or after smoking a cigarette.  After having blood taken, 
some very minor bruising sometimes occurs but every effort will be made to prevent this  from happening.  
Samples will be taken by people experienced in taking blood samples. 
What will happen if I do not want to carry on with the study? 
You are free to withdraw your consent for the study at any time, without giving any reason; this will in no 
way affect your clinical treatment. If you do decide to withdraw from the study you will be asked to sign an 
‘early termination’ form.  All identifiable data will be withdrawn from the study but data that is not 
identifiable to the research team will be retained and used in this research.   
In the (perhaps unlikely) event of a loss of capacity to consent, the research team will retain tissue and 
personal data collected during this study and continue to use it confidentially for research purposes.  This 
could include further research after the current project has ended.   
 
What if there is a problem? 
If you wish to complain, or have any concerns about any aspect of the way you have been approached or 
treated by members of staff you may have experienced due to your participation in the research, National 
Health Service or UCL complaints mechanisms are available to you. Please ask your research doctor if you 
would like more information on this.  
 
In the unlikely event that you are harmed by taking part in this study compensation may be available.  If 
you suspect that the harm is the result of the Sponsor’s (University College London) or the hospital's 
negligence then you may be able to claim compensation.   
 
After discussing with your research doctor, please make the claim in writing to the Mr Toby Richards who 
is the Chief Investigator for the research and is based at UCL Division of Surgery and Interventional Science, 
9th Floor, Royal Free Hospital, NW3 2QG.  The Chief Investigator will then pass the claim to the Sponsor’s 
Insurers, via the Sponsor’s office. You may have to bear the costs of the legal action initially, and you should 
consult a lawyer about this. 
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Harm: 
We will take every care in the course of this study. We have no reason to believe that you will come to any 
harm as a result of this research; if you are harmed due to someone’s negligence then you may have 
grounds for a legal action but you may have to pay for it. Regardless of this, if you wish to complain about 
any aspect of the way you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you. 
 
Officers from the Patient Advice and Liaison Service (PALS) are available in all hospitals , details at the end 
of this document. They offer confidential advice, support and information on health-related matters to 
patients, their families and their carers. You can find your local PALS office on the PALS website 
http://www.pals.nhs.uk/officemapsearch.aspx. Please ask your study doctor if you would like more 
information on this. Details can also be obtained from the Department of Health website: 
http://www.dh.gov.uk. 
 
Alternatively, the Independent Complaints Advocacy Service (ICAS) is a national service that supports 
people who wish to make a complaint about their NHS care or treatment. Contact your local ICAS office 
through PALS, or ask your research nurse for your local contact number. If you wish you can find your local 
contact number on the following website:- 
http://www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplaints.aspx 
 
Will my taking part in this study be kept confidential?  
At point of entry to the research, each participant will be allocated a unique identification number for the 
purpose of sample and data storage.  Data will be pseudoanonymised; a register linking subject details and 
identification numbers will be kept to allow subject recall but will remain accessible only to the principal- 
and co-investigators and held on a password protected computer at University College London or NHS 
computer.  Identifiable data on the register will include name, date of birth and address.  Unique identifiers 
will be used from the time of data collection throughout the whole study duration. 
No data will be shared with third parties.  All data will remain confidential throughout the whole study and 
will adhere to Caldicott guidelines.   
 
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the subject 
being studied. Should this happen a member of the research team will tell you about it and discuss with 
you whether you want to continue in the study.  
 
Will my General Practitioner be notified? 
Your GP will be informed of your inclusion in this research study. 
  
What will happen to the results of the research study? 
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Following the completion of data collection from participants the research team will analyse the results. 
The results will be published in a medical/scientific journal as soon as possible after analysis ha s finished. 
You will not be identified in any report or publication. The study results can be sent to you if you wish to 
receive a report after completion of the study.  If so, please contact Mr James Otto via letter at University 
College London, Division of Surgery and Interventional Science, c/o 4th Floor Rockefeller Building, 21 
University Street, London, WC1E 6DE or email james.otto@nhs.net. 
 
Who is organising and funding the research? 
Mr James Otto (University College London and University College London Hospital) is organising the study.  
There is no direct external funding for this research project.   
 
Ethics Committee review 
All research using human subjects is reviewed before an ethics committee before they can proceed. The                     
London – Camden and Islington Research Ethics Committee reviewed and approved this proposal. 
 
Contact for further information. 
If you have any concerns or questions about the study or the way it has been carried out, you should 
contact: Mr Toby Richards: 020 7679 6454 
 
If you wish to speak to an independent advisor you should contact: 
Patient Advice and Liaison Service (PALS) 
Ground Floor Atrium 
University College Hospital 
235 Euston Road 
London   
NW1 2BU 
T: 0203 447 3042 
 
THANK YOU FOR TAKING TIME TO READ THIS SHEET. 
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University College Hospital 
Department of Surgery 
235 Euston Road 
London 
NW1 2BU 
 
Direct line: 020 3447 5173  
Switchboard: 0845 155 5000/ 020 3456 7890 
Ext: 75173 
 
Email: toby.richards@uclh.nhs.uk 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
 
 
Informed Consent Form 
Version 1.4 – 13/02/2015 
 
Title of Project: The assessment of oxygen carrying capacity in the clinical setting – a pilot 
Student’s research project 
 
Chief Investigator: Mr Toby Richards      
Student Researcher: Mr James Otto 
 
 
Study number:_________________ 
Please initial box to indicate agreement. 
1. I confirm that I have read (or someone has read to me) and understood the Information Sheet 
dated 13th February 2015 (Version 1.4) for the above study and have had the opportunity to ask 
questions and have these answered satisfactorily. 
 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
 
 
 
 
 
 
Initial box 
Initial box 
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3. I understand that, relevant sections of my medical notes, and data collected during the study 
may be looked at by professional responsible individuals from the sponsor of the trial (UCH, 
UCL, Royal Free Joint Biomedical Research Unit), from regulatory authorities or from the NHS 
Trust where it is relevant to my taking part in research. I give permission for these individuals to 
have access to my records. I understand that my personal data will be processed and stored 
securely in compliance with the 1998 Data Protection Act.  In addition, stored data collected 
during the study maybe used for future research and I give permission for this to happen.  
 
 
 
 
 
Informed Consent Form 
Version 1.4 – 13/02/2015 
 
Title of Project: The assessment of oxygen carrying capacity in the clinical setting – a pilot 
 
Study number:_________________ 
 
Please initial box to indicate agreement. 
 
4. Additionally, I understand that the following samples will be collected for research purposes and I  
consent to these to be collected:  
 
a. Three blood samples via a cannula/butterfly needle or capillary tube 
as part of total haemoglobin mass measurement.  
 
OR 
 
b. Seven blood samples via a cannula/butterfly needle or capillary tube  
as part of validating total haemoglobin mass measurement in patients.  
 
 
c. One venous blood sample  
 
5. I give permission for these samples to be collected and stored, in accordance with the Human Tissue Act, for 
current and future research. 
 
OR 
 
 
6. I give permission for these samples to be collected and stored for this current research study but I do not give 
permission for my samples to be stored for use in future research projects. 
 
 
 
Initial box 
Initial box 
Initial box 
Initial box 
Initial box 
Initial box 
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7. In addition, I consent for DNA testing to be carried out on collected samples for the purposes of current and 
future research with the appropriate ethical approval. 
 
OR 
 
 
8. In addition, I consent for DNA testing to be carried out on collected samples for the purpose of this current 
research project but I do not give permission for my samples to be stored for use in future research projects.  
 
 
 
 
9. I understand that I am gifting my samples to the investigators and in so doing give up all future claims to its use 
that may include further research with the appropriate ethical approval. 
 
 
 
 
10. I agree to my GP being informed of my participation in the study. 
 
 
 
 
11. I agree to take part in the study requiring three blood samples as part of total haemoglobin 
mass measurement (see Section 4a above). 
 
 
OR 
 
12. I agree to take part in the study requiring seven blood samples as part of validating total 
haemoglobin mass measurement in patients (see Section 4b above). 
 
 
 
 
 
 
            ____    _________ 
Name of patient   Date   Signature 
 
 
 
                         ____    _________ 
Name of person taking consent Date   Signature 
 
 
 
             __      _________ 
Investigator    Date               Signature 
Initial box 
Initial box 
Initial box 
Initial box 
Initial box 
Initial box 
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University College Hospital 
Department of Surgery 
235 Euston Road 
London 
NW1 2BU 
 
Direct line: 020 3447 5173  
Switchboard: 0845 155 5000/ 020 3456 7890 
Ext: 75173 
 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
 
Participant Information Sheet 
Version 1.6 – 10th February 2015 
 
Title of Project: Blood oxygen carrying capacity, iron status, cardiopulmonary exercise testing, and 
postoperative morbidity in patients awaiting major surgery - a pilot study. 
 
Student’s research project 
 
 
Chief Investigator: Mr Toby Richards 
Student Researcher: Mr James Otto 
 
Introduction 
As a patient of University College London Hospitals NHS Trust you are being invited to take part in a 
research study. Before you decide whether you would like to take part, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the following 
information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
What is the purpose of the study? 
This study is being conducted to fulfil of the requirements of a Graduate Research Degree (PhD) being 
undertaken by Mr James Otto, Division of Surgery and Interventional Science at University College 
London (UCL). 
Assessing the physical status of patients before surgery is a difficult task for doctors.  A test that helps 
doctors assess physical capacity is the cardiopulmonary exercise test (CPET).  CPET provides an objective 
assessment of physical status, and more specifically an assessment of heart and lung function; this is 
useful for identifying risk in surgical patients. Current research suggests that fitter people, measured by 
CPET, recover more quickly after surgery.  
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Haemoglobin, found in red blood cells carries most of the oxygen in the blood and is reduced in patients 
with anaemia.  Haemoglobin is dependent on adequate iron that when reduced can lead to iron 
deficiency and anaemia.  Both anaemia and iron deficiency can result in reduced physical status.  Anaemia 
is routinely defined by measuring haemoglobin concentration [Hb] in the blood and is common in patients 
awaiting surgery.  However, the measurement of [Hb] can be affected by a number of factors that may 
impact its accuracy.  A recently developed test measures the total amount of haemoglobin (tHb-mass) in 
the body, which may provide more information on the capacity of the blood to carry oxygen than [Hb] 
alone.   
The purpose of this study is to assess the relationship between iron status, tHb-mass and physical 
capacity using CPET to determine the impact on surgical outcome.  
 
Specifically, the aims of this study are: 
 
1.  To assess total haemoglobin mass in surgical patients and establish its effects on exercise capacity and 
surgical outcome.  
2. To investigate the relationship between total haemoglobin mass, iron status and exercise capacity.  
 
Why have I been invited to take part in this study? 
We have invited you because you are scheduled to undergo surgery at University College London Hospital 
and have been referred for a Cardiopulmonary Exercise Test (CPET). 
 
Do I have to take part in the study? 
It is up to you to decide whether or not to take part. If you decide to take part you will be given a copy of 
this information sheet and a signed copy of the consent form to keep and be asked to sign a consent 
form. If you wish to withdraw from the study you may do so at any time without giving a reason. If you 
decide not to take part in the study, this will not affect the standard of care you receive. Furthermore, if 
you chose to withdraw from the study at any point in time your clinical management in the hospital will 
remain unaffected and your study data will be removed from the study database.  
 
What will happen to me if I take part in the study? 
For this study you will undergo one exercise test on a stationary bicycle. This test will be done at the 
earliest opportunity. Before your exercise test we will ask you standard questions to establish your health 
status to ensure it is safe to carry out the test. We will also ask you to blow into a tube to assess how your 
lungs are working. During the test we will analyse the gases in your inhaled and exhaled breath using a 
facemask. Your heart trace will also be continually monitored and your blood pressure will be monitored 
regularly. An Exercise Physiologist will be present throughout the test. This appointment will last 
approximately one hour.  This test will be carried out as part of your normal hospital care before surgery.  
In addition, you will undergo one test to measure the total amount of haemoglobin in your body.  This will 
entail breathing normally through a tube that is attached to a bag for 2 minutes.  The bag contains a very 
small amount of carbon monoxide (CO) that is rebreathed during this short period.  Before and at defined 
time points after CO exposure, we will take blood samples to measure carboxyhaemoglobin 
concentration (COHb [%]).  In total 3 blood samples are required.  This appointment will last 
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approximately 30 minutes and where possible, we will try to arrange this appointment to fit in with other 
hospital appointments that you have but this cannot be guaranteed.  
Finally, a blood test will be carried out to determine your iron status.  This will be carried out at the same 
time as your appointment to measure tHb-mass and will not involve an extra needle stick. 
After surgery, your recovery will be monitored until you are discharged from hospital.   
 
What data will be collected? 
During CPET we will make observations about how well you are using the oxygen when you are breathing. 
We will collect information from you to help establish your health status, including but not exclusively, 
your diagnosis, medical history and current medications.  Where information is missing, your medical 
notes will be looked at to obtain this information.  . To determine your tHb-mass we will collect three 
capillary blood samples from your earlobe to measure carboxyhaemoglobin concentration.  The amount 
of blood required in total is 5-10 ml or 1-2 teaspoons, which is analysed immediately and will not be 
stored.  In the unlikely event that an insufficient amount of blood is obtained by capillary sampling, a 
venous sample maybe necessary and would require an additional needle stick.  Samples will be taken by 
people experienced in taking blood samples. 
 
After you have had your surgery we will record information about your hospital stay, including details of 
certain treatments you received, where you were cared for whilst in hospital and for how long. We will 
monitor your progress by looking at your electronic records at several time points after your surgery, up 
to your discharge from hospital.   
 
In addition, we wish to collect a urine sample (20-30 ml, 5-6 teaspoons) and venous blood sample (10-15 
ml, 3-4 teaspoons), from one needle stick for the purposes of current and future research.  These samples 
will be obtained at the same appointment that your tHb-mass is measured and are additional to routine 
care.  Samples will be labelled with a unique ID number and so will be stored anonymised for personal 
identifiers.  However, members of the research team who have legitimate access to the samples will be 
able to link the ID numbers with corresponding personal information.  This is known as a 
pseudoanonymised system.  Samples will be stored in UCL research freezers in the Division of Surgery and 
Interventional Science in accordance with legislation in the Human Tissue Act (HTA) and UCL policy.  We 
wish to store samples for future research as in recent years, as new technologies and approaches are 
developed, the analysis of stored samples can contribute substantially to the clinical relevance of research 
and maximise its value.  This research will involve the analysis and use of human DNA in the samples 
(genetic testing), and proteomic (study of protein structure and function) and metabolomic (study of 
chemical processes involving metabolites) analyses.   
 
What are the benefits of taking part? 
It is unlikely that you will benefit by taking part in this research.  However, the addition of measuring iron 
status may highlight those who are iron deficient who might otherwise not have been tested for this 
condition.  In this case, your direct care team may implement appropriate treatment if necessary.  In 
addition, the results of this study may help future patients who have major surgery. 
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What are the disadvantages or risks of taking part? 
The cardiopulmonary exercise test is part of the routine management of patients undergoing this type of 
surgery at this hospital and many hospitals across the UK. There is a small risk (1:10,000) associated with 
CPET (for example risk of an abnormal heart rhythm brought on by exercise or heart attack). Highly 
experienced physiologists who are trained in advanced life support carefully monitor exercise tests . If you 
have any significant changes to your heart rhythm during the test, we will refer you to a Cardiologist for 
an independent review. 
 
There exists the possibility that your muscles may feel achy or sore following exercise but any soreness or 
aches should subside within a day or two. Your safety will be continually monitored during your visits to 
the CPET laboratory by the researchers.  
Side effects of carbon monoxide on health and wellbeing are very rare, especially at the low dose used 
during our test.  However, a very small number of individuals have reported a headache or dizziness.  The 
dose used is less than would occur when in road traffic or after smoking a cigarette.  
 
What will happen if I do not want to carry on with the study? 
You are free to withdraw your consent for the study at any time, without giving any reason; this will in no 
way affect your clinical treatment. If you do decide to withdraw from the study you will be asked to sign 
an ‘early termination’ form.  All identifiable data will be withdrawn from the study but data that is not 
identifiable to the research team will be retained and used in this research study.    
In the (perhaps unlikely) event of a loss of capacity to consent, the research team will retain tissue and 
personal data collected during this study and continue to use it confidentially for research purposes.  This 
could include further research after the current project has ended.   
 
What if there is a problem? 
If you wish to complain, or have any concerns about any aspect of the way you have been approached or 
treated by members of staff you may have experienced due to your participation in the research, National 
Health Service or UCL complaints mechanisms are available to you. Please ask your research doctor if you 
would like more information on this.  
 
In the unlikely event that you are harmed by taking part in this study compensation may be available.  If 
you suspect that the harm is the result of the Sponsor’s (University College London) or the hospital's 
negligence then you may be able to claim compensation.   
 
After discussing with your research doctor, please make the claim in writing to the Mr Toby Richards who 
is the Chief Investigator for the research and is based at UCL Division of Surgery and Interventional 
Science, 9th Floor, Royal Free Hospital, NW3 2QG.  The Chief Investigator will then pass the claim to the 
Sponsor’s Insurers, via the Sponsor’s office. You may have to bear the costs of the legal action initially, 
and you should consult a lawyer about this. 
 
Harm: 
We will take every care in the course of this study. We have no reason to believe that you will come to 
any harm as a result of this research; however, if you are harmed by taking part in this research project, 
there are no special compensation arrangements available to you. If you are harmed due to someone’s 
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negligence then you may have grounds for a legal action but you may have to pay for it. Regardless of 
this, if you wish to complain about any aspect of the way you have been approached or treated during the 
course of this study, the normal National Health Service complaints mechanisms are available to you.  
Officers from the Patient Advice and Liaison Service (PALS) are available in all hospitals , details at the end 
of this document. They offer confidential advice, support and information on health-related matters to 
patients, their families and their carers. You can find your local PALS office on the PALS website 
http://www.pals.nhs.uk/officemapsearch.aspx. Please ask your study doctor if you would like more 
information on this. Details can also be obtained from the Department of Health website: 
http://www.dh.gov.uk. 
 
Alternatively, the Independent Complaints Advocacy Service (ICAS) is a national service that supports 
people who wish to make a complaint about their NHS care or treatment. Contact your local ICAS office 
through PALS, or ask your research nurse for your local contact number. If you wish you can find your 
local contact number on the following website:- 
http://www.nhs.uk/choiceintheNHS/Rightsandpledges/complaints/Pages/NHScomplaints.aspx 
Will my taking part in this study be kept confidential?  
All information, which is collected, about you during the course of the research will be kept strictly 
confidential at all times. The information will be held securely on paper at the University College Hospital, 
London. Data will be entered onto the study database on a password-protected computer, under the 
provisions of the 1998 Data Protection Act. A unique identification number will replace identifiable 
patient information. This will be used on the data collection forms; therefore any information about you 
that leaves the hospital will not be recognisable. We are required to keep the data for a minimum of 5 
years after the study has been completed. It will be stored securely during this time in a locked filing 
cabinet in a locked office and electronically on a password protected, encrypted computer in a locked 
office.  
 
What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available about the subject 
being studied. Should this happen a member of the research team will tell you about it and discuss with 
you whether you want to continue in the study.  
 
Will my General Practitioner be notified? 
Your GP will be informed of your inclusion in this research study. 
  
What will happen to the results of the research study? 
Following the completion of data collection from participants the research team will analyse the results. 
The results will be published in a medical/scientific journal as soon as possible after analysis has finished. 
You will not be identified in any report or publication. The study results  can be sent to you if you wish to 
receive a report after completion of the study.  If so, please contact Mr James Otto via letter at University 
College London, Division of Surgery and Interventional Science, c/o 4th Floor Rockefeller Building, 21 
University Street, London, WC1E 6DE or email james.otto@nhs.net. . 
 
Who is organising and funding the research? 
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Mr James Otto (University College London and University College London Hospital) is organising the 
study.  There is no direct external funding for this research project.   
 
Ethics Committee review 
All research using human subjects is reviewed before an ethics committee before they can proceed. The                     
London – Camden and Islington Research Ethics Committee reviewed and approved this proposal. 
 
Contact for further information. 
If you have any concerns or questions about the study or the way it has been carried out, you should 
contact: Mr James Otto 
Email: james.otto@nhs.net 
 
If you wish to speak to an independent advisor you should contact: 
 
Patient Advice and Liaison Service (PALS) 
Ground Floor Atrium 
University College Hospital 
235 Euston Road 
London   
NW1 2BU 
T: 0203 447 3042 
 
THANK YOU FOR TAKING TIME TO READ THIS SHEET. 
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University College Hospital 
Department of Surgery 
235 Euston Road 
London 
NW1 2BU 
 
Direct line: 020 3447 5173  
Switchboard: 0845 155 5000/ 020 3456 7890 
Ext: 75173 
 
Email: toby.richards@uclh.nhs.uk 
Website: www.uclh.nhs.uk 
 
 
 
 
 
 
 
 
Informed Consent Form 
Version 1.6 – 10th February 2015 
 
Title of Project: Blood oxygen carrying capacity, iron status and cardiopulmonary exercise testing in patients 
awaiting major surgery, and their relationship to postoperative morbidity: a pilot study  
 
Student’s research project 
 
 
Chief Investigator: Mr Toby Richards 
Student Researcher: Mr James Otto 
 
Study number:_________________ 
Please initial box to indicate agreement. 
1. I confirm that I have read (or someone has read to me) and understood the Information Sheet 
dated 10th February 2015 (Version 1.6) for the above study and have had the opportunity to ask 
questions and have these answered satisfactorily. 
 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
 
 
3. I understand that, relevant sections of my medical notes, and data collected during the study 
may be looked at by professional responsible individuals from the sponsor of the trial (UCH, 
Initial box 
Initial box 
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UCL, Royal Free Joint Biomedical Research Unit), from regulatory authorities or from the NHS 
Trust where it is relevant to my taking part in research. I give permission for these individuals to 
have access to my records. I understand that my personal data will be processed and stored 
securely in compliance with the 1998 Data Protection Act. 
 
 
 
 
 
Informed Consent Form 
Version 1.6 – 10th February 2015 
 
Title of Project: Blood oxygen carrying capacity, iron status and cardiopulmonary exercise testing in patients 
awaiting major surgery, and their relationship to postoperative morbidity: a pilot study  
 
Study number:_________________ 
 
Please initial box to indicate agreement. 
 
4. Additionally, I understand that the following samples will be collected for research purposes  and I 
consent to these to be collected:  
 
a. Three blood samples via a cannula/butterfly needle or capi l lary tube 
as part of total haemoglobin mass measurement.  
 
 
b. One venous blood sample  
 
 
5. I give permission for these samples to be collected and stored, in accordance with the Human Tissue Act, for 
current and future research. 
  
OR 
 
 
6. I give permission for these samples to be collected and stored for this current research study but I do not give  
permission for my samples to be stored for use in future research projects.  
 
 
 
 
 
7. In addition, I consent for DNA testing to be carried out on collected samples for the purposes of current and 
future research with the appropriate ethical approval. 
 
OR 
 
Initial box 
Initial box 
Initial box 
Initial box 
Initial box 
Initial box 
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8. In addition, I consent for DNA testing to be carried out on collected samples for the purpose of this current 
research project but I do not give permission for my samples to be stored for use in future research projects.  
 
 
 
 
9. I understand that I am gifting my samples to the investigators and in so doing give up all future claims to its use  
that may include further research with the appropriate ethical approval. 
 
 
 
 
10. I agree to my GP being informed of my participation in the study. 
 
 
 
 
11. I agree to take part in the above study. 
 
 
 
 
 
 
 
 
 
 
 
            ____   _________ 
Name of patient   Date   Signature 
 
 
 
 
                         ____    _________ 
Name of person taking consent  Date   Signature 
 
 
 
 
             __      _________ 
Investigator    Date               Signature 
 
Initial box 
Initial box 
Initial box 
Initial box 
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concentration and cardiopulmonary exercise variables: a multicentre 
study 
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